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Binding studies showed that optimal uptake of I-EGF was achieved within 60-90
minutes at 37°C. Other binding characteristics demonstrated the saturability of
the receptor sites and also revealed two classes of binding sites of higher
(mean dissociation constant Kd + SD = 0.8 + 0.2cnmol/l) and lower (Kd + SD = 7.6
_+ 2.8 nmol/1) affinities. The binding of I-EGF is specific since it is
abolished by excess unlabelled EGF in a dose dependent manner but not by excess
unlabelled insulin, venom nerve growth factor, luteinising hormone, follicle
stimulating hormone, growth hormone, and prolactin. Furthermore the biochemical
studies revealed that the receptors were recognised by both mouse EGF and human
urogastrone. Subcellular distribution of the receptors revealed that the bulk
(60-70%) of the receptors were associated with the 800g heavy pellet and the
rest distributed between the 15000g (mitochondrial) and the 105000g (microsomal)
fractions. Binding was also found to be linear with protein concentration up to
1 mg/ml. Other conditions of the receptor assay were optimised: polyethylene
glycol (PEG) precipitation and centrifugation followed by aspiration of
supernatant as a method for separating specific from non specific binding was
found to be superior to filtration approach. Low speed centrifugation for 30
minutes in the separation technique produced better results than shorter
spinning time. Heat and trypsin pretreatment abolished the specific binding
.indicating the proteinaceous nature of the EGF receptor. MgCl? and dextrancoated charcoal pretreatment did not improve the specific binding. Storage of
prostatic tissues and homogenates at -70°C for 16 weeks did not have adverse
effect on the receptor binding. Use of enzyme and enzyme inhibitors exhibited
diffe.re.nt binding characteristics: PMSF, Leupeptin and anti-trypsin improved the
binding but achymotrypsin and trypsin abolished the binding.
Comparison of receptor levels in BPH and cancer of the prostate (CaP) revealed
that BPH receptor levels (mean +_ SD = 125 +_ 20 fmol/mg protein) were twice as
high as in CaP (mean + SD = 50 +_ 11 fmol/mg protein) (P<D.01). Furthermore the
receptor expression in the CaP varied according to the histologic
differentiation of the tumour as assessed by Gleason score (G/S): Well
differentiated CaP (G/S:2-4) expressing more receptors (mean + SD = 84 + 13
fmol/mg protein) whilst poorly differentiated tumour (G/S^IO) expreTsing
little or no receptors at all (mean + SD = 25 + 15 fmol/mg protein) (P^O.Ol).
The biochemical findings were confirmed by an immunocytochemical approach using
a specific monoclonal antibody to the receptor sites which were localised at the
basal layers of the epithelium. The ligand and antibody recognise two different
binding sites on the receptor.
Evidence that EGF binding and kinase activity observed in the human prostate
reside in the same protein, is provided by results obtained for affinity
labelling studies which showed that EGF was bound to and increased the
autophosphorylation of a macromolecule of 170000 daltons molecular weight
measured by sodium dodecylsulphate-polyacrylamide gel electrophoresis
(SDS-PAGE).
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Defective regulation of cell growth and differentiation are some
of the physiological alterations which underlie the gross derangements
of disease. An important goal of basic cancer biology and for that
matter the biology of any other diseases is to provide molecular
explanations for the defective cellular processes.
With recent developments in molecular and cellular biology,
investigators have obtained penetrating insights into cell processes
and their respective derangements. These are being investigated at
different experimental levels including work on growth factors and
their receptors.
The results of these approaches are interrelated and integrated
within the framework of cell proliferation and differentiation.
The binding characteristics of epidermal growth factor (EGF) and
its receptor (EGF-R) in the human hyperplastic prostate (BPH) and
cancer of the prostate (CaP) is the subject of investigation described
in this report.
1.2 THE HUMAN PROSTATE GLAND
a) The Normal Prostate: The normal prostate gland is a firm, part-
glandular, part-muscular body and surrounds the beginning of the
urethra. It is roughly the size and shape of a chestnut and is
thought to serve a function in male fertility.
i) Location; It lies in the pelvis, behind the pubis, and in
front of the rectum. Its base is directed upwards and is
continuous with the bladder neck, as illustrated in Figure 1.
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ii) Genesis; Morphogenesis is initiated in the fetus with the
appearance of solid epithelial outgrowths (prostatic buds) which
grow peripherally from the urogenital sinus (prostate urethra
into surrounding mesenchyme (stroma). The prostate buds become
the main collecting ducts and eventually form an extensive
glandular network in the stroma. (Cunha et al, 1986)
iii) Growth; The prostate gland grows slowly from birth to
puberty, then rapidly to the age of 30. Thereafter it remains
more or less constant in size until the age of about 45 (Swyer, 1944).
From the mid-forties, prostate weight begins again to increase
gradually. Berry et al (1984) correlated the size of the human
prostate gland and age using data from major autopsy series
(n = 740). Figure 2 is showing a graph of the mean values.
iv) Anatomy: The prostate gland consists of two sets of glands,
an inner or periurethral zone, which surrounds the urethra, and an
outer zone which surrounds the inner zone and is separated from
the prostatic plexus of veins by a thick fibrous capsule (Figure 3).
The urethra is about 20 cm long and is divided into three parts
but only the prostatic part is relevant to this discussion.
The prostatic part lies within the prostate gland. It is the
widest part and runs vertically through the prostate. On its
posterior aspect is the prostatic eminence or verumontanum, on
either side of which the prostatic glands and the ejaculatory
ducts open (Figure 4). The verumontanum indicates the level of
the external sphincter at transurethral resections of the prostate
and it must therefore be preserved.
The peripheral zone is part of the true functional prostate
(McNeal, 1975) whilst the inner zone is made up of small simple
5













































Figure 3. The transverse section of the human prostate






Transverse cection of the prostate.
Figure 3-
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structures which are not thought to contribute to the production
of seminal fluid.
v) Histology: Histologically, the normal prostate is made up
of small to large acinar glands and their ducts arranged in radial
fashion. The prostate acini are lined with a columnar epithelium
that is characteristically two cell layers thick (basal and
principal cells) and peripheral ducts lined by a single layer of
cuboidal epithelium that merges with the transitional epithelium
of the central prostatic urethra (McNeal 1972, 197s"). These
glands are separated by an abundant fibromuscular stroma. The
glandular and muscular elements are barely detectable in the child.
They enlarge with puberty and in middle age they develop the
nodules and whorls of benign prostatic hyperplasia.
vi) Function: The normal physiological function of the prostate
is unknown. It was originally thought to play some role in
reproductive function but the role is still not clearly defined.
During emission the prostate is believed to secrete
0.5 ml of thin milky alkaline fluid containing citric acid,
calcium act'd phosphatase, a clotting enzyme and a profibrinolysin
(Guyton, 1981). The prostatic capsule contracts simultaneously
with the vas deferens so that the thin fluid of the former adds
to the bulk of the semen. The alkaline characteristics of the
prostatic fluid serves to neutralise the acidity of the vas
deferens secretions thereby achieving an optimal ? H environment
for the spermatozoa (pH 6.0 - 6.5). Apart from this small
contribution to reproductive function, it is thought that the
prostate may be non-essential to life (Franks, 1983). It may
be rather a source of more clinical problems, and also may be as
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useless as the appendix vermiformis (Farnsworth, 197 ).
b) Benign Prostatic Hyperplasia (BPH): BPH is one of the most
common diseases affecting 60% of men within the age group of 40 - 59
years of age and more than 95% of those over 70 years (Habitz, 1972).
i) Genesis: of BPH is not clearly understood but it
is thought that it begins in the inner or periurethral region of
the prostate gland as fibrous nodules which induce the ingrowth
of adjacent epithelial elements (Le Due, 1939; Deming and
Neumann, 1939). The nodules are formed presumably as a result
of cellular disturbance arising entirely at the local level
within its susceptible region.
ii) Presentation: The usual clinical presentation of BPH is
that of urinary flow obstruction caused by bladder neck
constriction. About 10% of men show clinical symptoms that
merit surgical intervention and relief by transurethral
resection (Robbins, 1984).
iii) Incidence: This was studied within different age groups
using prostatic enlargement as the major criterion. It was
found to be low in the age group below 20 year old males,
whilst among octogenarians the incidence was over 50% (Randal,
1931) but using histological criteria, BPH was found to be
absent in individuals below the age of 30 years, whilst over 70%
of octogenarians had the condition (Moore, 1935).
Franks (1954) used classification based on "possible BPH",
"microscopic BPH", "macroscopic BPH" to investigate 211 prostate
specimens in relation to age. He concluded that octogenarians
had 53% macroscopic, 32% microscopic and 16% possible BPH.
c) Cancer of the Prostate: In marked contrast to BPH, adenocarcinoma
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of the prostate is distinctly associated with epithelial cells in the
peripheral region of the prostate (McNeal, 1972; Robel, 1980).
Cancer of the prostate is the commonest cancer found in the male
urocjttnitod tract (Smith et al, 1976). Mortality from prostate
cancer is the fourth most common cause of death from malignant
diseases in men. Approximately 4,000 fatalities occur in every year
in England and Wales (Annual Report DHSS, 1974). About 6,000 new
cases are also recorded in the United Kingdom every year (Tate et al,
1979). In the USA, it is the second most common cancer and the
third most prevalent cause of cancer deaths for men. About 42,000
new cases are recorded every year (Klein, 1979; Silverberg, 1982).
It was estimated that approximately 96,000 new cases of prostate
cancer would be diagnosed in 1987 (National Institute of Health
Consensus Development Conference Statement (1987)).
i) Incidence: The incidence is generally accepted as age
related. The condition is rare before the age of 50. It is
greatest in men between 65 and 75 years of age, although it is
uncommon in those aged between 45 and 55 years,
ii) Presentation: Cancer of the prostate can remain undiagnosed
and asymptomatic in aged men and be revealed only at autopsy.
Conversely, it may remain dormant in younger men for many years
(Griffiths et al, 1979).
iii) Aetiology: The classical work of Huggins & Hodges(1941) ; Huggins et al
(1941) clearly demonstrated that prostatic carcinoma was androgen dependent.
Objective tumour regression was obtained with castration and
treatment with oestrogens. But although androgen secretions
are necessary to the development of prostatic cancer, their
role seems only permissive (Bouffioux, 1983). Many other
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factors, e.g. genetic, infection, socioeconomic, dietetic and
biochemical have also been suspected of playing a role in the
occurrence of the disease (Alderson et al, 1981; Baba, 1982;
Bouffioux, 1983). These observations were confirmed by Ch.
Bouffioux (1984). He concluded that prostate cancer, like most
malignancies, does not depend on a single aetiology but on a
complex interaction, some facilitating and others inhibiting any
potential oncogenic transformation. Chisholm (1980) and Chisholm
and Habib (1980) have outlined in their reviews, some of the
factors that may lead to prostate cancer. There is a geographic
variation in age-adjusted mortality rate among people with cancer
of the prostate. The rate is said to be highest in Sweden, Norway
and Switzerland but lowest in the Philippines, China, Japan and
Taiwan. Environmental and dietary factors may be implicated
since migration from low incidence area to high incidence area
increases mortality rate. Epidem<a logical factors have also
been found to be relevant. There is a higher occurrence of cancer
of the prostate among blacks in America than whites but there is
low occurrence among blacks in West Africa.
Sedentary occupation, sexual activity and venereal diseases
have all been associated with cancer of the prostate.
Zinc and cadmium have also been implicated in carcinogenesis
of the prostate.
Kipling and Waterhouse (1967) have shown that industrial
workers exposed to high levels of cadmium have a higher incidence
of prostatic carcinoma. This was confirmed by Habib et al (1976)
who showed that the cancerous prostate had higher levels of cadmium
than BPH tissues, but found that the zinc levels in cancer of the
prostate were much lower than normal counterparts. These reports
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would seem to mean that high cadmium concentrations and low zinc
levels in the prostate would place the prostate in a favourable
condition to develop cancer. It could also be that the levels
observed were the consequence of the cancer.
1.3 FACTORS AFFECTING PROSTATIC GROWTH IN HEALTH AND DISEASE
In order to control any disease or tumour of the prostate, it is
important to understand the factors involved in growth and the
mechanism by which they cause the disease. In recent years, the search
for information about factors regulating the growth of the prostate has
accelerated due mainly to progress made in the understanding of not only
steroid biochemistry but also the implication of stromal-epithelial
interaction and growth factors.
There is now a substantial volume of experimental data on the
factors that may influence the growth of the gland. These factors
will now be addressed:
a) Androgens: John Hunter (1786) established the relationship between
the testis and the development of male sexual characteristics. In his
first scientific report, he described an association between the presence
of testis and the secondary sexual organs: prostate, Cowpers gland and
seminal vesicles. About two and a half centuries later, Kutsher and
Wolbergs (1935) reported the presence of acid phosphatase activity in
the prostate gland. Gutman and Gutman (1938) established a relation¬
ship between acid phosphatase activity and the testis after observing
an increase m enz.ym.e. activity during puberty when testicular function is
established. This finding was confirmed by Gutman and Gutman (1939)
who observed an increase in prostate acid phosphatase activity after
injecting testosterone into prepubertal monkeys. These observations
were later strengthened by Huggins and Hodges (1941) who demonstrated
16
that a decrease in serum acid phosphatase activity in prostate cancer
following castration or injection with oestrogen correlated with improve¬
ment of clinical symptoms. But injection with androgens caused an
increase of both acid phosphatase activity and pain (Huggins eX oi,
RuO-
These studies on the prostate demonstrated that the growth and
maintenance of the gland were largely dependent on androgen availability
from the testis. The studies also laid the foundation for the endocrine
treatment of prostatic carcinoma. Castration and oestrogen therapy have
been the standard endocrine treatment of metastatic prostatic carcinoma.
Oestrogen treatment results in the reduction of plasma testosterone
levels to castrate levels, indirectly through inhibition of luteinizing
hormone (LH) output from the anterior pituitary , by a negative feedback
mechanism (Harper, Peeling and Cowley, 1976) or by a direct effect on
the biosynthesis of testosterone in the testicular tissue (Samuels et
al, 1964). But still the exact role of androgens in the prostate is
not clearly defined. Since the work of Huggins et al (1941), attempts
have been made to understand the actual role of testicular androgens
in the growth and development of the prostate. In a number of studies
describing the genesis of BPH various workers (Wojewski et al, 1965;
Siiteri& Wilson,1970; Schroedt & Foreman,1971; Robel et al,1971; Geller
et al, 1976) tried to find out the causal correlation between androgens
and development of BPH, but no evidence was presented after their
investigations in in vitro culture system to show the promotion of
prostatic cell proliferation by androgens. Habib et al (1979) looked
at testosterone and zinc levels in BPH and cancer of the prostate.
They concluded that biochemical classification of prostate tissue as
BPH was only acceptable provided that dihydrotestosterone and
testosterone ratio was greater than 1 (DHT : T > 1). This would seem
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to support direct androgen involvement in BPH development. It is
also consistent with the views of other workers (Webber, 1980; SymscJ,
1982; Sestili et al, 1983; Symsa.to^l'YSsjwho reported on direct
androgen stimulation. But recently McKeehan et al (1984)
thought that there was no direct androgen stimulation.
They showed that proliferation of the normal prostate epithelium in
serum-free media was enhanced by protein hormones and growth factors
but not by androgens. But very recently the growth rate and EGF
receptor activity of human prostate tumour cell line LN CaP has been
stimulated by androgens (Shuurmans et al, 1988). In earlier reports
Brehmer etal (1972) also indicated that androgens inhibited fibro¬
blastic cell proliferation.
The confusion regarding the status of androgens in the prostate
indicates that androgens per se are not able to cause BPH and CaP.
Their action must therefore be mediated via other factors. The
interaction between the stroma and the epithelium in the prostate
has been shown to be important.
One distinct feature of the human prostate is the capacity to
metabolise testosterone to a variety of metabolites of which dihydro-
testosterone is biologically the most important. The conversion of
testosterone to dihydrotestosterone is now believed to be an obligatory
step in the mediation of androgen action in the human prostate. The
widely accepted two step model for androgen action in the prostate is
as follows: Testosterone is converted in the cytoplasm into the more
potent androgen dihydrotestosterone (DHT) by membrane bound enzymes
5 reductase. The DHT then binds to the cytoplasmic androgen receptor
and the receptor DHT complex is translocated into the nucleus (King^MaUwa^^,
1974; Mainwaring, 1977; Jensen This model is in the process
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of modification. The demonstration that oestradiol receptor is
localised in the nucleus in the rat uterus and other tissues (King et
al, 1984) has led to the suggestion that the androgen receptor is
similarly restricted. This speculation was confirmed by Houston et
al (1985) who looked at 5reductase activities in human prostatic
nuclei and microsomes and concluded that the human prostatic tissue
contains only one form of 5^reductase which is located exclusively
in the nucleus. This finding is having important implications for
the mechanism of steroid action in the prostate. The new mechanism
would seem to be based on a one step model and not a two step model as
proposed. Regardless of the initial localisation of the receptor, it
is the binding of the nuclear steroid receptor complex to the acceptor
site in the prostatic chromatin possibly associated with the nuclear
matrix (Wang et al, 1984; ColvardwvlWllsoi(1984) that is assumed to
initiate specific gene transcription and/or replication,
b) Stromal Epithelial Interaction: From histological analysis, the
prostate is now known to be composed of both stromal and epithelial
elements. This knowledge has helped to elucidate the role of
androgens in the prostate and has extended the mechanism of action to
encompass stromal epithelial interaction. Findings of several
investigators have emphasised the importance of the stroma in the
control of prostatic growth development, maintenance and disease.
Cowan et al (1977) demonstrated that although testosterone was
metabolised in both the stroma and epithelium, the majority of the
5c<reductase activity resided in the stromal fraction. Subsequent
studies also showed that androgen receptor levels in the stromal-
epithelial compartments were not the same (Lahtonen et al, 1982).
These results suggest that the prostatic stroma plays an important role
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both structurally and biochemically in maintaining the normal function
of the prostate. Franks et al (1970) showed that epithelial cells
derived from hyperplastic prostate did not grow well in culture in
absence of stroma. Cunha (1972; 1973), Cunha et al (1980); Lasnitzki
and Mizuno (1980) and Cunha (1984) also established the importance
of the stroma in the development of the normal morphology of the
prostate and in normal function of the epithelial cells within the
gland. By tissue recombinant experiments consisting of murine
epithelium and mesenchyme from the embryonic urogenital sinus of
normal and testicular feminised mice, these workers demonstrated that
the mesenchyme was responsible for the androgen induced development of
the tissue. At this early stage of development of the prostate,
Shannon and Cunha (1983; 1984) showed that 5^-DHT receptors were
already present in the mesenchyme but were undetected in the epithelial
cells. These results confirmed that the stroma was in control of the
gland's growth and development. But other workers had previously
established the presence of androgen receptors in the prostate
epithelium (Coffey, 1974; Touchimaa and Niemi, 1974; Bruchovsky et al, 1975;
Stumpf and Sar, 1976; Liao, 1977; Krieg et al, 1981) . Administration of
androgens to castrated males elicited growth of the prostate and
specifically stimulated epithelial proliferation as judged by analysis
of thymidine labelling index and mitotic index of the epithelium.
Although the presence of androgen receptors has been established in
both the stroma and the epithelium, the evidence from the literature
suggest that the bulk of the receptors reside in the stromal compartment
(Franks et al, 1970; Cowan et al, 1977; Krieg et al, 1981; Lahtonen
et al, 1982; Shannon and Cunha, 1983; 1984). This follows that the
biological action of androgen is achieved by complexing with its
nuclear receptor in the stroma (Cunha, 1984; Wang et al, 1984;
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Colvardart,! 1*41^,1984; Houston et al, 1985). The result of the
complexing is the synthesis of specific growth factor or factors
which then proliferate the epithelial cells (McKeehan et al, 1984;
Smith et al, 1985).
It has been suggested that BPH is basically a stromal disease
which is made up of nodules consisting of a mixture of stromal and
epithelial elements (Franks, 1976). Furthermore, it has been shown
that in BPH, there is an increase in fibrostromal volume over the
volume of glandular elements in the normal gland of young males
(Bartsch et al, 1979).
c) Growth Factors: Growth is accompanied by change that results
from either an increase in cell size (hypertrophism) or cell number
(hyperplasticity). Various agents are involved in the growth
regulatory process. One group of such agents is referred to as
growth factors. They are molecules which have emerged as a major
subset of hormones that will probably far eclipse the more classical
endocrine polypeptide hormones. Polypeptide growth factors differ from
classical hormones by the method of transport to target cells.
Endocrine substances are transported to distantly removed target
cells, by means of the blood stream. Paracrine agents differ by
the fact that the released hormone or growth factor travels to its
target cell by diffusion. A third class, autocrine interaction,
described by Sporn and Todaro (1980) differ from paracrine in that
the target cell is the same as that actually producing the growth
factor. The three basic models are illustrated in Figure 5.
But the consensus of opinion is that the majority of polypeptide
growth factors act in a paracrine model (James and Bradshaw, 1984).
i) Mechanism of action: A clear picture of the mechanism
of action of any polypeptide growth factor is not available.
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Figure 5. Illustrating schematically, the endocrine,
paracrine and autocrine actions.
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AUTOCRINE
However, certain general characteristics common to the activity
of all polypeptide growth factors seem evident and these include:
initiation of the response by formation of a specific high
affinity cell surface receptor complex; generation of immediate
signal that is responsible for at least a part of the overall
mechanism; internalisation of both the ligand and its receptor,
largely through the mediation of clathrin-coated pits by
endocytosis; and the ultimate degradation of both the receptor
and ligand by the action of lysosomal enzymes. Although informa¬
tion continues to accrue regarding processes and events that are
stimulated by the interaction of growth factors with their
responsive cells, yet the basic signals that initiate long and
t&jrm effects are still not identified. For example, the
importance of internalisation of growth factor receptor complex
by endocytosis and the role of intracellular receptors as sites
for further activity or as messengers themselves, are not clearly
defined (James and Bradshaw, 1984).
ii) Growth Factor and Androgen Action: The view that
growth factors are the actual growth regulators in the prostate
has been supported by many workers. McKeehan et al (1984)
have shown that proliferation of rat prostate epithelial cell
populations was enhanced by protein hormones and growth factors
but not by androgens. Furthermore, the mitogenic effects of
prolactin and EGF on the rat prostate tumour have been published
(Smith et al, 1985). Tenniswood (1986) in an hypothesis
strengthened the work of Cunha et al (1986) by highlighting the
implication of growth factors in the mechanism of androgen action.
The nature of the growth factor or factors implicated is not
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known. This has therefore engaged the attention of many
biochemists and molecular biologists.
1.4 EPIDERMAL GROWTH FACTOR (EGF)
The literature has described a whole range of growth factors and
their receptors. But EGF is one of the best characterised mitogens
for the study of mammalian cell proliferation and/or differentiation.
Furthermore, its importance to biochemical research stems from the
fact that it has a potential role in human disease (Carpenter 2_t o-l, 'ITs)
EGF was therefore selected for this investigation.
a) Characteristics of EGF: EGF was discovered when fractions from
submaxillary glands not containing nerve growth factor (NGF) were
shown to induce premature eyelid opening and tooth eruption in the
new born mice (Cohen, 1962). EGF was soon isolated (Cohen and
Elliot, 1963) and its amino acid sequence determined (Savage et al,
1972). EGF isolated from human urine was found to be identical to
B- Urogastrone, a polypeptide inhibitor of gastric acid secretion
(Carpenter and Cohen, 1975; Gregory, 1975). EGF is mitogenic for
a variety of mesenchymal cells and epithelial cells in culture
(Carpenter and Cohen, 1975). EGF is a 6KDa polypeptide consisting
of a single chain of 53 amino acids with intrachain disulphide bonds
(Taylor et al, 1972). But a large protein precursor of 976 - 1217
amino acids was provided by Gray et al (1983); Scottet al, 1983);
Carpenter and Cohen (1984). They used the nucleotide sequence of
complete CDNA derived from a male mouse submaxillary gland DNA.
The molecular weight of the precursor was about 130,000 dalton.
Within this prepro EGF molecule were 7 EGF-like peptides.
At tissue and cellular levels EGF stimulates protein, RNA and
DNA synthesis (Carpenter and Cohen, 1979; Das, 1982; King and
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Carpenter, 1983). It also increases uptake of nutrients including
Ca++ (Sawyer and Cohen, 1981) and alters phospholipid metabolism
including phosphoinosityl (PI) turnover (Sawyer and Cohen, 1981;
Smith et al, 1983) and increases release of arachidonic acid
(Shupnika^Toskjic^Hti. Aoyagi et al, 1985).
In most tissues, there are two major classes of cell membrane
linked receptor systems which control cell proliferation. The best
characterised is mediated by production of cyclic AMP from adenylcyclase
which become activated by different mitogens. The less well character¬
ised system in which EOF is involved activates PI turnover, Ca++
mobilisation, cyclic GMP production and the release of arachidonic
acid (Aoyagi et al, 1985). This establishes a link between EGF, PI
and cell proliferation (Michell ( lct^i+-').
b) EGF Receptor: The biological action of EGF is thought to be
mediated by the interaction with its specific high affinity cell
-9
surface receptors with apparent dissociation constant (Kd) of 10 -
lO-1^ M (Hollenberg and Cuatrecasas, 1973; Carpenter and Cohen, 1975,
1979; Hollenbergiyh; Taketani and Oka, 1982).
The cell receptor for EGF is the best understood growth factor
receptor and has served as a paradigm for other growth factor receptors.
The receptor was first purified from A431 cells, a cell line derived
from a human squamous carcinoma which has a large number of EGF
receptors (Fabricant et al, 1977; Cohen et al, 1982; Kawamoto et al,
1983). The receptor is an integral 150 - 170 KDo^ membrane protein
exhibiting an extracellular binding domain that serves to bind the
ligand EGF, a transmembrane region and intracellular domain facing the
cytoplasm. The cytoplasmic domain exhibits the tyrosine Krkusa. function
and presumably binding sites for ATP phosphorylation substrates (Cohen
et al, 1980, 1982). In response to EGF the receptor is capable of
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autophosphorylation on tyrosine residues (Dailey et al, 1978; Gill
J-aScw, 1981). The endogenous kinase mediates tyrosine phosphorylation
but other kinases are thought to be responsible for phosphorylation
of serine and threonine. Figure 6 is showing a schematic representa¬
tion of the EGF receptor. EGF binding sites appear to be functionally
heterogeneous because a small portion of the EGF receptor binds ligand
with high affinity and a large portion binds with low affinity
(Kawamoto et al, 1983; Gregoriouo^Jl (^5., 1984). It is
believed that the small number of high affinity receptors are involved
in the generation and maintenance of the mitogenic signals. The
function of the low affinity receptors is not clear but it is now
known to be inhibitor of differentiation (Boonstra et al, 1985).
Binding of EGF to the receptor leads to a decrease in the receptor
density on cell surface (down regulation), as the growth factor
receptor complex is internalised into the receptosomes pending
subsequent degradation which precedes the generation of the mitogenic
signal (Pastan-i-Cohen, 1987). But a recent evidence
indicates that the EGF receptor complex is not degraded but recycled
back to the surface of the membrane (Teslenko et al, 1987).
c) The Truncated Receptor: The oncogene v-erb B of the avian
erythroblastosis virus (AEV) codes for a product homologous to a
portion of the EGF receptor. There is a striking homology between
EGF receptor and the deduced amino acid sequence of the v-erb B
oncogene product (Downward et al, 1984). The chief difference
observed is the absence of EGF binding domain in the retroviral
version. This remarkable finding established that the receptor
protein itself has the potential for transformation. A tyrosine
kinase activity was demonstrated for the v-erb B gene (Decker, 1985;
Gilmore et al, 1985). The v-erb B protein is truncated for the
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extracellular ligand binding domain of the EGF receptor but the
shortened cytoplasmic domain retains the protein kinase site
(Yamamoto et al, 1983). When activated by ligand the EGF receptor
is internalised whereas the v-erb B product in the absence of ligand
binding site remains at the cell surface. The kinase activity
associated with the v-erb B protein is constitutively expressed to
a "turned on" state regardless of the growth factor. The v-erb B
protein must reach the plasma membrane to be transforming (Schmidt et
al, 1985). Figure 6 is also showing the schematic representation
of the truncated EGF receptor. Oncogenes like v-erb B are capable
of causing carcinogenesis, because deletion of the gene from the viral
genome renders the virus incapable of causing cancer. 30% of trans¬
forming proteinsknown, including v-erb B oncogene product, have
tyrosyl kiV»<*s>a. activity (Gill*.^ kxw 1981; Hunter^-lCoo^ 1981).
In non-transformed cells phosphotyrosine represents less than 0.03%
of total phospho-.w>i*oacids, but in transformed cells this level is
increased approximately 30-fold (Sefton et al, 1980). Structurally,
the cytoplasmic portion of the EGF receptor has an average of 25%
homology to the kinase domain of several transformed proteins, but
95% homology has been observed with v-erb B product.
The identification of growth factors, oncogenes and their products
is shedding new light on the involvement of polypeptides in carcino¬
genesis. The mechanisms of oncogene activation are not fully
understood. This has therefore opened a way for cellular exploration
at the molecular level.
d) EGF in Carcinogenesis: Cancer cells appear able to take on
properties which allow them to escape from the controlling mechanisms
of their tissues of origin and to survive, independent of that tissue.
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Figure 6. Illustrating schematic representation
of the EGF receptor and the truncated






















Many lines of evidence have been produced to suggest that EGF is an
important growth factor implicated in the transformation and
proliferation of some neoplasms. For example, when EGF was added to
normal cells, it elicited certain responses which are associated with
neoplasia.
Many of these effects were reversed upon the removal of EGF
(Carpenter and Cohen, 1975; Westermark, 1976; Kirkland et al, 1979).
Furthermore, EGF has been found to enhance the carcinogenic effect of
methylcholanthrene in skin (Reynolds et al, 1965; Rose et al, 1976).
Some transformed cells produce transforming growth factor alpha (TGE^)
which interact with EGF receptors to stimulate EGF receptor autophos-
phorylation and achieve all the biological effects identical to EGF
(Todaro et al, 1980; Roberts et al, 1982; Anzano et al, 1983;
Carpenter et al, 1983). TGF*< will be described in detail under
Chapter 1.4 e (ii). EGF has been shown to suppress the immune system.
Immunosuppression is usually considered to permit cancer growth rather
than cause it. Injection of EGF one day before sheep red blood cell
(RBC) administration suppressed production of antibodies to the antigen.
It is believed that IgG response is more affected than 1^1 response.
IgG is more T cell dependent than Igjl. Helper T cell is suggested
to be the target of EGF induced immuno suppression. Furthermore,
delayed hypersensitivity response to 2, 4 dinitro fluorobenzene is said
to be caused by EGF. Salivary gland extract which contains EGF (Cohen,
1962) has been observed to cause atrophy of lymph nodes and the thymus
(Roberts et al, 1976). Finally, EGF enhances viral transformation of
cells. It produces effects similar to those produced by 12 - 0 tetra-
decanoylphorbol - 13 - acetate (TPA), a classic tumour promoter (Fisher
et al, 1979).
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e) Interaction of EGF, Protein KinaseC and Tumour Promoters
EGF may help to regulate its endogenous tyrosine kinase by
promoting Ca++ influx, phosphoinositol (PI) turnover, protein kinase C
activation and phosphorylation of receptor tyrosine kinase (Shupnik and
r"'1'1^,1982).
Tumour promoters such as tetradecanoylphorbol - 13 - acetate
(TPA) produce their effects on EGF receptor by their almost irreversible
_j
activation of protein kinase C and decreasing its need for Ca and
diacylglycerol (DG) (Nishizuka, 1984; Cochet et al, 1984; Friedman
et al, 1984).
TPA stimulates phosphorylation of the EGF receptor in the same sites
as purified protein kinase C (Hunter, 1984; Cochet et al, 1984; Iwashita
and Fox, 1984). Therefore, protein kinase C was found to be the major
binding site for TPA and other active phorbol esters as well as mediating
the actions of other chemically distinct tumour promoter (Nishizuka, 1984;
Friedman et al, 1984).
The consequence of either TPA or protein kinase C phosphorylating
the EGF receptor appears to be a decrease in its ability to autophos-
phorylate and inhibit EGF binding (King •
f) Other Growth Factors in Carcinogenesis: There are other growth
factors implicated in carcinogenesis, which transform cells through
different mechanisms. Two of such growth factors are (i) Platelet
derived growth factor (PDGF) and (ii) Transforming growth factor</-
( TGFpO : -
i) Platelet derived growth factor (PDGF): This is a major
mitogen in serum. It is synthesised in megakaryoc i"e.s (Chernoff
et al, 1980) packaged into platelets in granules and released
from platelets activated by thrombin or at sites of blood vessel
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injury (Witte et al, 1978; Kaplan et al, 1979). PDGF is
thought to bind to and initiate its biological function on
cellular substrates of the blood vessel wall. PDGF dimer is
composed of a 14 - 18 KDa A chain disulphide bonded to a
16 KDa B chain (Johnson et al, 1982). B chain is defined as
the product of thewc.-Ci'$> gene (Johnson et al, 198*1). The B
chain was found to have > 90% homology with the protein product
of the'V-cu^ oncogene P28 "v-ds" (Waterfield et al, 1983).
n * * wP28 v-cfiis the transforming protein of the simian sarcoma virus
(SSV), an acute transforming virus. The"v-ci's 'oncogene is
responsible for transforming and maintaining the transformed
state of SSV transformed cells. The protein encoded bye -ci^"
gene is shown to be nearly identical immunologically to PDGF.
ii) Transforming Growth Factory (TGFoQ: This was identified
when it was observed that transformed cell lines had reduced
numbers of binding sites for EGF (Todaro et al, 1976; Salomon
et al, 1987). It was later found to be due to an activity
secreted by the transformed cells, termed sarcoma growth factor
(after those cells had been transformed by murine sarcoma virus.)
(Delarco and Todaro, 1978; Anzano et al, 1983). The activity
was later isolated and is how known as TGF<^<. It has a mol.wt.
of 5.6 KDa. Amino acid sequence showed that it is a single
chain polypeptide of 50 amino acids with three disulphide bonds
in homologous positions (Derynck et al, 1984). TGFo< and EGF
have been shown to directly compete for binding to the EGF
receptor despite the 50% homology between EGF and TGFp<- (Derynck c-t oSf
1984).
TGF«* produces all the physiological responses expected of
EGF including precocious eyelid opening in new born mice (Smith
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et al, 1985). TGF^ has extensive sequence homomogy with EGF
and bincfeto EGF receptor. TGF«t< accelerates epidermal regenera¬
tion and healing of second degree burns. It has not so far been
demonstrated in non-neoplastic adult tissues and may represent
the embryonic form of EGF that is inappropriately expressed in
neoplastic cells.
g) EGF Receptor Levels in Normal and Cancer Cells: The development
of monoclonal antibody specific to the EGF receptor binding sites
(Waterfield allowed many investigators to combine the techiques
of radioligand assay (Carpenter and Cohen, 1975; 1979) and immunocyto-
chemistry (Guesdon et al, 1979; Delellis et al, 1979; Vcv-^ /iciordL.K oo-vri
Polc^K, 1983) to measure specifically, the receptors for EGF in many
normal and cancerous cells and tissues.
EGF receptor levels vary according to the cell type, the stage of
differentiation of the cell and the presence of other factors.
The receptor expression in cancer is higher than in normal counter¬
parts. Hendler402.^n«.(1984), Cowley et al (1986) observed higher EGF
receptor levels in human squamous cell lung cancers and squamous
carcinoma cell lines respectively than in normal cells. Furthermore,
some well differentiated tumours express higher receptor levels, whilst
poorly differentiated cancers express little or no receptors.
Libermann et al (1985), Ozanne et al (1985), Bradley et al (1986) observed
higher receptor levels in human glioblastomas, epidermoid malignancies
and human colon carcinoma cells respectively than in poorly-differentiated
counterparts. Overexpression of the EGF receptors has been associated
with gene amplification and rearrangement (Libermann et al, 1985), gene
translocation, amplification and rearrangement (Ozanne et al, 1985).
Furthermore, the presence of retinoic acid (Dicker and Rozengurt, 1979;
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Rees ex oi( i^TV; 1981) and glucocorticoid (Baker et
al, 1978) also increases EGF receptor levels. The influence of the
cell cycles on receptor level has been demonstrated (Robbinson et al,
1982). Loss of receptors in the poorly differentiated cancers is
mostly due to production of TGF (Todaro et al, 1980; Salomon et al,
1987), synthesis of v-erb B oncogene product (Downward et al, 1984) or
hormonal implication (Jia et al, 1985; Zachary and Rozengurt, 1985;
Traish et al, 1987). Furthermore, chemical transformation (Lee
Weinstein, 1978; Robbinson et al, 19 ; King( 1985) and cell
differentiation (Gospodarowicz etal,1978) have been shown to cause
loss of EGF receptors. Furthermore, receptor gene loss is also
implicated (Gamou et al, 1987). The development of the monoclonal
antibody to the internal domain of the EGF receptor allowed other
workers (Beguinot et al, 1985; Gullick et al, 1986; Berger et al,
1987) to search for the v-erb B oncogene product in the poorly
differentiated cancers. But these reports revealed absence of the
truncated receptors. Other reasons for loss of receptors are at
present unclear. In other tumours, the poorly-differentiated tissues
expressed more EGF receptors (Neal et al, 1985; Sainsbury et al,
1985; Yasui et al, 1988) than other histological grades of the
cancer. Whilst in some tissues, although an increase in receptor
level was observed in the cancer compared with normal, there was no
change in the receptor levels in the histological grades (Sakai et al,
1986; Hwang et al, 1986).
The presence of EGF receptors was also sought through the use of
crosslinking reagents which labelled the EGF receptor with
12G
I - labelled ligand, prior to SDS - PAGE electrophoresis.
The purpose of this was to demonstrate the molecular weight of the
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receptor which was usually in the range of molecular weight 150 -
170 KDa (Mukku t-SU^el, 1985) - To further understand the receptor
function, tyrosine specific kinase activity and other kinase activities
forming the inherent part of the receptor molecule were identified
through phosphorylation experiments (Mukku + 1985). EGF is
known to stimulate phosphorylation of substrates (Cohen et al, 1980;
King and Gates, 1985). The literature is full of information on EGF
receptor expression in normal and cancerous cells and tissues. The
general picture is that the receptor expression is low in normal cells
and tissues. But in cancer the pattern of receptor expression varies
according to the type of cell or tissue and the grade of differentiation,
some tissues expressing more in the well differentiated than the poorly
differentiated, whilst in other tissues the reverse is observed.
But there is no such information available on the human prostatic tissue.
h) Association of EGF and other growth factors with
the prostate:
Studies on growth factors associated with humans date back to
the late 1930s when it was observed that human urine contained a potent
inhibitor of gastric acid secretion (J Gray et al, 1939) and possibly
other antiulcer factors (Sandweiss et al, 1941).
However, Cohen (1962) isolated EGF from the submaxillary gland
of the mouse (Chapter 1.4), which Gregory (1975), Hollenberg and
Gregory (1976) showed was identical to urogastrone isolated
from human urine. The view that growth factors are the actual growth
regulators of the prostate led many workers to direct their attention
to identify the nature of the growth factor in the prostate. Identity
was sought through detection of the ligand or the receptor in the
prostate tissue, but most of the earlier investigators concentrated
on the detection of EGF in the gland. Elder et al (1978) were the
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first to investigate the human prostate for the presence of urogastrone
EGF using antiserum to the ligand in an immunocytochemical technique,
but this revealed the absence of fluorescence in the prostate with
antiserum to the ligand. On the other hand, Hirata and Orth (1979)
using radioimmunoassay technique, measured less than 1 ng EGF in the
prostate obtained from a 48 year old man at autopsy. This was the
first demonstration of EGF in the human prostate. In the meantime,
Jacobs and Lawson.(1980) demonstrated the presence of a growth promoting
factor in crude extracts of human prostate tissue prepared from BPH,
well differentiated adenocarcinoma and postpubertal prostate. This
was based on the original idea of Deming and Neumann (1939) who
suggested that a growth promoting substance produced by the prostate
might be the cause of BPH. Story et al (1983) undertook to compare
the BPH crude extract with EGF but after a number of studies involving
the interaction of the BPH extract and EGF with human cultured fibro¬
blast , they concluded that EGF and the extract did not recognise the
same receptor, and that the major growth factor activity of BPH extract
was not due to EGF. This report, coupled with the findings of Hirata
and Orth (1979) showed that there were more than one growth factors
present in the human prostate. It is also in line with the recent
suggestion that multiple growth factors were required to provide the
maximum stimulation of specific cell type and to provide the fine
tuning necessary for co-ordinated development, and to maintain tissues
in adult state (Walthallahd 1981; Leof et al, 1982; Sporn and
Roberts, 1988). See also Chapter 1.3 (cii).
The mechanisms by which the fine tuning effect is achieved by
the presence of multiple growth factors is not understood, but it is
suggested that the presence of one growth factor may modulate the
mitogenic activity of another growth factor. Transforming growth
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factor p stimulates the growth of certain fibroblasts in vitro in
the presence of PDGF but inhibits this effect in the presence of EGF
(Robertset «■ Similarly, PDGF decreases the affinity of EGF
receptor for its ligand (Bowen-Pope et al, 1983; Zachary iq-fcO -
In this regard, whether the activity of the BPH extract is PDGF-like
substance or not, is yet to be determined. This was undertaken by
Jinno et al (1986), who investigated the biochemical and physico-
chemical properties of the BPH extract. This revealed that it has a
multi-molecular form comprising three active components (80,000, 43,000
and 10,000 daltons). It is acidic and susceptible to heat and trypsin,
and is devoid of esteropeptidase. These properties make the BPH extract
different from other growth factors like EGF, PDGF, TGF and Fibroblast
growth factor. For example, EGF is heat resistant even to 100°C for
10 minutes and has esteropeptidase. PDGF and FGF are basic. The
characterisation makes the prostate growth factor (PGF) a separate growth
factor, probably working in concert with other growth factors in the
prostate. Examination of the activity according to prostatic disease
revealed that there was no difference between the levels of activity
in BPH and CaP, but there was a big difference (P<o.co<) between levels
in normal and BPH as well as CaP, BPH and CaP having more activity
than normal prostate. In the meantime, other workers searched for
the growth factor in prostates of other experimental models. Shikata
et al (1984) using immunocytochemical technique involving antiserum
to EGF, demonstrated the presence of the growth factor by observing
fluorescence in the guinea pig prostate with antiserum to the ligand.
Recently, Traishf IVctiz (1987) using radioimmunoassay method based on
the commercial EGF RRA Kit (Biomedical Technologies, Stoughton MA),
were able to demonstrate the presence of measurable amounts of EGF or
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EGF-like substance (5-10 ng/g tissue) in the prostate homogenate
from intact rats.
Furthermore, prostate derived growth factor(PrDGF) obtained from
the rat prostate was purified and partially characterised (Maehama et
al, 1986). When PrDGF was compared with other known growth factors
(EGF, PDGF, FGF, TGF^k. and TGFJ3) in chemical composition and biological
properties, it was found to be different, suggesting that PrDGF had
not been previously described, but it has a lot in common with TGF J3
with regard to molecular weight, presence of disulphide bonds, and
stability in heat and acid. Whether PrDGF is truly different from
TGF p requires further work to establish this fact. However, PrDGF
appears to be a growth promoting activity with the potential to mediate
some of the activities related to prostatic growth, development and
perhaps hyperplasia and neoplasia, but the search for EGF in the human
prostate had not been abandoned. Recently Gregory et al (1986), using
immunocytochemical method involving antiserum to urogastrone EGF, made
another attempt, after Elder et al (1978) to localise EGF in the human
prostate but again this revealed the absence of the ligand in the
human prostate.
This report is interesting. The immunocytochemical technique
using identical antiserum produced positive result in the guinea pig
prostate but the same technique failed to show evidence of the presence
of the ligand in the human prostate and this happened on two separate
occasions. This may be due to the low quantity of EGF in the human
prostate (less than Ing/g) (Hirata and Orth, 1979) compared to the
large quantity in the rat prostate (5 - 10 ng EGF/g) (Traish + Woti:z_
1987)- It is therefore reasonable to speculate that the positive
immunocytochemical result obtained in the guinea pig prostate was
probably due to the presence of a much higher quantity of EGF in the
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guinea pig prostate than the human's. The low level in the human
prostate might be below the detection limit of the technique.
Secondly, the fact that using radioimmunoassay technique, it was
possible to measure less than lng EGF/g showed that radioimmunoassay
technique was more sensitive to be able to pick smaller quantities of
the ligand than the immunocytoehemical method would be capable of.
Gregory et al (1986) then investigated the human prostate for the
presence of urogastrone EGF receptor using radio ligand assay technique
as described by O'Keefe et al (1974), but this technique also revealed
the absence of the EGF receptor. On the other hand, Traish + WoTiz.
(1987) using identical radio ligand technique was able to measure EGF
receptors in the rat prostate convincingly. This was a confirmation
of speculations made by previous workers that EGF receptors might be
present in the rat prostate (McKeehan et al, 1984; Smith et al, 1985).
Here again, the EGF receptors have been measured in the rat prostate,
but their presence could not be demonstrated in the human prostate.
Does this reflect a lower quantity of the receptors in the human
prostate than there is in the rat's? Or does it mean the receptors are
not present at all in the human prostate? To address these questions,
the author has decided to investigate again the human prostate for
the presence of the EGF receptors.
However, in another experiment, Gregory et al (1986) measured
large quantities of urogastrone EGF in the human prostate fluid using
radioimmunoassay method. When they compared the levels of the ligand
in BPH and normal prostatic fluids a clear-cut difference between the
two groups was revealed. The levels in BPH were half those found in
the normal age matched controls. This report was the first to
establish the presence of EGF in the human prostatic fluid, which is
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closely associated with the prostate tissue. The significance of
this finding has not yet been established. Probably successful
localisation of the receptors in the prostate may provide a link
between the ligand in the prostatic fluid and the prostate, since
the biological action of EGF is thought to be mediated via its
receptor (Hollenberga^vt. Co<*tf«_cR.scus>
^
Since the development of the monoclonal antibody specific to the
EGF receptor sites (Waterfield drai, no-one has used it to detect
the presence of the receptor in the human prostate. However, it has
been successfully used to measure EGF receptors in a whole range of
other tissues (Hendler + Oxanne., 1984) ; Sainsbury et al, 1985; Lau et al,
1988) to mention only a few, employing the technique of immunocytochemistry.
In the meantime, Koutsilieris et al (1987) also recently isolated
two peptides of molecular weights of 13,000 and 10,000 daltons from BPH,
but found that the 10,000 dalton mol. weight was only associated with
adenocarcinoma tissues. These peptides were also found to be different
from those previously described (Jinno et al, 1986; Maehama et al,
1986) in terms of biochemical composition. Both peptides were thought
to be implicated in osteoblastic metastasis since they increased cell
numbers and alkaline phosphatase activity in osteoblast-like cells
with effects on both growth and differentiation.
It would seem that the prostate is full of growth factors; some
are already known and characterised, others have just been described.
Their real identities and role in the development of BPH and CaP are
yet to be established. Yet new ones are still being added to the
list as the days unfold. This truly underscores the concept that
multiple peptide growth factors are necessary for tissue growth
(Sporn and Roberts, 1988). These authors further suggested that
the use of combinations selected from a larger number of peptide
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signalling molecules, increases the amount of information that can
be transmitted.
Another piece of work which related to the human prostate was
undertaken very recently by Shuurmans et al (1988). They showed
that androgens stimulated both growth rate and EGF receptor activity
of the human prostate tumour cell (LNCaP). This suggests the presence
of EGF receptors in the human prostate tumour cells. Furthermore,
using radio ligand technique, they demonstrated the presence of the
receptors in the tumour cells. But results obtained from such cell
lines should be interpreted with caution. These cell lines have been
passaged over the years. It is possible that they might have under¬
gone phenotypic changes which could have important implications on the
EGF receptor expression.
The literature suggests that EGF is present in the guinea pig
and rat prostate but in the human prostate, either it is there in
smaller quantities, or the ligand is not there at all. Furthermore,
the presence of the EGF receptors in the rat prostate has been demonstrated
by a number of biochemical techniques, but in the human prostate tissue
the presence of the EGF receptors is still not clearly defined. The
uncertainty about the presence of the receptors for EGF in the human
prostate tissue makes it difficult to assess the status of the ligand
in the gland.
However, the presence of both ligand and the receptor in the rat
prostate argues for a role for the ligand in the rat prostate. It is
therefore speculated that EGF may have a similar role in the human prostate
in view of the large quantities of EGF found in the human prostatic
fluid. But it is clear now, that even if EGF has a role in the prostate
with regard to BPH development, and CaP, it may not be functioning alone.
The existence of other growth factors, e.g. NGF in the guinea pig prostate
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(Harper et al, 1979) and the discovery of other mitogenic factors in
both the animal and human prostates, clearly shows that these other
peptides might be functioning in concert with EGF.
In the human, as well as the animal models, the only way to
demonstrate, if EGF has any role in BPH or CaP development, is to
establish the presence of the ligand or its receptor in the tissue.
It was therefore decided to combine the two techniques of immunocyto-
chemistry involving the use of the monoclonal antibody to the receptor
site now available and radioligand assay to localise and characterise
the EGF receptor in the human prostate. The author is of the opinion
that the use of the two techniques should provide adequate guarantee
for the detection of the receptors.
It is speculated that the level of EGF receptor or EGF expression
may vary from one tissue to another. In some cases, it is possible
that the quantity may be so low as to fall below the detection limit
of a less sensitive technique used. If this happens, that tissue may
be easily classified as negative.
The reasons for undertaking this research are now summarised
a) It is hoped that the localisation of the EGF receptors in the
human prostate tissue may provide a link between the large quantities
of urogastrone EGF in the human prostatic fluid and the human prostate
tissue. This, it is hoped, may also provide explanation for the high
and low levels of the ligand observed in normal and BPH prostatic
fluids respectively.
b) The improved sensitivity of immunocytochemistry, due to availability
of monoclonal antibodies to the external and internal domains of the
EGF receptor, prompted many workers to use the technique, involving the
monoclonal antibodies, to measure EGF receptors in a whole range of
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tissues. But the fact that no-one has used the technique involving
the monoclonal antibodies on the human prostate tissue, prompted the
author to use it to measure and localise the EGF receptor in the human
prostate.
c) Furthermore, EGF and its receptor are convincingly established in
the rat prostate. This argues for a role for the ligand in the rat
prostate. It is speculated that a similar role for the ligand may
operate in the human prostate. Localisation of the EGF receptor or
the ligand in the human prostate tissue may help to throw light on
this speculation. Further-more, it may also establish that EGF
activity is part of a whole array of mitogenic activities which are
now known to be also present in the prostate.
1.5 OBJECTIVES
1. To localise and characterise the epidermal growth factor
receptor in the human prostate by biochemical and
immunocytochemical methods.
2. To compare EGF receptor levels between BPH and CaP.
3. To correlate EGF receptor levels with the histologic
grades of CaP.
4. To demonstrate the presence of external and internal
domains of the EGF receptor.
5. To further characterise the receptor by chemical cross-








i) Na"*"^ [(Specific Activity 350 - 600 mCi/ml)
ii) []f 32P] ATP 3000 G'i / mmol
were purchased from Amersham International pic, Berks.
b) Non-Radioactive:
i) Hormones and growth factors:
Mouse epidermal growth factor (EGF)
Venonv nerve growth factor (VNGF)
were purchased from Sigma Ltd, Poole, Dorset, as electrophoreti-
cally pure and were used without further processing.
Human prolactic (hPRL)
Human follicle stimulating hormone (hFSH)
Human luteinizing hormone (HLH)
Human growth hormone (hGH)
h Insulin
were generously donated by NIADDK, Bethesda, MD USA.
ii) Enzymes and enzyme inhibitors:
Leupeptin , aprotinin, phenylmethylsulphonylfluoride, trypsin,
antitrypsin (soybean), chymotrypsin and deoxyrV ^ „ yiSt)
were supplied by Sigma Ltd.
iii) Other chemicals:
Disuccinimidyl £>vborate (DSS) was purchased from Pierce and
Warriner Chemical Co UK Ltd, 44 Northgate Street, Chester,
CHI 4EF.
Electrophoresis reagents and equipment were obtained from
Bio-Rad Laboratories Ltd, Caxton Way, Watford Business Park,
Watford, Hertfordshire, WD1 8RP.
The antihuman EGF receptor monoclonal antibody (EGF-R1) was
a generous gift from Drs M.D. Waterfield and P. Bennet of
Imperial Cancer Research Fund Laboratories, London.
Monoclonal antibody to the cytoplasmic domain of the EGF receptor (MA.BF4)
was also a generous gift from Dr W. Gullick, Imperial Cancer
Research Fund Laboratories, London.
Normal rabbit serum was obtained from Scottish Antibody
Production Unit, Carluke, Lanarkshire.
Human urogastrone was purchased from Sigma Ltd and was
used without purification.
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Peroxidase conjugated antiraouse immunoglobulin was from
Daka Ltd, Glostrup, Denmark.
Diaminobenzidine (DAB) and Harris haematoxylin stain were
obtained from BDH Chemicals Ltd, Poole, Dorset.
All other reagents were of analytical grade except bovine
serum albumin ((BSA) fraction V) which was obtained from
Sigma Ltd.
2.2 a) BUFFERS (GENERAL)
The following buffers were used throughout the investigation:-
i) Buffer A: Containing Tris (10 mmol/L), EDTA (l.mmol/L), EGTA
(Immol/L), sucrose (0.25 mol/L) and phenylmethylsulphonyl-
fluoride (PMSF) (0.05 mmol/L. pH 7.4).
ii) Buffer B: Containing Tris (10 mmol/L), sodium chloride (0.9% w/v)
and BSA(0.1% W/v) PH 7.4.
iii) Buffer C: Containing Tris (100 mmol/L) and MgClp (4 mol/L) pH 5.8.
iv) Buffer D: Containing Tris (25 mmol/L) MgCk (10 mmol/L) charcoal
(0.3% w/v) and dextran (0.03% ) pH 7.5.
v) Buffer E: Containing Na2HP04. 2HX0,(0.05 mol/L), NaH2P04. H^O.
(0.05 mol/L) and NaCl (0.9% w/V) pH 7.4.
vi) Buffer F: Containing Tris-HC.l (10 mmol/L) pH 7.4.
Note: The half life of PMSF in aqueous solution is about 30 minutes.
For this reason a solution of PMSF in absolute alcohol was made
up on the day of the experiment and added in appropriate amount
to the buffer to give 0.05 mmol/L final concentration.
b) ELECTROPHORESIS: Buffers and Reagents
i) 30% /krylamide containing acrylamide 30g, bisacnjlaimide 0.85,
distilled water 100 mis.
ii) Resolving gel buffer containing Tris HC1 (3M) made up of
Tris (36.8g)I fl HCl (48 mis) , water (100 ml) pH 8.8.
iii) Stacking gel buffer containing Tris-HCl (0.5M) made up of Tris
(6.0g), | ri HCl (48 mis), water (40 ml), pH 6.8.
iv) Electrophoresis buffer containing Tris (6g), Glycine (28.8g),
sodium dodecylsulphate (SDS) (2.0g), water to 2L, H 8.5.
Preparation of gels
v) Stacking gel 3% (20 ml volume)
Acrylamide 2ml
Stacking gel buffer 5ml
10% SDS (not added)
Water 13 ml
TEMED 80 ml
lojoAmmonium persulphate 120 jul
48















5% J3 - mercaptoethanol
0.05 bromophenol blue




0.1% brilliant blue R 250 (W/V) in 20% methanol and 10%
glacial acetic acid mixture.
Destaining solution
20% methanol and 10% acetic acid mixture.
Acrylamide 15 mis
Resolving gel buffer







NaCl 128 nM 0.748g
KC1 5mM 0.037g
MgSO, .7HO 1.3 nM 0.032g
Presence of Ca++ (1.3 nM) is optional.
OTHER BUFFERS AND REAGENTS
Dissolve in 100 mis
water and pH to
7.4 using IN NaOH
Michaelis Veronal acetate buffer pH 9-2
Sodium acetate trihydrate 9-7g
Sodium barbitone 14.7g
Distilled water 500 mis
Formaldehyde 10 drops
To above add 4M HC1 dropwise to bring pH to 9-2.
Napiitkol ASBI phosphate solution:- Dissolve 0.l4g of napWind
ASBI Phosphate in 2 ml of dimethylformamide (DMF).
0.05 M Levamisole solution:- Dissolve 0.24g levamisole in
20 mis of distilled water.
Alkaline phosphatase chromogen :- To 10 mis of Michaelis
Veronal buffer pH 9.2 add:
5 mg fast red ITR
200 ul 0.05 M Levamisole
Mix and add 1 drop of nap Wind ASBI phosphate in DMF
Mix well and filter onto slides
Incubate 10 - 20 minutes at room temperature
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Immunoperoxidase staining: ■
Preparation of 2nd antibody: Rabbit antimouse peroxidase
conjugated immunoglobulin (RAMPC) -
■¥- jgt
1720 ul NRS/TBS 1/6 dilution
80 " RAMPC
200 " TBS containing 2mg |gG
NRS = Normal rabbit serum
TBS = Tris buffered saline
50
2.3 METHODS
Iodination: The method selected involved the use of a water
insoluble reagent 1, 3, 4, 6 - Tetrachloro 3o<. 6,^ di phenyl glycouril
Clodoqen1) first described by Fraker and Speck (1978) as a reagent
for iodinating proteins and cell membranes. It offers many
advantages over chlortamine T and lactoperoxidase methods.
a) Principle; 'Iodov " usually coated on the inside of reaction
tubes mediates rapid iodination in the solid phase with aqueous solu¬
tions of I~ and proteins.
b) Preparation of coated tubes: "iodoqe-n* reagent dissolved in
methylene chloride or chloroform at a concentration of 150 jug/ml was
pipetted into plastic Eppendorf tubes in 200 jul aliquots. Each tube
was placed under a gentle stream of nitrogen gas with hand warming
until all the methylene chloride was evaporated, leaving a coating of
"iodo'^n" reagent on the inside of the tubes. Coated tubes were
stored at —20°C until required.
c) Iodination procedure: Into the iodogen coated tube was
pipetted 10 ug EGF contained in 100 jul of buffer B. 500 pCi/5hl of
125 125
Na I was used. The mixture of Na I and EGF was whirl-mixed,
incubated for 20 minutes and purified by column chromatography as
described below.
d) Purification (by Column Chromatography): A chromatography
column (1 x 46 cm) was packed with Sephadex G-50. 5g of .Sephadex G-50
was soaked in 50 ml buffer E and was allowed to equilibrate overnight
prior to the packing.
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The mixture of Na I and EGF was transferred to the column which
was mounted on a retort stand. The reaction vessel was washed twice with
buffer E and the washings added to the column.
e) Collection of fractions: Fractions of 1 ml/2 minutes were
collected from the column into glass tubes, vsin^ a fharmacia fraction
collector programmed to collect 1 ml fractions (Fraction Collector
Frac 300 Pharmacia Fine Chemicals).
f) Measurement of fractions: Each fraction was counted on a
gamma counter (Crystal II Multidetector Gamma System Model 5412
efficiency 84%). ' When the unit counts obtained in each tube were
plotted against the tube numbers, it was revealed that three distinct
peaks were eluted, namely A, B, C, with A being the first to be eluted.
Furthermore, binding studies with the three peaks demonstrated that
the highest binding was achieved using peak B. Peaks A and C produced
little or no binding at all. Peak B was therefore always kept for
binding studies.
The percentage bound was calculated after precipitation with
trichloroacetic acid. The final specific activity varied between 30
and 70 uCi/ug.
2.4 PROTEIN DETERMINATION: Protein determination was by the method
of Bradford (1976).
a) Reagents: Coomassie Brilliant Blue G (100 mg) was dissolved
in 50 ml of 95% (v/v) ethanolic solution. To this 100 ml of phosphoric
acid 85% (v/v) was added and mixed. The solution was made up to 1L with
distilled water and finally filtered through Whatman paper to remove
insoluble material.
b) Bovine serum albumin (BSA) standard solution: A solution of
BSA in distilled water(approximately 1 mg/ml) was made and its
absorbance read at 280 nM, using a Pye Unicam (Model 550 UV/VIS)
spectrometer which was zeroed with distilled wateriaa quartz, cuvette:
The concentration of the BSA solution was adjusted to give absorbance
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reading of 0.650 units, corresponding to a protein concentration of
1 mg/ral. Aliquots of this solution were stored at -20°C until
required for use.
c) BSA calibration curve: 20 ul amounts of BSA standard
solutions (0-80 jag) were dispensed into standard tubes. 5 mis of Bradford
reagent were added to each tube and the contents vortexed. The
spectrophotometer was zeroed(with Ojig BSA) and the contents of the
tubes read for absorbance at 595 nra. Absorbance values obtained for
each tube were plotted against protein concentration.
280 nm wave-length is normally used to measure amino acids with
phenolic group in txsWxcUrA. solution, whilst 595 nm is used to measure
peptide bonds in the test solution.
2.5 PRELIMINARY EXPERIMENTS;
a) Iodination peaks: Figure 7 skew's a typical pattern
obtained after plotting unit counts/tube against fraction number as
detailed in 2.3 (a) - (1). Three distinct peaks were revealed
(/.,E>o.NiC\After using an aliquot from each peak for binding studies,
only peak B showed high specific EGF binding. Peak B was therefore
kept at 4^C for subsequent use.
b) Protein standard calibration curve: Figure 8 sUowjs. «
typical pattern of protein standard calibration curve. When concen¬
tration against absorbance was read at 595 rovi, it was found that the
curve was linear over a protein range of 0 - 80 jig BSA.. n excess of
80 jag BSA, a plateau forms. Details of the technique are described under




10 jig EGF was iodinated with 500 uCi of
125
Na I in iodo-gen coated tubes. The iodinated






Increasing amounts (10 - 80 jug) of a BSA
solution (1.0 mg/ml) were mixed with Bradford




2.6 SELECTION AND PREPARATION OF TISSUES AND STORAGE
a) Prostate (General procedures); Human prostate clinically
and histologically diagnosed as hyperplastic or malignant was removed
by transurethral resection (TUR) or open prostatectomy and trans¬
ported to the laboratory in ice-cold saline (0.9% w/v). The tissue
. was washed three times with Tris-Hci buffer -pH 7.4 (buffer F) and
blotted dry with tissue paper. Prostatic tissue removed by open
prostatectomy was cut into 2 gm blocks and then divided into 2-3
blocks per glass universal bottle. All tissues were snap frozen
in liquid nitrogen and stored at -70°C until required. In the case
of TUR all burnt areas of prostate chips were carefully removed and
only the clean juicy tissues not affected by resection loop were
stored.
b) Prostate: Selection of benign prostatic hyperplasia (BPH)
and cancer of the prostate (CaP) tissues:
Separate prostate specimens were taken from 18 patients with
BPH, and 19 patients with CaP. None of the patients from whom the
tumour samples were obtained received chemotherapy or radiation prior
to the removal of the tissues. Histopathologically the cancerous
specimens consisted of 4 well differentiated, 5 moderately differen¬
tiated and 10 poorly differentiated tumours.
Grading was carried out by a single pathologist according to the
Gleason system (Gleason, 1966).
The specimens were immediately frozen in liquid nitrogen and kept
at -70°C pending analysis.
c) Placental tissue: Term human placenta from spontaneous normal
deliveries were brought to the laboratory on ice. The tissues were
scraped off from the underlying blood vessels and repeatedly washed
with chilled physiological saline to remove blood. It was either
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used fresh, or snap frozen in liquid nitrogen and kept at -70°C.
d) Plasma: Preparation: Blood drawn from patients diagnosed with
benign prostatic hyperplasia was collected in containers with
coagulant and delivered to the laboratory on ice. The blood was
transferred to low speed centrifuge tubes and cells removed at 800 x g
for 15 minutes. The clear supernatant (plasma) was aspirated and
divided into 1 ml aliquots for storage at -20°C.
2.7 PREPARATION AND HOMOGENISATION OF TISSUE
a) The procedure is the modified version of the method
described by Hock+tto(.W*W^(ns&) and Mukku+StaiM^i. (1985) and Sainsbury
et al (1985).
Briefly, about 1 - 2g tissue was washed in buffer A, blotted dry
and cut into small pieces with scissors. Unless specified, all
procedures were carried out at 4°C. Preliminary dispersion of the
tissue was carried out on a microdismembrator (B. Braun, A.G. Melsungen
FRG) for 20 seconds in a prechilled teflon container. The tissue was
further homogenised in 3 vols of buffer A using Ystral homogeniser
(Scottish Scientific Instruments CmK-e, Ltd, Edinburgh) for two periods
20s and 15s respectively at position 6 with lmin cooling intervals.
The homogenate was subsequently filtered through a metal strainer and
the filtrate dispersed into 10 ml capacity polycarbonate centrifuge
tubes (Sorva.ll, Herts, U.K.) which were loaded in an angled T865.1 rotor
(Dupont Instruments, Herts, U.K.). Ultracentrifugation was carried
out at 105,000 xg for 40 minutes. The resultant pellet (total parti¬
culate fraction) was resuspended in buffer A and dispersed further in
a glass Bounce homogeniser using 50 strokes with the loose fitting
pestle followed by a second ultracentrifugation at 105,000 x g for
20 minutes. The resultant pellet was suspended in buffer B followed
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by 10 strokes with the tight fitting pestle. The protein concentra¬
tion of the final particulate fraction was measured by the method of
Bradford (1976). The protein concentration in the
was then adjusted to 1 mg and stored at -70°C.
b) Method of membrane preparation for molecular characterisation
of the EGF receptor
i) For crosslinking experiments: The method was based on the
technique described under 2.7(a) with slight modifications.
Briefly, homogenate preparation was centrifuged at 800 x g
for 10 minutes. The supernatant was saved. The pellet was
resuspended in buffer B and the centifugation process repeated.
The two 800 x g supernatants were combined and centrifuged at
105,000 x g for 60 minutes. The pellet was suspended in buffer B and
protein concentration adjusted as described under 2.7(a). 1ml aliquots
containing 1 mg protein were stored at -70°C for subsequent use.
ii) For phosphorylation experiments: Homogenates designed for
phosphorylation experiments were stored in 1 ml aliquots
containing 6 - 8 mg protein at -70°C.
c) Subcellular fractionation: Subcellular fractions were prepared
according to the method of Leake et al (1983) with slight modification.
Briefly, prostate homogenate was prepared as described under
2.7(a). • The homogenate was
centrifuged at 800g for 20 minutes to obtain a crude heavy pellet.
The supernatant was also centrifuged at 15,000g for 20 minutes to
obtain the mitochondrial pellets. The supernatant resulting from
this was centrifuged at 105,000g to obtain a pellet for the micro¬
somal fraction and the 105,000g supernatant fraction (cytosol).
The pellets were reconstituted in 1 ml of buffer B and were either
used immediately or stored at -70°C until required.
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2.8 ASSAY OF TISSUE PROTEIN
This was based on methods of Bradford (1976) and Mukku-t ianc.el O'vss)
Equal volumes of particulate fraction and 2N NaOH were boiled for
15 minutes. The mixture was diluted with on e»uai volume of distilled
water and allowed to cool. 20 pi of mixture was added to 5 mis of
Bradford reagent and mixed. 20 pi of standard solutions containing
0 - 80 ug protein were added to 5 mis of Bradford solution and mixed.
The spectrophomoter was zeroed using 20 pi distilled water and 5 mis
Bradford reagent. A calibration curve was constructed using the
absorbance at 595 mi against standard protein concentrations.
The value of the homogenate protein suspension was read off the
standard protein calibration curve described under 2.4(c).
2.9 125I-EGF BINDING WITH BPH
Binding of EGF was determined by a modification of the methods
of Carpenter and Cohen (1975; 1979), Sainsbury et al (1985) and Mukku txv>JL
SW«lL(1985).
Briefly, 100 pi homogenate samples were incubated with 100 ul
125 -9
I-EGF solution at a one point concentration in the 10- M range
in the presence and absence of 50-fold excess unlabelled EGF.
The final volume of the incubation mixture was 400 jul made up of
200 pi buffer B without unlabelled EGF and 100 pi ^2^I-EGF and 100 ul
sample. Incubation took place at 4°C, 25°C and 37°C respectively.
The reaction was terminated after 40 minutes by adding 1 ml cold (4°C)
buffer B. The samples were harvested by filtration under reduced
pressure on glass microfibre filters (Whatman GF/A, Whatman Ltd,
Maidstone, Kent) and rapidly washed with aliquots of buffer B.
The radioactivity retained by the filter was measured on a gamma
counter (Crystal II Multidetector Gamma System, Packard Co) with an
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efficiency of 84%. The specific binding was calculated by subtrac¬
tion of non-specific from the total binding.
2.10 SEPARATION OF SPECIFIC EGF BINDING FROM NON-SPECIFIC
Experiments described in this section were aimed at selecting
suitable technique for separating specific binding from non-specific.
The techniques are now described:-
a) Filtration and washing.
b) Filtration.
c) PEG precipitation: Aspiration and pouring.
d) PEG precipitation: Centrifugation.
125
a) Effect of filtration and washing on: Binding of I-EGF
to BPH particulate fraction: This was based on the method described
under 2.9.
Briefly, four 100 pil aliquots of particulate fraction were
125 -9
incubated with I-EGF in the 10 M concentration range in the
presence and absence of 50-fold excess unlabelled EGF at 37°C
for 40 minutes. At the end of the incubation, the reaction was
terminated by the addition of 1 ml cold (4°C) buffer B to each of
the four incubation mixtures. The samples were harvested by
filtration under reduced pressure on glass microfibre filters
(Whatman GF/A, Whatman Ltd, Maidstone, Kent). Thereafter radio¬
activity retained on the filter paper was washed once, twice, thrice
or four times using 1 ml buffer B in each case. The final radio¬
activity retained on the filter paper was measured on a gamma counter.
The specific binding was calculated by subtraction of non¬
specific binding from total.
Relationship between specific binding and the effect of washes
on pellet retained on filter was established.
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b) Filtration technique and polyethylene glycol (PEG)
precipitation technique compared
The filtration method is described under 2.9.
The PEG technique is a modification of the method of Hwang
et al (1986). The receptor binding assay was essentially the same
as described under 2.9.
125
Briefly, after an incubation of I-EGF with prostate particulate
125
fraction, the I-EGF receptor complex was precipitated with 1 ml 20%
PEG in buffer B at ^°C and allowed to stand for 10 minutes. The
mixture was centrifuged at 3000 rpm for 20 minutes and the pellet
washed once with 10% PEG and 0.05% BSA and centrifuged again as before.
The bound radioactivity retained in the pellet was measured by a gamma
counter.
Relationship between the level of specific binding obtained by
the filtration technique and the PEG method was established.
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c) PEG precipitation methods of removing free I-EGF
investigated. Pouring compared with aspiration
The receptor binding assay was the same as described under
125
2.9. At the end of the incubation period, the I-EGF participate
fraction bound complex was precipitated by 20% PEG and centrifuged.
In one set of experiments the supernatant was poured off
touching the tip of the reaction tube on a tissue.
In another set of experiments the supernatant was aspirated
off using a venturi pump which provided a negative pressure.
The process was repeated after washing the pellet once with 10% PEG.
Bound radioactivity retained by each method was measured on a gamma
counter.
Comparison between the level of specific binding achieved by
the pouring technique and the aspiration method was made.
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d) PEG precipitation: duration of centrifugation
The receptor binding assay was identical as described under
121
2.9. The I-EGF bound complex was precipitated using 20% (w/v)
PEG in buffer B. The mixture was centrifuged at 3000 rpm for 5, 10,
15, 20, 30 and 45 minutes in 6 separate experiments. After washing
the pellets with 10% (w/v) PEG and 0.05% BSA the mixture was again
centrifuged at 3000 rpm, for the same periods of time, and supernatant
again discarded. Specific radioactivity retained after each period
of centrifugation was measured on the gamma counter.
Relationship between specific binding and duration of centri-
125
fugation of I-EGF bound complex was established.
2.11 VALIDATION OF THE ASSAY FOR EGF RECEPTOR
a) The human placenta was used because it is a tissue known to
contain EGF receptors (Hock-fHolU^Lcv^SO; Ramani et al (1986).
i) Measurement of EGF urogastrone binding: The binding method
was based on modifications of the methods of Hock* fe'.UwU ,(1980);
Sainsbury et al (1985); Ramani et al (1986); Hwang et al (1986)
Briefly, placenta 105,000g particulate fractions were incubated with
125 . -9
I-EGF solution at one point concentration in the 10 M range
in the presence and absence of excess unlabelled EGF. The
final volume of the incubation mixture was 400 Ail, made up of
125
200 pi buffer B, with or without unlabelled EGF, 100 Jul I-EGF
and 100 pi sample. Incubation took place at 37°C for 40 minutes
and the reaction was terminated by the addition of 20% poly-
1 PS
ethylene glycol (PEG) in buffer B to precipitate the I-EGF
receptor complex, at 4°C for 10 minutes. The mixture was
centrifuged at 3000 rpm for 20 minutes and the pellet washed
once with 10% PEG and 0.05% BSA and centrifuged again as before.
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The supernatant was aspirated each time. The bound radio¬
activity retained in the pellet was measured on a gamma counter.
Specific binding was calculated by the difference between total
binding and non-specific binding.
ii) Saturation studies: Placental membrane aliquots were
125
incubated with increasing concentrations of I-EGF (0.5 -
12nM) in the presence and absence of excess unlabelled EGF.
After 40 minutes incubation at 37°C and PEG precipitation to
separate bound complex from free, the specific binding
was calculated as above, i.e. by the difference between total
and non-specific binding.
iii) Scatchard plot analysis: Data obtained from the saturation
studies outlined above was used in calculating the dissociation
constant (Kd) and estimating the number of binding sites..,of the
receptor by the method of Scatchard (1949).
iv) The outcome of the validation experiments: TABLE 1 indicates
that the human placenta contains a high level of EGF receptors,
as demonstrated by the level of specific binding/mg of protein.
v) Saturation studies: Human placenta: Figure 9 demonstrates
the relationship between specific binding and concentration of
125
I-EGF. It is observed that saturation of the binding occurs
125
from 6.0nram/ of I-EGF concentration which is indicated by
plateau formation.
vi) Scatchard analysis on placenta binding: Figure 10 shows
the Scatchard plot obtained from the saturation analysis, a single




EGF BINDING TO HUMAN PLACENTA
The method of the assay was as described
under section 2.11(a).
125
6.0 run I-EGF was incubated with placenta
particulate fraction (1 mcj protein/ml) in the
presence of 50-fold excess unlabelled EGF.
Non-specific binding was determined by running
a parallel assay in absence of unlabelled EGF.
Specific binding was determined after PEG
precipitation and subtraction of non-specific
from total binding.
Values were means of four different


























Saturation Studies: Human Placenta
125
Briefly, I-EGF in a range of concentrations
from 0.5 - 12renol/L were incubated with placenta
particulate fraction in the presence and absence of
unlabelled EGF at 37°C for 40 minutes.
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Separation of I-EGF bound complex from free
and subsequent calculation of specific binding was
essentially as described under 2.11(a)(i).
Values were means of 4 different









Seatchard analysis on placenta binding
Data obtained from the saturation studies
as described under section 2.11(a)(ii) was used in
calculating the dissociation constant (Kd), using
the method of Scatchard (19^9).
Values were means of 4 different





These experiments demonstrated that the I-EGF binding
technique was working well.
b) Binding with human plasma
100 p "^I-EGF in the 10~^M concentration range was
incubated with 100 pi of plasma diluted with buffer B to give 1 -
5 mg/ml protein in the presence of excess unlabelled EGF. Non¬
specific binding was determined by running a parallel assay in the
prx^.pnce Df unlabelled EGF. Specific binding was calculated by
subtracting non-specific from total binding as described under
section 2.11.
TABLE 2 indicates that no specific binding was observed
125
when I-EGF reacted with human plasma.
2.12 CHARACTERISATION OF THE EGF RECEPTOR
After the selection of a suitable method for separating
specific binding from non-specific, it was next decided to characterise
the EGF receptor by the following biochemical techniques described in
this section:-
a) Subcellular distribution of the EGF receptors in BPH
Subcellular fractions were prepared according to a modified
version of the method of Leake et al (1983) and this is detailed in
section 2.7(c).
Briefly, prostate homogenate was centrifuged at 800g for
20 minutes to obtain crude heavy pellet. This was followed by
centrifugation of the supernatant at 15,000g for 20 minutes to obtain
the mitochondrial pellet. Finally, the supernatant resulting from
this was spun at 105,000g for 40 minutes to obtain the microsomal
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TABLE 2
EGF BINDING TO PLASMA
TABLE 2 indicates that no specific
125
binding was observed when I-EGF reacted
with human plasma.
Values were means of 4 different
specimens, each analysed in duplicate.
Bound complex was separated from free











pellet and cytosol. Each pellet was reconstituted in 1 ml
buffer! receptor binding. 100 pi aliquots of the resuspended
pellets, (i.e. 800g, 15,000g, 105,000g) and the cytosol were
125 -9
incubated with 100 pi I-EGF in the 10 M concentration range
in the presence and absence of 50-fold excess unlabelled EGF.
125
I-EGF bound complexes were separated by PEG precipitation and
centrifugation as described under Section 2.12.Specific binding
shown by each fraction was calculated by ike. difference between non¬
specific and total binding.
b) Effect of protein concentration on receptor
estimations:
Protein concentration in the BPH particulate fraction was
measured as described under section 2.8.
Briefly, particulate fraction suspension was adjusted with
buffer B to give protein concentrations in the range 0.1-8 mg/ml.
100 pi of suspension containing each protein concentration was
125 -9
incubated with I-EGF in the 10 M range concentration in
the presence 50-fold sixcjess cx^. unlabelled EGF for 40 minutes
at 37°C.
Non-specific binding was assessed by running parallel
incubations in the absence of unlabelled EGF. Specific binding
was calculated by subtracting non-specific binding from total.
Relationship between radioligand uptake and particulate
fraction protein concentration was established.
125
c) Effect of time and temperature on binding of I-EGF
to BPH particulate fraction:
EGF receptor binding assay was essentially as described under
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2.11 and in this report.
125 -9
Briefly, I-EGF in the 10 M concentration range was incubated
with total particulate fraction (105,000g pellet) prepared from human
BPH. ioojuI aliquots of the pellet suspensions (lmg/ml protein) were incubated in the
presence and absence of 50-fold excess unlabelled EGF at 4°C, 25°C
and 37°C for a period ranging from 0 - 360 minutes. Specific binding
obtained for each temperature and time were calculated after separation
125
of I-EGF bound complex from free and counting on gamma counter
(2.11).
Relationship between the level of binding achieved in relation to
time and temperature was established.
125d) Dissociation of particulate fraction bound I-EGF in the
presence and absence of excess unlabelled EGF in medium of
incubation mixture:
100 jul aliquots of particulate fraction (1 mg/ml protein)
125
were incubated with I-EGF as described under 2.11. The unbound
125
I-EGF was removed by centrifugation at 3000 rpm for 20 minutes.
125
The pellets containing bound I-EGF were resuspended in 100 Jul
buffer B. Samples were diluted 4-fold with buffer B containing no
unlabelled EGF or 50-fold excess unlabelled EGF and then incubated
for indicated lengths of time at 37°C up to 180 minutes. The
controls were precipitated with PEG immediately after dilution and
bound and free separated. The specific binding in this tube was
considered 100%.
This method was based on the method of Ramani et al (1986) .
e) Saturation analysis: The method was based on modification
of the technique described under 2.11(a) (t0.
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Briefly, the binding assay was performed using I-EGF over a
range of 0.5 - 24 nvnol/L and BPH particulate fraction (1 mg/ml protein)
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in the presence and absence of 50-fold excess unlabelled EGF at
125
each concentration of I-EGF.
After PEG precipitation and counting, specific binding at each
125
concentration of I-EGF was obtained by subtracting the non-specific
binding from total.
125
Relationship between specific binding and concentrations of I-EGF
was established.
f) Scatchard analysis: Data obtained from the saturation studies
detailed under 2.12(e) was used in calculating the dissoc: .tion constant
(Kd) and estimating the number of binding sites of the receptor protein
by the method of Scatchard (19^9).
g) Competition studies: "^"*I-EGF8.0 nmol/Lwas incubated with 100 pi aliquots
of BPH particulate fraction (1 mg/ml protein) in the presence and absence
of 250 - 3000 ng/ml of the following unlabelled competitors: human
growth hormone (h GH) h FSH, human prolactin, human insulin, human LH,
mouse EGF (mEGF), veroiv> nerve growth factor at 37°C for 90 minutes.
At the end of the incubation, bound complex was separated from
125
free I-EGF and specific binding was calculated as described under
2.11 after counting on gamma counter.
The degree of inhibition of specific binding by each competitor
was established.
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h) The effect of pH of incubation media on I-EGF binding
to BPH particulate fraction:
The method was a modification of the method of Ramanie"< 11 >yL).
Briefly, 100 ajI samples of particulate fraction (1 mg/ml
protein) were incubated for 90 minutes at 37°C with 8 nM "'"^I-EGF in
the presence and absence of 50-fold excess unlabelled EGF in media of
various pH values.
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10 mM Tris-HCl was adjusted to give pH values of 2 - 11.
The particulate fractions incubated at pH 7.4 served as controls.
At the end of the incubation period, bound complex was separated
from free by PEG precipitation and aspiration of supernatant
as described under Chapter 2.11(a)(i) described by Hwang et
Specific binding was subsequently calculated by the difference between
total and non-specific binding.
Relationship between specific binding and pH of reaction medium
was established.
i) Thermal sensitivity of EGF binding sites in BPH
particulate fractions:
Particulate fractions containing 1 mg/ml protein were
preincubated for 10 minutes at 45°C, 65°C, 75°C and 95°C. After
cooling the tubes, 100 jal aliquots containing 100 pig protein were
tested for binding at 37°C for 90 minutes with£-On*»«l(l-1^I-EGF j_n
the presence and absence of 50-fold excess unlabelled EGF. Particulate
fraction preincubated at 37°C for 10 minutes served as control.
Specific binding was calculated according to methods described under
section 2.11.
In another experiment particulate fractions were incubated with
8.0 nM ^^I-EGF at 65°C, 75°C and 95°C for 60 minutes. Specific
binding profiles were noted.
j) Effect of pretreatment of particulate fraction with
——————————————— — ———^____________125
different enzymes and enzyme inhibitors on subsequent I-EGF
The method was based on modification of the method of Ramani
et al (1986).
Briefly, 100 pal BPH particulate fraction (1 mg/ml protein)
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were pretreated with enzymes or enzyme inhibitors for 1 hour at 37°C.
They were centrifuged (3000 rpm 20 minutes), washed once and resus-
pended in 100 pi of buffer B. The particulate fractions were tested
for binding at 37°C for 90 minutes with 8.0 nmol/L 12^I-EGF (final concentration).
The particulate fraction (1 mg/ml protein) used for controls were •
pretreated without enzymes but subjected to the same steps as the
treatment tubes. After incubation, separation of bound from free
125
I-EGF and subsequent calculation of specific binding after counting,
was as described under section 2.11.
The following amounts of enzymes and enzyme inhibitors were used:-
1 mg trypsin 2 mg soybean (trypsin inhibitor), 1 mg phenyl-
methylsulphonylfluoride, 0.1 mg aprotinin, 0.05 leupeptin, 1 mgo< chymo-
trypsin, all per mg of protein.
Relationship between specific binding and the effect of enzyme
or enzyme inhibitor was established.
k) Pretreatment with MgCln and dextran coated charcoal (DCC):
This method was based on the technique of Leake et al
(1983).
Briefly, BPH particulate fraction was mixed with 2 ml buffer
C containing 4 M MgC^ (2.2c) at room temperature for 10 minutes.
The particulate fraction suspensions were subsequently centrifuged at
3000 rpm and the resultant pellets reconstituted in buffer B and the
receptor binding assay performed as described below
For the experiments designed to determine the effect of dextran
coated charcoal on EGF binding, particulate fraction suspensions were
exposed to 0.2 ml buffer D containing DCC (2.2d) for 10 minutes at
room temperature. The suspensions were subsequently layered on buffer B
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and centrifuged at 800 rpm for 10 minutes, to remove the DCC.
Receptor binding assay was carried out by incubating 100 pi of
125
supernatant or reconstituted pellet with 8.0 nmol/L I-EGF in the
presence and absence of 50-fold excess unlabelled EGF at 37°C for 90
minutes. Separation of non-specific from total binding was achieved
by PEG precipitation technique (2.11). Specific binding was subse¬
quently calculated as described under section 2.11.
Relationship between specific binding and effecto^4-|Y\ MgCl^ and
DCC was established.
1) Effect of storage at -70°C on prostate tissue and
particulate fraction:
The method was based on modification of the method of Boyd
(1985).
Briefly, a fresh prostate tissue, removed by retropubic
method, was prepared as described under section 2.7(a). A portion
of the tissue was homogenised immediately, and protein content was
adjusted to 1 mg/ml.
The remaining tissue was divided into two halves. One half was
homogenised and protein level adjusted to 1 mg/ml with buffer B.
0.5 ml aliquots of the homogenised preparation were dispensed into
Eppcndorf tubes. The other half of the tissue was also cut into
very small portions with scissors. The well mixed mixture was
divided up into lg portions. Each portion was placed in a Universal
container and frozen in liquid nitrogen. The Eppendorf tubes
containing the homogenate and the Universal containers with the mixed
prostate portions were stored at -70°C. EGF receptor assays were
performed on the homogenate and the minced tissues after 24 hours,
1 week, 2 weeks, 4 weeks, 6 weeks, 2 months and 4 months by the method
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described under section 2.11(a)(1). Specific binding obtained after
each period of storage was calculated.
Relationship between specific binding and effect of storage was
established.
m) Comparison of EGF and urogastrone binding to BPH
particulate fraction:
1 PS
100/al 8.0 nrnol/L I-EGF was incubated with 100 Jul parti¬
culate suspension (1 mg/ml protein) in the presence and absence of
50-fold excess unlabelled EGF or urogastrone (purchased from Sigma
Ltd, Poole, Dorset).
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In another experiment, 8.0 nmol/L I-urogastrone was used
125
in place of I-EGF in the presence and absence of 50-fold excess
unlabelled EGF or urogastrone. Incubation took place at 37°C for
90 minutes. Thereafter, separation of bound complex from free ligand
was achieved by PEG precipitation. Specific binding was subsequently
calculated as described under section 2.11(a).
Specific binding achieved by each ligand was compared.
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2.13 MOLECULAR CHARACTERISATION OF THE EGF RECEPTOR (EGF-R)
This was carried out by the following methods: a) Chemical
crosslinking of EGF to its receptor and establishment of the molecular
weight of the receptor; b) Stimulation of EGF receptor phosphory¬
lation by EGF.
a) Affinity labelling and crosslinking experiments:
The method for the experiments was based on modification of
the techniques of Mukku+StoncaX (1985) and Fanger et al (1986). The
procedure involved a number of steps which are described below:-
i) Affinity labelling: Briefly, 1 ml aliquots of BPH membrane
suspensions (1 mg/ml protein) prepared as described under 2.7(b)(i)
in Epphndorf tubes were centrifuged at l4,000g for 10 minutes
on Mini Centaur Centrifuge (MSE) at 4°C.
The supernatants were discarded and pellets reconstituted
in 200 pi HEPES buffer. 100 pi aliquots were transferred into
second Eppendorf tubes to be incubated in the presence of excess
unlabelled EGF. 100 pi aliquots of 8 nMol/L "'"^I-EGF were
placed into both tubes. One tube received 200 pi HEPES buffer
containing 50-fold excess unlabelled EGF whilst the other tube
received 200 pi buffer. After mixing and incubation for 90
minutes at 37°C, unbound complex was separated by centrifuga-
tion at l4,000g for 10 minutes after addition of 1 ml cold
(4°C) HEPES buffer,
ii) Crosslinking with disuccinimidylsuberate (DSS): The pellets
were reconstituted in 50 pi of 1 mM DSS dissolved in dimethyl-
sulfoxide (DMSO) so that the final dilution of DMSO was about
5%. Crosslinking continued for 15 minutes at room temperature.
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iii) Solubilisation: Thereafter 25 ul of boiling mixture (8% SDS,
20%glycerol, 5%]3-Mercuptoethanol, 0.05% BromophenolBlue R in 50mMTris
buffer pH, 6.8) was added to solubilise the receptor from the membrane.
The mixture was heated at 100°C for 3 minutes and centrifuged for
5 minutes at 3000 rpm to remove undissolved complex.
iv) Sodium dodecyl-sulphate polyacrylamide gel electrophoresis
(SDS - PAGE)
The mixture was analysed and characterised by SDS-PAGE. The
procedure was based on the discontinuous Tris-glycine buffer system
described by Laemmli (1970) and was performed in a vertical slab
gel electrophoresis apparatus from Bio-Rad. Current was supplied
to the apparatus by a Vokam power supply unit.
7.5% resolving gel with 3% stacking gel was used. A mixture
of molecular weight markers (200,000, 116,000, 92,000, 65,000, 45,000
and 29,000) purchased from Sigma were run in parallel lanes. There¬
after, electrophoresis took place at 35 mA/gel for 2\ hours at 22°C.
v) Staining and destaining: Gels were stained with Cooin^ssie.
brilliant blue R250 (0.1% in 25% methanol and 10% acetic acid) for
20 minutes. The gels were destained with a mixture of 25% methanol
in 10% acetic acid,
vi) Drying of gel: Gel was dried at 80°C for 2 hours, using a gel
dryer obtained from Bio-Rad.
vii) Autoradiography: Autoradiography was performed at -70°C for
2-3 weeks using hyperfilm TM obtained from Amersham placed in a
cassette with intensifying screens,
viii) Film development: Film was developed in Kodak Developer LX-24
(1/5.6 dilution) and fixed in Kodak X-ray liquid fixer
FX40 (1/5 dilution).
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b) EGF receptor phosphorylation: The technique was based on
the methods of Mukku+T; rl(1985) and Yarden et al (1987).
The method involved a number of steps and these are described below:-
i) Preparation of pellet: Briefly, 800pl of 105,000g crude membrane
fraction (6 mg/ml protein) prepared as described under 2.7(b)(i-ii)
was centrifuged at 3000 rpm for 20 minutes at 4°C using the Chilspin
centrifuge. The supernatant was discarded whilst the pellet was
saved.
ii) Pellet solubilisation: The pellet obtained above was resus-
pended in 100 pi Triton X -100 buffer (1% Triton X -100, 20%
glycerol in 0.25 MTris pH 6.8). The mixture was shaken vigorously
for 30 minutes at 26°C, to solubilise the membrane proteins.
iii) Incubation with EGF: The mixture was then centrifuged at
I4,000g for 20 minutes on Mini Centaur Centrifuge (MSE) at 4°C.
50 pi of supernatant was incubated in the presence and absence of
60 ng unlabelled EGF in buffer B, so that the final volume was
62 pi, for 30 minutes at 37°C.
iv) Phosphorylation: Incubation tubes were placed on ice and the
Op
contents of each tube added to dried-down residue of 10pC.i [, - P]
ATP. Incubation on ice was continued for a further 5 minutes.
The reaction was stopped by adding equal volume, i.e. (62 pi) of
Tris glycine electrophoresis buffer (1% SDS, 10%Triton X -100,
15% glycerol, 0.05% bromophenol blue, 5% p - mercaptoethanol in
50 mM Tris, pH 6.8.
v) Electrophoresis: The mixture was boiled for 3 minutes.
Aliquots containing 100 pg protein were used for SDS-PAGE.
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vi) Autoradiography: After the electrophoresis as described
under 2.13(iv-vi), the dried gel was subjected to autoradio¬
graphy at -70°C for 2 weeks, using hyperfilm TM obtained from
Amersham as described under 2.13(vii).
2.14 IMMUNOCYTOCHEMISTRY
Two immunocytochemical techniques using monoclonal antibodies
to the external and internal domains of the EGF receptor, are described:-
a) Indirect immunoperoxidase technique.
b) Labelled avidin-biotin technique.
a) Indirect immunoperoxidase technique using a monoclonal anti¬
body to the binding site (external domain) of the EGF
receptor:
The method was a modification of the methods of Delellis et al
(1979); Van Noorden and Polak (1983).
i) Briefly, 3 - 4 jjM cryostat sections were cut and collected
on lysine coated slides and allowed to dry with a fan for 30
minutes.
ii) Endogenous peroxidase activity was blocked by immersing
sections for 30 minutes in a solution of 0.3% hydrogen peroxide
in acetone. Sections were then rinsed inTris buffer containing
0.9% (w/v)NaCl, pH 7.6 (TBS) and 1%". riton X -100 to decrease
background staining. Slides were dried except for the area
of the section and placed in damp chamber.
iii) Background blocking was achieved by layering 100 /ul normal
rabbit serum (NRS) 1/4 dilution in TBS on sections and incuba¬
ting for 10 minutes at room temperature, after which NRS was
gently poured off.
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iv 1st layer: 100 ;ul of a 1/30 dilution of primary antibody
raised in mouse, diluted in NRS (1/6 dilution in TBS) was
layered on the section. The section was incubated for 30
minutes and rinsed twice with TBS for 5 minutes each. 100 pil
of NRS (1/4 dilution in TBS) was layered on the section and
incubated for 10 minutes. Excess NRS was gently poured off.
v) 2nd layer: 100 /ul of (1/25 dilution) rabbit antimouse
peroxidase conjugated immunoglobulin (RAMPC) (2nd antibody)
(Dako) was applied on the section and incubated for 30 minutes.
At the end of the incubation the section was washed twice for
5 minutes each.
vi) Peroxidase development: The section was incubated in
freshly prepared diaminobenzidine (DAB) in Tris buffer (pH 7.6)
containing hydrogen peroxide (final concentration 0.04%) for
20 minutes. The experience of the author has shown that
prostate sections required up to 20 minutes incubation with
DAB to achieve full colour development.
All sections were therefore incubated with DAB for this
period of time.
Note: DAB is carcinogenic and therefore must be handled with
care.
vii) Counter staining; The section was subsequently counter-
stained with Harris haematoxylin (1 - 5%) for up to 5 minutes,
and washed in running tap water for 2 minutes.
viii) Mounting: The section was dried at room temperature for
up to 1 hour, and mounted in DPX.
ix) Controls: As a negative control NRS was substituted for
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the primary antibody. For positive control, prostatic
acid phosphatase (PAP) antibody was substituted for the
primary antibody to check the technique and reagents,
b) Labelled avidin-biotin method:
The method was a modification of the method of Guerdon et
al (1979).
i) Briefly, 3 - 4pm cryostat sections were cut and
collected on lysine coated slides and were allowed to dry.
ii) Sections were fixed in acetone for 20 minutes and
rinsed in^'ris buffered saline (TBS) for 5 minutes.
iii) Primary antibody to external domain (EGF-R-^) 1/30
dilution in 1/6 dilution of NRS in TBS was applied over¬
night at 4°C.
iv) Sections were rinsed 2 x in TBS for 5 minutes each.
v) Sections were then covered with biotinylated sheep
antimouse immunoglobulin for 30 minutes at room temperature.
vi) Sections were again rinsed in TBS 2 x for 5 minutes
each.
vii) Streptavidin - AP was then applied to sections for 15 -
30 minutes at room temperature.
viii) Again, sections were rinsed 2 x for 5 minutes each in TBS.
ix) Sections were covered with fresh alkaline phosphate
substrate (Fast red 1 TR, Levamisole, NapMV>ol ASB1 phosphate)
for 20 minutes, after which sections were washed in tap water.
x) Counterstaining was achieved by using Mayers haematoxylin
for 1 minute. They were then washed and differentiated in
0.25% aqueous HC1.
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xi) After blueing the sections in lithium carbonate
solution, they were finally washed and soaked in 0.1%
Triton X -100.
xii) Sections were thereafter drained and mounted in
glycerine jelly.
2.15 EGF RECEPTOR LEVELS IN BPH AND CaP. (TECHNIQUES USED IN
MEASUREMENT)
a) Radioligand exchange assay.
b) Indirect immunoperoxidase method
i) using monoclonal antibody to the external domain
of the EGF receptor (EGF-R^) .
ii) using monoclonal antibody to the internal domain
of the EGF receptor (F4).
c) Labelled avidin biotin technique
i) using monoclonal antibody to the external domain
of the EGF receptor (EGF-R^) .
ii) using monoclonal antibody to the internal domain
of the EGF receptor (F4).
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a) Radioligand exchange assay: The receptor binding assay was essentially
the same as described under Section 2.11 with minor modification.
1 2E
100 pi of 8nmol/L I-EGF was incubated with 100 pi of prostate parti¬
culate fraction for 90 minutes at 37°C. After PEG precipitation of
the bound complex radioactivity retained in the pellet was measured,
specific binding was calculated as described under Section 2.11, i.e. by
subtracting non-specific from total binding. The mean number of binding
sites obtained for both the BPH and CaP tissues were calculated.
Also calculated were the receptor levels expressed according to the
histologic classification of the tumour based on Gleason score.
b) Indirect immunoperoxidase method using monoclonal antibody to
EGF receptor binding site (external domain)
i) This is identical to the method described under Section 2.14
employing DAB. Briefly, 3 - 4 pm thick frozen sections were trans¬
ferred to microscope slides coated with lysine and fixed in acetone.
Sections were subsequently incubated at room temperature with
murine monoclonal antibody (EGF-R^) at a dilution of 1 : 30 (v/v)
for 30 minutes, followed by a peroxidase conjugate of rabbit
antimouse immunoglobulin. Colour was developed with diamino-
benzidine made in Tris-HCl saline pH 7.6 containing 0.04% hydrogen
peroxide. Sections were finally counterstained with 5% haema-
toxylin for 2 minutes, dried and mounted using DPX. Normal rabbit
serum (NRS) replaced the primary antibody and served as negative
control.
The intensity of the staining of each prostate section was
assessed by 3 independent investigators using reference slides.
The scores for staining ranged from 1 + (weak staining) to 3 +
(intense staining). 1 - represents a negative reaction.
Staining characteristics were noted for BPH and CaP and also for
the various grades by histologic classification according to
Gleason score.
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Demonstration of internal domain of the EGF receptor (F4):
ii) (Use of monoclonal antibody F4):
F4 is a monoclonal antibody to the intracellular domain of
the EGF receptor raised against peptide 2E having the sequence
of residues 985 - 996 of the EGF receptor (Gullick et al, 1986;
Berger et al, 1987).
Immunoperoxidase technique: The technique was identical to
the one described under section 2.14(a). Briefly, 3-4 pi.. frozen
cryostat sections of BPH, well differentiated and poorly differ¬
entiated tissues were passed through the same staining steps as
described under section 2.14(a) but using monoclonal F4 at concen¬
tration of 0.05 mg/ml as the primary antibody.
The sections were finally mounted in DPX.
c) Labelled avidin biotin technique:
i) and ii) Use of monoclonal antibodies F4 and EGF-R^ (Monoclonal
antibodies to the internal and external domain of the EGF receptor)
The method was based on the technique of Guesdon et al (1979)
as described under section 2.14(b). Briefly, frozen sections were
treated with primary antibody EGF-R^ (1/30 dilution) or F4 (0.05 mg/ml
concentration) and incubated overnight.
Sections were further treated with biotinylated sheep anti-
mouse immunoglobulin followed by strepto v; - AP and alkaline
phosphatase substrate (Naphf.-.i' ASB1 phosphate). Colour was developed
by fast red ITR. Sections were counterstained with Mayers haematoxylin
and finally mounted in glycerine,jelly.
The above procedure was repeated but using F4 instead of EGF-R^
2.16 OTHER EXPERIMENTS
Experiments designed to test the EGF receptor blocking in BPH:-
a) Receptor site blocking with monoclonal antibody to the EGF receptor
sites (EGF-R^).
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b) Receptor site blocking with EGF.
Experiments designed to block EGF receptor sites in BPH
Two methods were employed (1) radioligand exchange assay and
(2) immunocytochemistry.
a) Radioligand exchange assay: A reaction tube containing
particulate fraction suspension was pretreated with buffer B and
used as control.
Another tube also containing particulate suspension was pretreated
with monoclonal antibody (1/30 dilution v/v) to EGF receptor site.
After incubation at room temperature for 30 minutes, the tubes
were centrifuged at 3000 rpm for 20 minutes. The supernatants
were discarded. The pellets were thereafter taken up with 100 pi
"I pc
buffer B. 100 pi I-EGF 8.0 nmol/L was added and receptor
binding assay was carried out in the presence and absence of 50-fold
excess unlabelled EGF, as described under section 2.11(a). Specific
binding in the control sample was compared with the test sample.
b) Immunocytochemistry: A cryostat section of BPH was pretreated
with TBS and used as control. Another section was pretreated with
300 rvnol/L unlabelled EGF.
After incubation for 30 minutes at room temperature, the sections
were rinsed with Tris buffered saline (TBS) . 100 pi of primary
antibody (EGF-R^) was applied to the sections and were subjected to
all the steps in immunocytochemistry as described under section
2.14(a)(i-x).
Staining of the test slide was compared with that of the control.
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2.17 STATISTICAL ANALYSIS
a) All experimental analyses were carried out in duplicate
and mean values used.
b) Coefficient of variation (CV) values of between and within
batches were calculated.
c) Students't' test as described by Swinscow (1982) was used to
analyse statistical differences between means of receptor levels in
BPH and CaP and also between means of receptor levels in well differen¬






In this chapter results will be presented as follows:
3.1 Separation methods
3-2 Validation of EGF receptor assay
3-3 Characterisation of EGF receptor
3.4 Molecular characterisation of the EGF receptor
3.5 i) Immunocytochemical demonstration of the presence of the
EGF receptor
ii) Comparison between radioligand assay and immunocytochemistry
3.6 Demonstration of the presence of EGF receptors in CaP
3.7 EGF receptor levels in BPH and CaP compared
3.8 Demonstration of the presence of internal domain of the
EGF receptor
3.9 Other experiments: EGF receptor blocking experiments
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3.1 Separation of bound complex from free:
Filtration and centrifugation are the two main techniques used
by many workers to separate specific from non-specific binding when
radioligand assay technique is used, but no-one has established which
of the two techniques is more suitable to apply when using radioligand
assay technique on human BPH. In view of this, steps were taken to
optimise and compare the two techniques of filtration and centrifugation.
The following observations were made on the experiments undertaken:-
a) Filtration and washing effect: As indicated by Figure 11,
two washes of the radioactivity retained on the filter paper were
optimal. Beyond the two washes specific binding started to fall.
This showed that the number of washes of the retained radioactivity
on the filter paper has important implications on the receptor levels
in the human BPH tissue.
b) Filtration and centrifugation compared: In order to improve
upon the separation technique the method of Hwang et al (1986), which
involved polyethylene glycol (PEG) precipitation prior to centrifuga¬
tion, was adopted and compared with filtration technique. Figure 12
showed that the PEG precipitation and centr'fugation was superior to
the filtration technique, because the PEG method produced 25% more
specific binding than what was achieved by filtration method.
Furthermore, the background count for the PEG method was 26% lower
than the filtration technique, whilst the levels of non-specific
binding were identical in both cases.
c) Aspiration compared with pouring of supernatant: Given the
above encouraging results produced by the PEG method, it was decided
to identify and optimise factors that might improve the PEG method
further. In this regard, after PEG precipitation and centrifugation,
95
Figure 11.
Effect of filtration and washing on EGF binding
125 -9
I-EGF in the 10 concentration range was
incubated at 37°C for 40mins with particulate fraction
of BPH as described under section 2.9. At the end of the
incubation period the bound complex was separated from the
fre^ -125i_EGF using filtration technique as described
under section 2.9.
Briefly, the bound complex was filtered through
a microfibre filter under reduced pressure. The radio¬
activity retained by the filter was either washed once,
twice, thrice or four times in separate experiments
with 1 ml cold buffer B (4°C) as described under 2.9.
The final washed pellets on the filter paper were
counted for specific binding.
The values were means of 3 different samples,
each analysed in duplicate.
The relationship between specific binding and the


















I-EGF binding: Filtration and polyethylene glycol
(PEG) separation methods compared
125
100 nl I-EGF and 100 jul BPH particulate fraction
were incubated in the presence and absence of 50-fold excess
unlabelled EGF in 200 nl buffer B for 40 minutes at 24°C.
125 125
Bound I-EGF complex was separated from free I-EGF
either by (A) filtration under reduced pressure or (B) by
PEG precipitation and centrifugation.
The filtration technique has been described under
section 2.9 but, briefly, after incubation the mixture was
filtered through Whatman microfibre filters (Whatman GF/A)
under reduced pressure. The radioactivity retained on the
filter paper was washed and counted.
The PEG method is also described under section 2.11 but,
briefly, after incubation 1 ml of 20% PEG and 0.1% BSA was added
to the mixture. After 10 minutes, the mixture was centrifuged
for 20 minutes at 3000 rpm. The supernatant was discarded
and the pellet washed with 10% PEG and 0.05% BSA and the process
of centrifugation repeated.
In each of the two experiments the radioactivity left in
the microfibre filter or in the pellet was counted and specific
binding calculated as in section 2.9- The two results (A and B)
were compared.






























aspiration of supernatant was compared with pouring off the supernatant.
Figure 13 showed that aspiration of the supernatant produced a much
more consistent result, but the pouring method produced about 12.5%
more specific binding than the aspiration technique. The pouring
method, however, had a drawback of producing very high background
count. PEG precipitation and centrifugation followed by aspiration
was therefore selected as the most reliable and reproducible method of
separation for the human BPH.
d) Impact of centrifugation: In order to precipitate the bound
complex more efficiently after the addition of PEG solution, the
incubation medium was subjected to various centrifugation times to find
the impact of centrifugation on the level of EGF specific binding.
Figure 14 shows that centrifugation at 3000 rpm for 5 minutes as
practised by other workers (Hwang et al, 1986), grossly underestimated
the specific binding.
Centrifugation for 30 minutes produced the maximum specific
binding (mean - SD = 800- 50 dprh), but this was also accompanied by
the highest non-specific binding. On the other hand centrifugation
for 20 minutes produced specific binding (mean - SD = 750- 45 dpm)
which was not statistically different from what was obtained for
30 minutes centrifugation. Furthermore, centrifugation for 20
minutes was accompanied by the lowest non-specific binding. Above
all, the specific binding after 20 minutes centrifugation was observed
to be the most reproducible. The level of specific binding started
to decline after 30 minutes centrifugation. 20 minutes centrifugation
was therefore adopted for use in all subsequent assays.
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Figure 13.
Aspiration compared with pouring of supernatant
Receptor binding assay, PEG precipitation and
centrifugation were carried out as described under 2.11.
Briefly, at the end of the incubation period, the
bound complex was precipitated by 20% PEG and 0.1%BSA and cen.tri-
fuged. In one set of experiments the supernatant
was poured off (A). In another set, the supernatant
was aspirated off using venturi pump which provided
a negative pressure (B).
The process was repeated after washing the pellet
once with 10% PEG and 0.05% BSA. Bound radioactivity retained by
each method was measured on a gamma counter. Levels
of specific binding achieved by both techniques (A and
B) were compared.
Values were means of 4 different samples,


























PEG precipitation: Impact of centrifugation time
on binding
The receptor binding assay was as described under
section 2.11.
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Briefly, after the precipitation of the I-EGF
bound complex with PEG, the mixture was centrifuged
for 5, 10, 20, 30 and 45 minutes respectively at
3000 rpm. After washing the pellet with 10% PEG in
0.05% BSA as described under section 2.11, the centri¬
fugation procedure was repeated. The pellet obtained
after each period of centrifugation was counted on a
gamma counter. The specific binding obtained for
the various centrifugation periods were compared.
Values are means of 3 different samples,
























3.2 Validation of the EGF receptor assay:
a) The assay was validated using the human placenta, because
it was known to contain high levels of EGF receptors (Hock«-wc
Ho\Ur,,I"Vso•Ramani et al, 1986).
The outcome of the validation experiments have been described
under section 2.11(a). These showed that the receptors were
saturable, specific and of high affinity. Scatchard plot analysis
revealed one class of binding site consistent with observation made
by Hock + although Ramani et al (1986) observed two
classes of binding sites. The rest of the characteristics
observed in this report were identical to those made by HocktfMU*.W
(1980) and Ramani et al (1986). This showed that EGF was bound
to its own classical receptor.
125b) In another set of experiments, binding between I-EGF
and human plasma was investigated. The outcome of this investiga¬
tion is described under 2.11(b). The absence of binding observed
shows that the binding in the placenta is not due to contamination
from human blood. This lends further support to the specificity of
the binding seen in the placenta.
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3-3 Characterisation of the EGF receptor:
The EGF receptor was characterised under the following
headings:-
Distribution of the EGF receptors in the subcellular
fractions of BPH
Effect of protein concentration on EGF binding
Effect of time and temperature on EGF binding




Impact of pH on binding
Thermal sensitivity
Effect of enzyme and enzyme inhibitors
Effect ofMgCl^ and DCC on binding
Effect of storage at -70°C on binding
Binding of urogastrone and EGF by BPH
The results of these investigations are now presented.
Characterisation of the EGF receptor in the human BPH tissue
EGF receptors have been characterised in the rat prostate by
various biochemical techniques (Traisht-U/ofiz., 1987) but earlier
attempts to characterise the receptor in the human BPH tissue using
biochemical method wire, not successful (Gregory et al, 1986).
This was one of the reasons which prompted the author to localise
and characterise the EGF receptor in the human BPH, using a whole
range of biochemical techniques.
The outcome of the characterisation are described as follows:-
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a) Subcellular distribution of the EGF receptors in the
human prostate:
In order to investigate the distribution of the EGF receptors
in the human prostate tissue, the homogenate preparation was subjected
to subcellular fractionation as outlined under section 2.12(a). Each
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fraction was subjected to I-EGF binding assay. TABLE 3 shows that
over 68% of the specific binding was associated with the 800g (crude
heavy pellet) fraction. The remainder of the binding was distributed
between the microsomal pellet (105,000g) and the mitochondrial pellet
(15,000g). No specific binding was observed with the 105,000g super¬
natant (the cytosol). In view of the low level of binding associated
with the microsomal fraction, it was decided to centrifuge the homogenate
at 105,000g to obtain a total particulate fraction (pellet) containing
all the receptors.
b) Effect of protein concentrations on receptor estimations:
In order to determine the limit to which tissue homogenates
must be diluted with buffer for accurate receptor estimations, total
particulate fraction pellets were resuspended in different volumes of
buffer to provide a wide range of protein concentrations, as described
under section 2.12(b). Figure 15(A) shows that EGF binding is linear
with dilutions corresponding to protein concentrations between 0.1 and
1 mg/ml. Beyond 1 mg/ml protein binding appears to decline.
A second linearity was, however, observed between 1.5 and 8 mg/ml
(Figure 15(B)). The appearance of this second linearity is not under¬
stood. The specific binding achieved at 8 mg/ml was only 30% above
that of 1 mg/ml.
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c) Effect of time and temperature on I-EGF binding:
Figure 16 illustrates the patterns of binding of EGF to the
105,000g particulate pellet at three temperatures. Clearly the
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TABLE 3
a) SUBCELLULAR DISTRIBUTION OF RECEPTORS FOR EGF IN THE
HUMAN PROSTATE
Subcellular fractions were prepared according to the
method of Leake, Chisholm and Habib (1983) as described
under section 2.7(c).
Briefly, particulate fraction was centrifuged at 800g
to obtain the crude heavy pellet. The supernatant was
centrifuged at 15,000g to obtain the mitochondrial pellet.
The supernatant was again centrifuged at 105,000g to
obtain the microsomal pellet, using the 5orvall ultra-
centrifuge as described under section 2.7(c). Pellets
were each reconstituted in 1 ml of buffer B, and aliquots
were used in binding studies as described under section
2.12(a). Briefly, 100 pi "^I-EGF and 100 pi particulate
fractions were incubated in the presence and absence of
200 ul 50-fold excess unlabelled EGF for 40 minutes at
24°C. After incubation 12^I-EGF bound complex was
125
separated from free I-EGF by PEG precipitation and
centrifugation. Specific binding was subsequently
calculated by the difference between total and non¬
specific binding.
The experiment was performed on 3 different samples
and values are expressed as means SD.
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TABLE 3
Fraction Specific Binding % Bound*
(dpm/100 jul) ~
800g crude pellet 1182 + 173 68 + 4
15000g pellet (Mitochondria) 365 + 53 21 + 5
105000g pellet (Microsome) 188 + 25 10 + 1
105000g supernatant (Cytosol) 0 0
*% of total binding
109
Figure 15.
Impact of protein concentration on EGF receptor
estimation
100 pi aliquots of BPH particulate suspension
containing 0.1 to 8 mg protein per ml were incubated
I pq
with 100 pi aliquots of I-EGF (8.0 nmol/L) in the
presence and absence of 50-fold excess unlabelled
EGF for 40 minutes at 24°C. At the end of the
125
incubation I-EGF bound was separated from free
by PEG precipitation and centrifugation as described
under section 2.12(b), Specific binding w&S calcu¬
lated by subtraction of non-specific from total.
Values are means of 4 different specimens,








Effect of time and temperature on I-EGF binding
100 jul BPH particulate fraction containing
1 mg/ml protein was incubated with 100 pi 8.0 nM
125
I-EGF in the presence and absence of 50-fold
excess unlabelled EGF (in 200 ul buffer B) forUj»
90 minutes at 4°C, 25°C and 37°C.
125
At the end of the incubation period, I-EGF
125
bound complex was separated from free I-EGF by
PEG precipitation and centrifugation as described
under section 2.11.
Specific binding was calculated by a difference
between total and non-specific binding after counting
on gamma counter.
Binding profiles obtained for each temperature
are illustrated.
The values are means of 3 different
samples, each analysed in duplicate.
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binding was time and temperature dependent, with maximal binding
obtained at 37°C after 45 minutes of incubation. The maximal
binding was sustained for a further 75 minutes beyond which a decline
was observed, probably due to the instability of the particulate fraction under
these conditions. Although the binding at 25°C was slightly lower
than that observed at 37°C, the binding profiles for both temperatures
were similar whereas at 4°C receptor-ligand interaction was considerably
slower and significantly reduced. It was therefore decided to under¬
take all subsequent incubations at 37°C for 90 minutes.
125
d) Dissociation of BPH particulate fraction bound I-EGF in
the presence of 50-fold excess unlabelled EGF
125
It has been observed that association of I-EGF with BPH
particulate fraction was time and temperature dependent (Figure 16).
125
In order to demonstrate if the dissociation of the I-EGF bound
complex was also time dependent and also to find the influence of
presence of unlabelled EGF on the dissociation, this investigation
was carried out.
125
Figure 17 (A and B) is showing dissociation of I-EGF bound
complex in the absence (A) and presence (B) of 50-fold excess
unlabelled EGF. The bound iodinated EGF complex was found to be
partially dissociated in the presence and absence of excess unlabelled
EGF as a function of time at 37°C. In the presence of excess
unlabelled EGF, the dissociation was considerably enhanced. These
125
observations indicated that both the association of I-EGF with BPH
125
and the dissociation of I-EGF bound complex were time dependent.
e) Saturation studies: Adamson4- fees (1981) expressed the view
that EGF may be considered as a hormone as well as a growth factor.




Dissociation of particulate fraction I-EGF bound complex
in the presence and absence of unlabelled EGF
The method is described under section 2.11. Briefly,
after EGF receptor binding assay, as described under
125
section 2.11, the unbound I-EGF was removed by centri-
fugation. The pellets containing bound complex were
resuspended in buffer B containing 50-fold excess
unlabelled EGF (B) or no unlabelled EGF (A). Samples were
reincubated for indicated lengths of time, i.e. 0 - 180
minutes at 37°C.
Controls were precipitated with PEG immediately and
125
centrifuged to separate bound from free I-EGF. This
represented 100% binding.
Specific binding for each time was calculated by the
difference between non-specific and total binding.
Dissociation took place in the absence of unlabelled
EGF (A) and in the presence of unlabelled EGF (B).
The experiment was performed on 3 different samples.
























of a hormone, a molecule whether it is a polypeptide or steroid in
nature must undergo a specific high affinity saturable interaction
with a receptor in the target tissue.
In order to investigate the saturability of the EGF receptor
sites, saturation studies as outlined under section 2.12(e) were
undertaken.
Figure 18. (insert) reveals that EGF receptors in the human prostate are
125
saturable at I-EGF concentrations above 8 nmol/L when binding is
observed to form a plateau. This finding is in agreement with the
report of Mukku+Sfe*c*l-(1985) who found that saturation of rat uterus
EGF receptors occurred between 5-8 nrnol/L EGF concentrations.
f) Scatchard analysis: Given that the receptor sites were
saturable, it was decided to investigate the number of binding sites
and the affinity of the receptors by Scatchard plot analysis
(Scatchard, 1949) , using the data obtained from the saturation
studies carried out on ten separate prostates. Figure 18 reveals
that there are two classes of binding sites. The first of higher
affinity (mean Kd = 0.8 - SD 0.2 nmol/L) and the second lower affinity
(mean Kd = 7.6 - SD 2.8 nmol/L). The mean binding capacities for the
two components are 14-1.4 fmol/mg protein and 137 - 23 fmol per mg
protein respectively.
g) Competition studies: Given that the EGF receptor in the
prostate was saturable and of high affinity, it was left to demonstrate
if the binding between the growth factor and the receptor was specific.
To do this, the approach outlined in section 2.12(g) was adopted.
Figure 19 demonstrates that increasing concentrations of unlabelled
125
EGF inhibited I-EGF binding to BPH particulate fraction, in a dose




The method is described under section 2.12(e).
Briefly, the receptor binding assay was performed
12G
using I-EGF over a range of 0.5 nMol - 24 nMol/L
and BPH particulate fraction containing 1 mg/ml protein
in the presence and absence of 50-fold excess unlabelled
125
EGF at each concentration of I-EGF. After incubation
for 90 minutes at 37°C, "*I-EGF bound complexes were
separated from free by PEG precipitation and centrifu-
gation as described under section 2.12(e).
Specific binding was obtained by subtraction of
non-specific from total binding.
Values are means of 3 different samples,




Data obtained from the saturation studies
detailed under section 2.12(e) was used in
calculating the dissociation constant (kd) and
estimating the number of binding sites of the
receptor protein by the method of Scatchard (19^9).
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The method is described in section 2.12(g).
125
Briefly, 100 pi I-EGF was incubated with
100 pi BPH particulate fraction in the presence and
absence of 250 - 3000 ng/ml of unlabelled m-EGF,
h-GH, h-FSH, h-LH, human PRL, human insulin and
venom nerve growth factor at 37°C for 90 minutes.
125
At the end of the incubation period, I-EGF
bound complex was separated by PEG precipitation
and centrifugation as described under section 2.12(g).
The displacement achieved by each competition
is noted.
The experiment was repeated on 3 different
samples. Results are means • of 3 samples, but
are expressed as a % of control.
Control sample was not incubated with any



























human PRL, GH, FSH, LH and venom nerve growth factor at concentra¬
tions between 250 - 3000 ng/ml were ineffective in competing with
125
I-EGF for the particulate fraction receptors. This demonstrates
the specificity of the EGF binding to its receptor in the BPH
particulate fraction. However, human growth hormone was able to
exhibit only a slight competition (<20%).
125
h) The impact of pH of incubation media on I-EGF binding
to particulate fraction of BPH:
125
In order to find the optimal pH for I-EGF BPH binding,
incubation media with various pH values were investigated, for their
effect on EGF binding. Figure 20 shows that specific binding increased
with increase in pH values, within the pH range of 2 - 7.4. Optimal
125
pH observed for I-EGF binding to particulate fraction of BPH was
7.4. Level of binding dropped sharply at pH 8.0. At pH 9 binding
had returned to basal level. These observations indicated that the
influence of pH on EGF binding in the human prostate was considerable.
Strict adherence to optimal pH is therefore important.
125 -
i) I-EGF binding: Thermal sensitivity of the EGF receptor
protein:
The response of cells to heat shock has been known since the
work of Ritossa (1962) on Drosophila embryo. Since then, studies
on heat shock protein (HSP) have been carried out by other workers
(Kelly and Schlesinger 1978). Recently Hock and Hollenberg (1980);
Ramani et al (1986) looked at the thermal sensitivity of the EGF
receptor in the human placenta at higher temperatures. They observed
an irreversible inactivation of the receptor at 65°C.
These studies prompted an investigation to find out the effect
of higher temperatures on EGF receptor binding. Figure 21 shows




The impact of pH of incubation media on I-EOF
binding to particulate fraction of BPH
The method is described under section 2.12(h).
Briefly, BPH particulate fractions (1 mg/ml protein)
were incubated with 8.0 nmol/L for 90 minutes at 37°C
in the presence and absence of 50-fold excess unlabelled
EGF in media of various pH values. lOmM Tris-HCl p H 11
was adjusted to give pH values of 2 - 11 for use.
The particulate fraction incubated in medium pH of
7.4 served as control. Specific binding for each pH
was calculated as described under "Materials and Methods"
(section 2.12(h)).
Values are means of 3 different specimens, each
analysed in duplicate but expressed as % of control value.
124





Prior to receptor binding assay, particulate
fractions were preincubated at 45°C, 65°C, 75°C and 95°C
for 10 minutes. Another fraction was preincubated at
37°C and that served as control. Thereafter, aliquots
125
of the treated samples were incubated with I-EGF as
detailed under section 2.12(i).
Briefly, 100 jul of each treated sample, and 100 ill of
1258.0 nmol/L I-EGF were incubated in the presence and
absence of 50-fold excess unlabelled EGF at 37°C for
125
90 minutes. At the end of the incubation period, I-EGF
bound complex was separated from free by PEG precipitation
and centrifugation.
Specific binding was calculated by the difference
between non-specific and total binding.
Values are the means of 3 different samples,




prior to binding studies, the level of binding fell by up to 80% of
control value. But heating the same particulate fraction at 65°C,
and 75°C for 10 minutes prior to binding studies, it was observed
that the level of binding unexpectedly rose again quite significantly
by 33% and 66% respectively of control value. Total inactivation
of the receptor was not realised until the particulate fraction was
preheated at 95°C for 10 minutes prior to binding studies.
In another experiment, incubation of the particulate fraction
and 125I-EGF mixture took place at 37°C, 65°C, 75°C and 95°C for
60 minutes, using 37°C as control. Figure 22 shows that incubation
at 37°C revealed a steady rise in binding and formed a plateau after
45 minutes incubation which was maintained to 60 minutes, but at 75°C
binding rose sharply by 40% of control level. But this rise was
found to be only transient because it fell sharply after 20 minutes
by 60% of control level. The same picture was observed at 65°C
but the rise at 10 minutes was slightly lower and the fall slower.
However, after 30 minutes the fall had reached almost the same level
as that of the 75°C. Gradual fall in binding continued in both
temperatures to 60 minutes. Because there was complete inactivation
of receptors at 95°C, no binding was observed at all at that tempera¬
ture .
j) Effect of enzyme and enzyme inhibitors on EGF binding
with BPH:
It is well documented that the human prostate contains high
levels of endogenous proteases (Gotterer et al, 1956; Mann
1981; Isaacs and Coffey, 1984). It was therefore decided to





I-EGF binding: Effect of thermal EGF receptor
sensitivity
The procedure is described under section 2.12(i).
125
Briefly, 100 jul aliquots of I-EGF and 100 jul
aliquots of BPH particulate fractions were placed in
various incubation tubes and incubated at 65°C, 75°C
and 95°C from 0-60 minutes, but control sample was
incubated at 37°C. At 10-minutes intervals, specific
binding was assessed for the various temperatures after
PEG precipitation and centrifugation and counting.
Values are means SD of 6 different samples,














Figure 23 shows that pretreatment of particulate fraction of
BPH with trypsin and ^ chymotrypsin completely digested the receptor
protein resulting in total loss of binding. However, simultaneous
addition of soybean antitrypsin completely reversed the trypsin
induced binding losses and improved the binding by 10% over control
values. Leupeptin and phenylmethylsulphonylfluoride (PMSF) enhanced
the binding by 15% and 10% respectively over control values whilst
DHASE and aprotinin had no effect on the binding.
These reports indicate that leupeptin, PMSF and soybean are
effective enzyme inhibitors of the human prostate profess.st> ■
k) 12^I-EGF binding: Effect of BPH particulate fraction
pretreatment with MgCl^ and dextran coated charcoal (DCC):
MgCl2 is known to dissociate tightly bound endogenous ligand
receptor complexes and DCC to remove possible binding inhibitors from
tissue extracts (Kelly et al, 1979). Consequently, Leake et al (1983)
used these reagents to improve prolactin binding in the human prostate,
suggesting c| endogenous prolactin in the human prostate.
However, Traish et al (1987) did not observe any improvement in EGF
binding in the rat prostate, also suggesting absence of endogenous EGF
in the rat prostate.
In view of the fact that MgClp and DCC reagents have not been
used yet to test for the presence of endogenous EGF in the human
prostate, it was decided to use the reagents to investigate if the
human prostate contained any endogenous EGF.
Figure 24 shows that MgCl2 pretreatment resulted in increases
of both total and non-specific binding (non-specific binding being
more than total), whereas DCC pretreatment inhibited binding
with the overall impact being that of net loss in specific binding.




I-EGF binding: Effect of pretreatment of BPH
particulate fraction with enzymes or enzyme inhibitors
The method for this investigation is described in
section 2.12(j).
Briefly, BPH particulate fractions were pretreated
with enzymes or enzyme inhibitors, at 37°C for 60 minutes.
125
After washing, the treated samples were tested for I-EGF
binding at 37°C for 90 minutes, using 8.0 nwol/L 12^I-EGF
in the presence and absence of 50-fold excess unlabelled
EGF. The control fraction was preincubated in buffer B
only but was subjected to the same steps as the test
fractions.
The following are the enzyme or enzyme inhibitors and
the corresponding quantities used in this experiment.
Quantities are expressed per mg protein:-
1 mg trypsin andLVtflSE(2 mg soybean trypsin inhibitor,
1 mg phenylmethylsulphonylfluoride, 0.1 mg aprotinin,
0.05 leupeptin, 1 mg chymotrypsin, all per mg of
protein.
Details of the procedure are described under section 2.12(j).
Values are expressed at % of control value, but are
means of 3 different samples, each analysed in
duplicate.
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I-EGF binding: Effect of MgCl^ and DCC pretreatment of
particulate fraction:
Two tissues were used: (A) human prostate, (B) human
placenta.
The procedure for this experiment has been described
under section 2.12(k).
Briefly, after BPH particulate fraction (Figure 24A)
pretreatment with MgCl2 or DCC, 100 jul aliquots of the
125
treated samples were subjected to I-EGF receptor binding
assay as described under section 2.12(k).
The experiment was repeated using human placenta
particulate fraction (Figure 24B). Specific binding
obtained on BPH control sample and the treated samples
were compared (Figure 24A). Results obtained on the human
placenta were also compared (Figure 24B).
























whilst DCC produced 90% in specific binding respectively. Placenta
(Figure 24B) on the other hand exhibited about 84% fall after MgCl^
pretreatment and 70% fall after DCC pretreatment, all compared with
control values. The use of these reagents therefore indicated
that the human prostate does not contain endogenous EGF.
1) "*"^I-EGF binding: Effect of storage at -70°C on prostate
tissue and particulate fraction:
The human prostate is known to contain a lot of proteolytic
enzymes (Gotterer et al, 1956; Mann and Mann, 1981; Isaacs and
Coffey, 1984). It is also known that the enzymes are activated during
storage and therefore storage may play a role in the physical and
proteolytic degradation of receptors in the prostate tissue. In the
course of scientific work, it is inevitable that tissues or particulate
fraction are kept for later use. In fact this is the practice of
many workers. In view of all these considerations, it was decided
to look at the effect of storage at -70°C on prostate tissues and
particulate fraction for 16 weeks. Figure 25 shows that at the end
of 16 weeks, specific binding of both tissue and particulate fraction
were still within reasonable range of the starting point. In the
first few weeks of storage, however, binding rose above the starting
level. After the second and fourth weeks, binding by tissue and
particulate fraction respectively started to settle by approaching
the starting level. The initial increase was due to alterations in
non-specific binding, whilst the total binding remained constant.
This showed that storage at -70°C for 16 weeks did not affect the EGF
specific binding with prostate tissue or particulate fraction.
136
Figure 25.
"^I-EGF binding: Effect of storage at -70°C on
BPH tissue and particulate fraction:
The method of tissue preparation and particulate
125
fraction preparation and I-EGF receptor assay
procedures have been described under section 2.12(m)
Briefly, BPH tissue was divided into 2 halves.
One half was cut into very small pieces and the other
half homogenised as described under section 2.12(m)
making it a particulate fraction prepared. Protein was
determined in the particulate fraction and the level
of protein adjusted to 1 mg/ml and divided up into
£ppendorf tubes (0.5 ml aliquots).
100 pi aliquot of the particulate fraction was
125
incubated with 100 pi aliquot of I-EGF in the
presence and absence of 50-fold excess unlabelled
EGF at 37°C for 90 minutes. Specific binding
observed was noted as 100% control. Thereafter,
the portion that was chopped into little bits,
together with the particulate fraction in 0.5 ml
aliquots (in £ppendorf tubes) were stored at -70°C.
125
I-EGF receptor assay was performed on both tissue
and particulate fractions at regular intervals for
16 weeks.
The experiment was performed on 3 different tissues
and mean values have been expressed as % control.
137
 
m) Binding of BPH particulate fraction to urogastrone and EGF:
Mouse EGF and human urogastrone have already been shown to
be ?,imiIligands(Savage, ••'°-"t 1972; Gregory,
1975). This provided justification for using mEGF to interact
with human BPH tissue, but interaction of urogastrone with human BPH
failed to produce positive binding (Gregory et al, 1986). This
prompted the author to investigate the binding characteristics
between mEGF and human urogastrone with human BPH. The outcome of
the investigations are now presented
TABLE 4 shows that both EGF and urogastrone showed specific
binding with BPH particulate fraction, indicating that the two
ligands recognised the same receptor and shared the same receptor
sites. The use of urogastrone was therefore not the explanation for
the absence of EGF receptors in the human BPH observed by Gregory et
al (1986). However, as indicated in TABLE 4, urogastrone,
whether in its labelled form or unlabelled form, when used for
displacement always produced lower results than mEGF at any time.
125
For example, BPH binding with ImEGF in the presence and absence
of unlabelled mEGF produced specific binding of 3594 dpm, whereas
only 815 dpm specific binding was achieved when the same reaction
took place in the presence and absence of unlabelled urogastrone,
thus underestimating the level of receptors by 77%. Furthermore,
125
in another experiment BPH binding with I-urogastrone in the
presence and absence of unlabelled mEGF produced 2078 dpm specific
binding, whereas only 775 dpm specific binding was obtained in the
presence and absence of unlabelled urogastrone, here again under¬
estimating the receptor level in the prostate by 63%. These results
mean that even though urogastrone and mEGF recognise and bind the
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TABLE 4.
BINDING OF BPH PARTICULATE FRACTION TO 125I-mEGF AND
"^I-UROGASTRONE
The procedure is described under section 2.12(m).
125
Briefly, 100 pi I-EGF was incubated with 100 pi
BPH particulate fraction (1 mg/ml protein) in the presence
and absence of 50-fold excess unlabelled EGF or unlabelled
urogastrone at 37°C for 90 minutes (Column A).
125
In another experiment 100 pi I-Urogastrone was
incubated with 100 pi BPH particulate fraction in the
presence and absence of 50-fold excess unlabelled m EGF
or urogastrone at 37°C for 90 minutes (Column B).
125
At the end of the incubation period I-ligand
bound complex was separated from free by PEG precipitation
and centrifugation. Specific binding was calculated by
the difference between non-specific and total bindings.
Results were reproduced on 3 different samples and




























same receptor, urogastrone underestimates the EGF receptors in the
human BPH by as much as 70%. This, therefore, may provide some
explanation for the negative results obtained by some workers.
The reason for the different binding characteristics may be due to
differences in the affinities of the two ligands for the EGF receptor
in the human BPH tissue.
142
3.4 Molecular characterisation of the EGF receptor:
Two techniques were employed
a) Affinity labelling and chemical crosslinking of
EGF to its receptor
b) Phosphorylation of the EGF receptor
125
a) Affinity labelling and crosslinking of I-EGF receptor,
SDS - PAGE and autoradiography:
The specific high affinity receptor is a single chain poly¬
peptide with a molecular weight in the range 150,000 - 170,000 daltons.
To determine whether the prostatic EGF receptor has a similar molecular
weight, the experiments detailed under section 2.13 were carried out.
"I pjT
Figure 26 (Lane A) shows that I-EGF was eovaUwtly attached to proteins
with approximate molecular weights in the range 150,000 and 170,000
daltons, which was identical to the molecular weight of the classical
molecular weight of the EGF receptor. These complexes appear to be
specific for EGF since labelling in the presence of excess unlabelled
EGF resulted in disappearance of the bands (Figure 26', Lane B).
Specific labelling of some low molecular weight proteins were also seen.
The relevance of these is not immediately clear; but they could repre¬
sent the cytoplasmic domain of EGF receptors since they occupy the same
position as albumin as demonstrated by molecular weight markers.
This finding could be confirmed using the newly developed monoclonal
antibody to the internal domain (F4) in immunoprecipitation studies.
b) Stimulation of membrane protein phosphorylation by EGF:
125 125
Crosslinking of the I-EGF receptor revealed that I-EGF
was bound specifically to both 170,000 and 150,000 molecular weight
species. Given these results it was next sought to determine whether
the EGF binding would also stimulate the phosphorylation of the




Affinity labelling: Crosslinking of I-EGF, SDS -
PAGE and autoradiography
The methods for these investigations have been
described under section 2.13, but briefly, 100 pi
aliquots of plasma membrane were incubated with 100 pi
aliquots of I-EGF (8.0 n pl/L) in the absence (Lane A)
or presence (LaneB) of 50-fold excess unlabelled EGF in 200 pi
HEPES buffer at 37°C for 90 mins. At the end of the incubation
period, 1 ml HEPES buffer was added to the medium to
stop the reaction. After centrifugation to separate
125
I-EGF bound complex from free, the labelled bound
complex was crosslinked using the chemical crosslinker
DSS prior to SDS - PAGE followed by autoradiography,
using intensifying screen and x-ray hyperfilm as described
under section 2.13-





Figure 27 shows the result of the phosphorylation experiment which
was performed in the presence of EGF ( Lane A ) and absence of EGF
( Lane B ). Since a band has appeared in the 170,000 molecular
weight range in Lane A but not in Lane B, it only follows that
EGF has stimulated phosphorylation of the EGF receptor. It also
follows that in vitro phosphorylation does not take place in the
human prostate in the absence of EGF.
3-5 Immunocytochemical techniques:
The development of monoclonal antibody to the external domain of
the EGF receptor (Waterfield has enabled many workers to
measure specifically EGF receptors in a whole range of human and
animal tissues and cells, employing the technique of immunocyto-
chemistry, but no-one has used the technique to measure EGF receptors
in the human BPH tissue, yet. It was therefore decided to confirm
the presence of the EGF receptors in the human prostate tissue by
immunocytochemistry involving the use of the monoclonal antibody to
the EGF receptor sites (external domain). Two immunocytochemical
techniques were used: a) the indirect immunoperoxidase method and
b) the labelled avidin biotin technique. These techniques were used
to demonstrate the presence of the EGF receptor in the prostate.
a) Plates 1 and 2 the pattern of immunoperoxidase
reactivity observed in BPH. Plate 1 "SUoMS a negative control in
which the use of the monoclonal antibody was omitted. Plate 2
sUo wS positive staining in which the monoclonal antibody was used.
Staining by the antibody was confined to the basal layers of the
epithelial cells whilst the adjacent stroma remained clear. There
was no apparent nuclear staining but the immunoperoxidase fraction
was limited to cell membranes. Staining of the epithelial cells was
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Figure 27
Stimulation of membrane protein phosphorylation by EGF
Details of the procedure are described under
section 2.13(b).
Briefly, BPH membrane was first extracted for
30 minutes with Triton buffer (1% v/v) pH 6.8, and the
extract incubated in the presence ( Lane A ) and
absence ( Lane B ) of 60 ng unlabelled EGF at room
temperature.
At the end of the incubation period, phosphorylation
was performed for 5 minutes in the presence of 10 juCi
<r32p) ATP. The products were then analysed by SDS -
PAGE followed by autoradiography.




Plates 1 and 2
Indirect immunoperoxidase method, using monoclonal
antibody to the external domain of EGF receptor
Details of the technique are described under
section 2.14.
Briefly, 3 - 4 um cryostat sections were fixed in
acetone for 20 minutes. Sections were thereafter
treated with primary antibody (1/30 dilution).
This was followed by secondary antibody conjugated
with peroxidase. Reaction was detected by diamino-
benzidine (DAB) in the presence of hydrogen peroxide.
Sections were counterstained with dilute haema-
toxyiiri and finally mounted in DPX.
Plate 1 was not treated with the monoclonal
antibody and therefore served as negative control.
Plate 2 was treated with the monoclonal
antibody and therefore indicates positive staining.
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Plate 1A (x 133)
Plate IB (x 333)
150
Plate 2A (x 133)
Plate 2B (x 333)
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predominantly uniform throughout the same specimen, but there was
considerable variability in the intensity of staining between
different tissues. Staining of sections was assessed by three
independent observers and the intensity was graded as negative (-),
moderate (+) or intense (++) - (+++).
b) Labelled avidin biotin technique: Results were identical to
those produced by the indirect immunoperoxidase technique. Plate 3
is showing a negative staining.
Positivity was indicated by a red colour and was confined to the
basal layers of the epithelial cells. The stromal areas and the
nuclei were sWn,i.cls(^WV\^. Staining of sections was semiquantitatively
scored as described above (Plate 4).
c) Comparison between immunocytochemistry and radioligand assay:
The results of the two immunocytochemical techniques were
compared with those obtained using radioligand assay technique.
Figure 28 shows that there was very good correlation between the
intensity of staining and receptor positivity as measured by ligand
exchange assay. Agreement between the two techniques occurred in all
ten tissues examined. Six specimens demonstrated intense immunocyto-
c.
chemical staining (> 6 dpm/1 x 10~ ) whereas moderate or negative
—6
staining corresponded to binding less than (6 dpm/1 x 10 ).
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Plates 3 and 4
Labelled avidin-biotin method using MAB to the
external domain of the EGF receptor
The method used has been outlined under section
2.14(b).
Briefly, 3 - 4 torn BPH frozen sections were fixed
in acetone.
Sections were then treated with primary anti¬
body (1/30 dilution) for 24 hours. Sections were
next subjected to treatment with sheep antimouse
biotinylated immunoglobulin and subsequently followed
by streptavidin alkaline phosphatase.
Colour was developed by fast red ITR in the
presence of fresh alkaline phosphatase substrate
(naphthol ASBI phosphate).
Sections were counterstained and mounted in
glycerine jelly.
Plate 3: Showing BPH stained section, negative
control.
Plate 4 Showing BPH stained-section, positive
control.
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Plate 3A (x 133)
Plate 3B (x 333)
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Plate 4A (x 133)
Plate HB (x 333)
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Figure 28
Comparison between immunocytochemistry and
radioligand assay on BPH tissue
BPH tissues were analysed for EGF receptor
levels by two techniques and these are (a) Immuno¬
cytochemistry and (b) Radioligand assay.
Details of the two techniques are described
under section 2.11 (radioligand assay) and section
2immunocytochemistry).
125
Briefly (radioligand assay), I-EGF and
BPH particulate fraction are incubated at 37°C
for 90 minutes in the presence and absence of
unlabelled 50-fold excess unlabelled EGF.
125
After free and bound I-EGF complex were
separated, specific binding was calculated (xa*is).
With regard to immunocytochemistry, cryostat
sections were treated with primary and secondary
monoclonal antibodies. After counterstaining,
the sections were mounted.
Results of the two techniques are compared.






























Immunocytochemical staining (intensity of staining)
Figure 28,
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3.6 Demonstration of the presence of EGF receptors in adenocarcinoma
of the prostate:
Transformed cells show varying responses to exogenous EGF.
This characteristic is influenced by the histologic grade of the
tumour. Thus Bradley et al (1986) observed high EGF receptor levels
in well- differentiated cells but .1 ow /A were observed in poorly
differentiated cells. Sainsbury et al (1985) observed higher levels
of EGF receptors in poorly differentiated breast tumour than he observed
in other histologic grades.
This prompted the author to examine adenocarcinoma of the prostate
for the presence of EGF receptors, using (a) radioligand assay and (b)
immunocytochemical techniques: (i) Indirect immunoperoxidase and (ii)
Labelled avidin biotin method. Monoclonal antibody to the external
domain of the EGF receptor (EGF-R^) was used in the immunocytochemistry.
Figure 29 shows that well differentiated CaP contains EGF
receptors. The biochemical binding characteristics were found to be
identical to those observed in BPH (section 3-3(f)) except that only
one class of binding sites was observed in the CaP.
Plates 5 and 6 e.onji rm the presence of the receptors in
the well differentiated CaP. Plate 5 was stained by the immuno¬




Demonstration of EGF receptor in adenocarcinoma
of the prostate
a) Radioligand assay technique
The methods were identical to those described
under 2.12(e; f).
Briefly, 100 |ul aliquots of CaP tissue
particulate fraction were incubated with varying
1 PS
concentrations of I-EGF (0.5 - 12.0 nmol/L) in
the presence and absence of 50-fold excess unlabelled
EGF at 37°C for 90 minutes.
At the end of the incubation period, specific
binding was separated from non-specific by PEG
precipitation and centrifugation as outlined under
section 2.12(e). Concentration at which saturation
occurred was noted (A).
Data obtained from the saturation studies
detailed above was used in calculating the
dissociation constant Kd by Scatchard plot analysis
(Scatchard, 1949) (B).










b) Plates 5 and 6
Demonstration of EGF receptors in CaP.
Immunocytochemical method
i) Plate 5 Indirect immunoperoxidase technique
Details of the procedure are described
under section 2.14(a).
Briefly, 3-4 ;um cryostat sections were
treated with monoclonal antibody to the external
domain of the EGF receptor. This was followed
by secondary antibody conjugated with peroxidase.
Reaction was detected by diaminobenzidine (DAB)
and finally counterstained with Harris haematoxylin
and mounted in DPX (Plate 5).
ii) Plate 6 Labelled avidin biotin technique
Details of the method are outlined under
section 2.14(b).
Briefly, 3-4 pim frozen sections were
fixed in acetone. Sections were then treated
with primary antibody (1/30 dilution) for 24 hours.
After treatment with sheep antimouse biotinylated
immunoglobulin followed by streptavidin alkaline
phosphatase, Colour was developed by fast red
ITR in the presence of fresh alkaline phosphate
substrate (napthol ASBI phosphate). Sections
were counterstained and mounted in glycerin*, jelly
(Plate 6).
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Plate 5B (x 333)
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Plate 6A (x 133)
Plate 6B (x 333)
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3.7 Comparison of EGF receptor levels in BPH and CaP:
Two techniques were used and these were:-
a) Radioligand assay technique
b) Immunocytochemical method -
i) Indirect immunoperoxidase method
ii) Labelled avidin biotin method
a) Radioligand assay:
Establishment of the presence of EGF receptors in both BPH
and CaP prompted the decision to compare the receptor levels in BPH
and CaP and also to correlate the EGF receptor levels with the various
grades of the CaP.
18 BPH and 19 CaP tissues representing the various histo¬
logical grades of CaP were selected for EGF receptor assay by radio¬
ligand assay technique. Figure 30A shows that the 18 BPH tissues
125
contain an average of 125 fmol of I-EGF/mg protein. In contrast,
the data on 19 patients with CaP shows a marked reduction in specific
EGF binding (mean - SD = 52 - 11 fmol/mg protein) (Figure 30A). As
demonstrated in Figure 30A, results of the two groups show a statisti¬
cally significant difference between the mean levels of EGF receptor
in BPH and CaP (P<0.01). The bulk of the BPH tissues (17/18) were
found to be positive for EGF receptors, whilst only 10 out of 19
malignant tissues were found to be positive. But when the EGF
receptor expression was correlated with the histologic grades of the
malignant tissues, a strong relationship between the levels of EGF
receptor binding and histological differentiation was observed
(Figure 30B). Weirdijj^KWW tG^0^(Gleason score 2-4) maintain
164
Figure 30
Presence of EGF receptors in BPH and CaP
a) Radioligand assay:
18 BPH and 19 CaP tissues were analysed by radio¬
ligand assay, as detailed under Section 2.11 for EGF
receptors.
1
Briefly, 100 pi of 8.0 nmol/L I-EGF was incubated
with 100 pi particulate fraction of either BPH or CaP
at 37°C for 90 minutes. Separation of bound complex
from free was achieved by PEG precipitation.
After counting radioactivity retained in the pellet,
specific binding was calculated by subtracting non¬
specific from total binding.
Relationship between specific binding obtained in
BPH and CaP was established. Also established was the
correlation between specific binding and the histologic
grades of the prostate tumour, based upon Gleason score.
A: Comparison of mean specific binding of BPH with CaP.
B: Comparison of mean specific binding with the histo¬
logic grades of CaP.
Values are means of 3 different samples, each
analysed in duplicate.
165







significantly larger concentrations of the receptor (mean - SD =
84 - 13 fmol/mg protein) than the poorly differentiated tumours
(Gleason score 8 - 10) in which the majority of the tissues were
devoid of EGF binding (Figure 30B).
b) Inmunocytochemical methods:
i) Indirect immunoperoxidase technique using MAB EGF-R^ (for
external domain of EGF receptor):
Comparison of the EGF receptor levels in BPH and CaP was
further confirmed by using indirect immunoperoxidase technique in which
a monoclonal antibody specific to the binding site of the EGF receptor
was used.
Plates 7 and 8 show that staining with the antibody was
confined to the basal layers of the epithelial cells. Furthermore,
BPH and well differentiated tumours (Gleason score 2-4) demonstrated
an intense immunocytochemical staining (+++), whereas the poorly
differentiated tumours (Gleason score 8-10) showed little or no
staining at all (-) (Plate 9). Histologically the well differentiated
CaP exhibited a marked increase in acinar glands which resulted in a
decrease in interacinar stromal tissue compared with the large inter-
acinar stromal spaces seen in BPH tissue. The intensity of staining
was also observed to correlate very well with the degree of receptor
positivity.
ii) Labelled avidin-biotin technique using MAB to the external
domain (EGF-R^) of EGF receptor:
The picture was identical to the one given by immunoperoxidase
staining using DAB as chromogen described under section 3.7(b)(i).
Briefly, positive staining of BPH indicated by red colour, was confined to
the basal layers of the epithelial cells, whilst the adjacent stroma
remained clear (Plate 10).
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b) Plates 7, 8, 9- Presence of EGF receptors
in BPH and CaP
i) Indirect immunoperoxidase technique:
18 BPH and 19 CaP tissues were analysed for EGF
receptors, as described under section 2.14.
Briefly, BPH and CaP cryostat sections were
fixed in acetone for 20 minutes. After blocking
endogenous interfering substances with normal rabbit
serum (NRS), the sections were treated for 30 minutes
with 1/30 dilution of monoclonal antibody (EGF-R^) .
This was followed by secondary antibody (peroxidase
conjugated rabbit antimouse immunoglobulin) and
subsequent colour development with diaminobenzidine
(DAB) and counter-staining with haematoxylin.
Finally, sections were mounted with DPX.
Relationship between colour intensity and
receptor level in BPH and CaP was established.
Secondly, correlation between colour intensity due to
receptor levels according to the histologic grades of
the tumour based on Gleason score was established.
Intensity was graded as negative (-), moderate (+) or
very intense (++) - (+++).
Scoring was the result of 3 independent
observers.
Plate 7: Showing BPH positive staining.
Plate 8: Showing well differentiated CaP stained
section.
Plate 9: Showing poorly differentiated CaP stained
section.
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Plate 7 (x 133)
Plate 8 (x 333)
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Plate 9A (x 133)
Plate 9B (x 333)
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BPH (Plate 10) and well differentiated (WD) tumours (Gleason
score 2-4) (Plate 11) demonstrated intense staining (+++), whilst
poorly differentiated tumours (8 - 10) showed little or no staining
(Plate 12). The WD tumours showed a closely packed acinar glands
with little or no stromal invasion, whilst the poorly differentiated
(PD) showed extensive stromal invasion. Good correlation was again
observed between the immunocytochemistry and biochemical results.
Summary of radioligand assay and immunocytochemical
results on BPH and CaP
Comparison between the immunocytochemical and biochemical
results, as indicated in TABLE 5, reveals that there is good correla¬
tion between the two techniques. This correlation is not only seen
in BPH tissues but also in CaP tissues. In the CaP intensity of
staining varies according to the histologic grades of the cancer.
These intensities also correspond to the receptor levels in (fmol/mg
protein) measured biochemically, thus confirming good correlation
between the results of the two techniques in all the 37 tissues
analysed.
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Plates 10, 11, 12: Presence of EGP receptors in BPH
and CaP:
ii) Labelled avidin biotln technique:
The method is identical to the one described
under section 2.14(b).
Briefly, frozen sections were treated with primary
antibody EGF-R^ (1/30 dilution) and incubated overnight.
Sections were furthehWtLt biotinylated sheep anti-
mouse immunoglobulin followed by streptavidin - AP in
the presence of alkaline phosphatase substrate (napthol
ASB1 phosphate).
Colour was developed by fast red ITR. Sections
were subsequently counterstained with Mayers haematoxylin
and finally mounted in glycenne. jelly.
Plate 10: Showing BPH stained section.
Plate l1. Showing well differentiated CaP stained
section.
Plate 12: Showing poorly differentiated CaP stained
section.
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Plate 10 (x 133)
Plate 12A (x 133)
Plate 12B (x 333)
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TABLE 5-
EGF RECEPTOR LEVELS IN BPH AND CaP:
SUMMARY OF RESULTS
Biochemical and immunocytochemical techniques
were used to measure the EGF receptors in BPH and CaP
tissues.
Details of the procedures are described under
section 2.11 (Biochemical technique) and 2.14(a) and
(b) (Immunocytochemical method). The results
obtained for BPH using the two techniques and
those obtained on various histologic grades of CaP
are summarised. The biochemical results are
expressed as number of binding sites in ftaol/mg
protein and as means - SD of samples analysed.
The Immunocytochemical results are, however,
expressed as scores of staining intensity and graded











BPH — 125 (+)-(+ + +) 18
[
2-4 84 ( + )-(+ +) 4
\
CaP j 5-7 52 (+)-(+ +) 10
8-10 20 — 5
176
3.8 Demonstration of the presence of the internal domain
of the EGF receptor using MAB F4:
This was investigated on 18 BPH and 19 CaP tissues by using a
newly developed monoclonal antibody to the internal domain of the BGF
receptor (F4) (Berger et al, 1987). In some tumours, loss of cell
surface receptors is explained in terms of expression of truncated
receptors which have no external domain and therefore are devoid of
binding sites. The introduction of the F4 monoclonal antibody has
enabled some workers (Berger et al, 1987) to look for truncated EGF
receptors, i.e. the internal domain of the receptor in tumours.
This prompted the author to look for the presence of truncated receptors
or the internal domain of the EGF receptor in the poorly differentiated
CaP which did not show any EGF binding, by using the monoclonal anti¬
body F4.
Two immunocytochemical techniques were used, namely:-
a) Indirect immunoperoxidase technique
b) Labelled avidcn-biotin technique
a) Indirect immunoperoxidase technique: MAB F4:
Staining with MAB F4, employing the above technique and using
DAB as chromogen, produced an intense non-specific stromal staining.
As can be seen, Plates 13, 14, 15,- 16 are stained sections of
BPH, well differentiated and poorly differentiated CaP respectively, but the
intensity of the stromal staining makes visualisation of the cyto¬
plasmic staining produced by MAB F4 difficult.
b) Labelled avidin-biotin technique using monoclonal
antibody MAB F4:
Staining with MAB F4, using the above technique, produced
a much clearer picture. Staining was mainly cytoplasmic. No
staining was associated with the basal layers of BPH (Plate 18).
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Plates 13, 14., 15, 16
Demonstration of internal domain of EGF-R^ using
MAB F4 (Indirect immunoperoxidase method)
The technique is fully described under
section 2.14(a).
Briefly, sections were fixed and treated
with primary antibody (MAB F4) at concentration of
0.05 mg/ml for 30 minutes. Sections were thereafter
passed through the whole staining procedure as outlined
in section 2.14(a). Sections were later counter-
stained with Harris haematoxylin and mounted using DPX.
Plate 13: Showing BPH stained section, negative control
Plate 14: Showing BPH stained section, positive control
Plate 15: Showing well differentiated CaP stained
section.
Plate 16: Showing poorly differentiated CaP stained
section.
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Plate 13 (x 133)
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Plate 14A (x 133)
Plate 14B (x 333)
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Plate 15A (x 133)
Plate 15B (x 333)
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Plate 16A (x 133)
Plate 16B (x 333)
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Well differentiated CaP (G/S 2 - *0 exhibited a much more intense
staining (+++) (Plate 19), whilst the poorly differentiated CaP
(G/S 8 - 10) was either weakly positive (+) (Plate 20) or was
negative (Plate 17). It appears that the poorly differentiated CaP
does not express any truncated receptors. Comparison of the intensity
of staining produced by BPH (Plate 18) with that of well differentiated
CaP showed that staining was more intense in CaP than BPH.
c) Comparison of staining results using monoclonal
antibodies F4 and EGF-F^
Immunocytochemical results on BPH and CaP using monoclonal
antibody to the external domain (EGF-R^) and the internal domain (F4)
were compared.
TABLE 6 <c>V->oi4^ a summary of results obtained. On BPH
the two monoclonal antibodies showed an intense staining: (++) - (+++)
indicating the presence of both internal and external domains of the
receptor in BPH, although the intensity of staining seen using EGF-R^
was greater than that observed using the F4, but the staining intensity
observed in the well differentiated CaP, using both EGF-R^ and F4 was
identical. The intensity was (+++) in each case. With regard to
poorly differentiated CaP, monoclonal antibody EGF-R^ did not show any
staining at all. This picture was repeated using the F4 monoclonal
antibody except an isolated patch which showed a faint positivity.
Furthermore, it is noteworthy that using the EGF-R^, staining
was confined to the basal layers of the epithelial cells of BPH,
whilst the staining produced by F4 was mainly cytoplasmic. The absence
of binding observed in the poorly differentiated CaP could stem from
total disappearance of the receptors, probably with the external
domain disappearing faster than the internal.
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Plates 17, 18, 19, 20
Demonstration of internal domain of EGF receptor
using MAB F4
The technique is described under section 2.14(b).
Briefly, frozen sections were fixed in acetone
and passed through the staining procedure as outlined
under section 2.14(b). Monoclonal antibody F4 was
used as the primary antibody at a concentration of
0.05 mg/ml and incubation lasted overnight. Sections
were subsequently treated with biotinylated sheep
antimouse immunoglobulin followed by streptavidin -
AP in the presence of alkaline phosphatase substrate.
Colour was developed by fast red ITR. Sections were
counter-stained with Mayers haematoxylin and finally
mounted in glycerin^ jelly.
Showing BPH stained section, negative control.









Plate 17B (x 333)
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Plate 18A (x 133)
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Plate 18B (x 333)
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Plate 18C (x 333) is also showing secretions into
the acinar.
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Plate 19A (x 133)
Plate 19B (x 333)
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Plate 20B (x 333)
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TABLE 6.
SUMMARY OF STAINING RESULTS USING MONOCLONAL
ANTIBODIES EGF-R-[ AND F4
Labelled avidin biotin staining technique was used
to demonstrate the presence of the external and internal
domains of the EGF receptor using monoclonal antibodies
EGF-R^ and F4 respectively.
The technique is identical to the one described
under section 2.14(b).
Briefly, frozen sections were treated with primary
antibodies EGF-R^ (1/30 dilution) and F4 (0.05 mg/ml
concentration) and incubated overnight. Sections were
further treated with biotinylated sheep antimouse immuno¬
globulin followed by streptavidin - AP in the presence
of alkaline phosphatase substrate (napthol ASB1 phosphate).
Colour was developed by fast red ITR. Sections were
subsequently counterstained with Mayers haematoxylin and
finally mounted in glyctrW jelly.
The procedure was performed on BPH, well (G/S 2-4)
and poorly differentiated CaP (G/S 8 - 10) tissues.
Staining intensity was scored as negative (-), moderate
(+) or intense (++) - (+++) by 3 different observers.
The staining localisation and intensity obtained by each




Tjssue (Ext. Domain) (Int. Domain)
B.P.H. +++ ++
Ca P (W.D.) +++ +++
Ca P (P.D.) - +-
Area stained Basal layers of epithelium Cytoplasmic
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Other experiments:
3-9 EGF receptor blocking experiment:
Radiolabelled monoclonal antibodies are now widely used in
immunotherapy. Increased expression of EGF receptors on human
glioblastomas prompted Epenestos et al (1985) to treat a patient with
glioblastoma multiforme which was EGF receptor positive, with mono¬
clonal antibody to the receptor, labelled with iodine 131. In view
of these reports, it was decided to investigate if the monoclonal
antibody could block the EGF binding with the human prostate.
Comparison of the data presented in TABLE 7 indicates that pre-
treatment of the prostate particulate fraction with monoclonal
antibody did not achieve any blocking effect (A). EGF binding studies
still showed high levels of specific binding as control (B).
Similarly, pretreatment of sections with EGF prior to immuno-
cytochemistry still showed positive staining. Plate 21 is showing
staining before treatment whilst Plate 22 indicates staining after
treatment.
These results show that the two treatments could not achieve
any blocking effect. The reason for these results may be due to
the fact that EGF may be recognising a site distal to the binding
site of the monoclonal antibody.
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TABLE 7.
BLOCKING OF EGF RECEPTOR SITE
BPH particulate fraction was pretreated with 1/30
dilution of monoclonal antibody to the EGF receptor site
(external domain) (Column A).
After washing the particulate fraction with buffer B
and centrifugation, pellet was reconstituted in 500 pi
buffer B. 100 pi aliquots of the treated sample were
125
incubated with 100 pi of I-EGF in the presence and
absence of 50-fold excess unlabelled EGF at 37°C for
125
90 minutes. I-EGF bound complex was separated
from free by PEG precipitation and centrifugation.
Specific binding was calculated by the method described
under section 2.11.
In another experiment the above procedure was
repeated, on the same particulate fraction, which was
not treated with monoclonal antibody and this served as
the control (Column B).
The test was repeated on 3 different samples and


























Plates 21 and 22
EGF receptor blocking experiment
Irnmunocytochemical technique
(Indirect immunoperoxidase method)
The method is outlined under section 2.14.
Briefly, 3 - 4 urn sections were fixed in acetone
and pretreated with EGF (300 ng/ml). Another section
was not pretreated with EGF and this served as control.
The two sections were subjected to the same steps
outlined in 2.14(a) using monoclonal antibody to the
external domain of the EGF receptor.
Plate 21: Before treatment.
Plate 22: After treatment.
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Plate 21 (x 333)






Data presented in this report demonstrate for the first time
that the human prostate contains high affinity binding sites for mEGF.
Biochemical and immunocytochemical techniques show that more than 85%
of BPH tissues examined contain the EGF receptors which are found to
be mostly concentrated in the basal layers of the epithelial cells.
Prior to characterisation of the binding proteins in BPH, it was
decided to study the pattern of EGF binding with subcellular fractions
of BPH tissue. Since no enzyme markers were used, these fractions
should not be described as pure. Furthermore, methods of separating
specific from non-specific binding were also investigated.
4.1 BINDING WITH SUBCELLULAR FRACTIONS; SEPARATION METHODS
Investigation into EGF binding with subcellular fractions of
BPH, demonstrated the pattern of distribution of the receptors among
the intracellular organelles. This revealed that the bulk of the
receptors (68%) are associated with the 800g crude heavy pellet,
whilst the remaining receptors were distributed between the microsomal
and mitochondrial fractions. There was no specific binding associated
with the cytosol fraction (TABLE 3). The presence of the ligand
binding sites in the intracellular organelles is difficult to explain.
Ramani et al (1986) made similar observations when they studied the
distribution of EGF receptors in the human placenta organelles.
The following are some possibilities which may explain the presence
of the receptors in the organelles. It is thought that receptors in
the organelles might represent those in a catabolic route following
125
internalisation. Binding with exogenously added I-EGF suggested
that the endogenous bound ligand dissociated during the experimental
procedure or during internalisation process. Furthermore, receptors
in the intracellular organelles might represent newly synthesised
receptors. A portion of the intracellular receptor might be a normal
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component of the organelles. Internalised I-EGF might associate
with the intracellular organelles leading to generation of biological
signals of the ligand action. The final fate of the receptor bound
complex, however, is not clear, but it is thought that internalised
receptors are either recycled or degraded (Stoscheck <x^A. Ccvr^ot-avr
Teslenko et al, 1987).
It is not certain whether the EGF binding proteins associated
with the various subcellular fractions of the BPH homogenate have
identical characteristics or are different proteins. Although
Ramani et al (1986) observed that all the EGF binding proteins
associated with the subcellular fractions of the placenta exhibited
curvilinear plots, these proteins also showed other different bio¬
chemical characteristics. Similar detailed investigation may help to
establish fully the binding characteristics of the proteins which are
associated with the various fractions of BPH.
Alternatively, since marker enzymes were not used to ensure the
125
purity of the subcellular fractions, it is also possible that I-EGF
binding associated with the various fractions could have resulted from
cross-contamination from one fraction to the other. In this regard,
it is possible that all the binding proteins could be identical.
The importance of separating bound complex from free
125
during I-EGF binding studies cannot be overemphasised. The
reliability and reproducibility of the binding assay depend in part on
a very efficient method of achieving separation between the specific
and non-specific binding.
Experiments designed to select a suitable method of separating
specific from non-specific binding show that PEG precipitation and
centrifugation technique is the most suitable method for achieving
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this effectively. Comparison between filtration and PEG methods
(Figure 12) shows that the PEG method produced 16% more specific
binding than the filtration technique compared to control values.
Furthermore, the background count for the PEG method is also 16% less
than that of the filtration technique, provided the centrifugation
time of the PEG method is restricted to 20 minutes (Figure 14), which
time has been shown to be optimal for EGF binding in BPH. Centrifu¬
gation for less than 20 minutes (Hwang et al, 1986) may have
undesirable effects on the binding and this may include underestimation
of the EGF binding in BPH.
4.2 CHARACTERISATION OF THE EGF RECEPTOR IN BPH
The features of EGF binding in BPH are similar to those observed
for other EGF target tissues. EGF binding in BPH is time and
temperature dependent (Figure 16). The dissociation of bound complex
is also time dependent, being faster in the presence than absence of
excess unlabelled EGF (Figure 17A and B). The EGF receptors are
saturable (Figure 18 (insert).
The specificity of binding is also demonstrated by the fact that
no other unlabelled polypeptide exhibited any competition apart from
mEGF (Figure 19), although slight competition (<20%) was offered by
human growth hormone, probably indicating a role for growth hormone
in the prostate. Scatchard plot analysis has revealed a curvilinear
plot suggestive of two classes of binding sites of higher dissociation
constant (Kd) (mean = 0.8 ^ SD 0.2 nmol/L) and lower dissociation constant
(Kd) (mean = 7.6 - SD 2.8 nmol/L) affinities (Figure 18). Curvilinear
plots have also been reported by many workers including Hofmann et al
(1984); Sainsbury et al (1985) and Ramani et al (1986). Although
the lower affinity values differ from one target tissue to the other,
it is noteworthy that the higher affinity values are all confined to
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a range of 0.2 nmol/L to 2 ntriol/L. In this regard, the value for
the higher affinity receptors obtained in this report (0.8- .2 ntnol/L)
falls within the usual range reported by other workers. Furthermore,
the workers who reported linear Scatchard plots consistent with single
class of binding sites (Hock+HolU^Wr^, l^o; Mukku+SW»c.«A(1985; Traish
+ Motix, 1987) also obtained only the higher affinities in the range
0.2-2 niriol/L. This range of affinities appears to be part of the
general characteristics of the EGF receptor. It is therefore in
order to conclude that these characteristics also apply to the EGF
binding protein in the human prostate.
The presence of curvilinear Scatchard plots has been explained
in many ways. Curvilinear plots are suggestive of multiple
binding sites resulting from heterogenous nature of the tissue, under
investigation. In a recent study on whole mammary glad membranes,
two sets of independent receptor sites were identified (EcLry et al,
1985), whereas only one class of receptors was demonstrated in isolated
epithelial cells from the same gland. Since the prostate also consists
of a mixture of epithelial and stromal cells (Cowan et al, 1977) it is
conceivable that the heterogeneity of the specimen analysed could be
responsible for the curvilinear Scatchard plots obtained in this study,
but the localisation of the EGF receptors to the basal layers of the
epithelium (Plate 2) makes this possibility unlikely. The significance
of the two binding sites is not well understood. In this report two
forms of protein have been described (Figure 15) and whether the
curvilinear plots observed stem from the presence of the two different
proteins is not very clear. However, recently Boni-Schnetzler t <°i l<^U,
(1987) showed that the presence of high and low affinity binding sites
was the result of formation of active receptor dimers from inactive
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receptor monomers. Active dimer formation was thought to be
necessary for the generation and maintenance of the mitogenic signal.
Furthermore, it is believed that only a small portion of the receptors
bind with high affinity and a large portion bind with low affinity,
as seen in this report (Figure 18). Other evidence for the
existence of two forms (higher and lower) affinities of EGF receptors,
was given by Adamson (1981) who suggested that EGF bound
preferentially to the higher affinity and later to the spare or lower
affinity receptors. The lower affinity receptors have recently been
implicated in inhibition of cell differentiation (Boonstra et al, 1985).
Investigation of effect of tissue protein concentration on EGF
binding in BPH shows that there are two forms of EGF binding proteins
(Figure 15 A and B). It appears that one form of protein is present
at a lower concentration up to 1 mg/ml (Figure 15A) whilst the second
form is present at a much higher concentration, between 1.5 and 8 mg/ml
(Figure 15B). This probably explains in part the two linearities
seen (0.1 - 1 mg/ml) and (1.5 - 8 mg/ml). Furthermore, the presence
of two forms of protein is again demonstrated when BPH particulate
fraction is exposed to higher temperature prior to EGF binding.
Exposure of the particulate fraction at 45°C for 10 minutes prior to
binding reversibly inactivates the EGF receptor by 90% of control, as
shown by the binding result (Figure 21A) , but exposure of the fraction
at higher temperatures of 65°C and 75°C for 10 minutes paradoxically
produced 30% and 40% increased binding respectively over control
value (Figure 21A). However, when the particulate fraction was
exposed to 95°C for 10 minutes prior to binding there was a complete
irreversible inactivation of the receptor, as shown by the binding
result (Figure 21A). But incubation of the fractions at 65°C, 75°C
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and 95°C show that the rise in binding observed for 65°C and 75°C
is only transient, as it falls sharply after 30 minutes and 20
minutes respectively. At 37°C (control) however, no such fall is
observed, whilst at 95°C no binding is observed at all (Figure 2U3).
This finding indicates that there must be two forms of EGF
binding protein present in BPH, and that one form is more sensitive
to heat than the other. Alternatively, the transient increase of
EGF binding observed at the higher temperatures may represent occupied
endogenous receptors which are dissociated from the EGF receptor
complex at a higher temperature and therefore bind exogenous EGF.
The tightness of the complex may be so strong that it may require
a higher temperature to dissociate it. EGF is known to be heat-
resistant up to 100°C for 10 minutes (Taylor et al, 1974), but not
much is known about the effect of heat on the EGF receptor. Hock ar>d
HolltKUrcj^Ko-Ramani et al (1986), however, observed irreversible
inactivation of the EGF receptor at 55°C and 65°C respectively in
the human placenta.
The literature is also full of information about proteins which
are formed as a result of heat shock. Whether one of the two forms
of proteins seen in the two experiments described above (Figures 15
A and B; 21 A and B) belong to this category of heat shock proteins
is not clear. The response of cells to heat shock has been known
since the work of Ritossa (1962), on J)rosophila Studies
on heat shock proteins (HSPS) have been carried out by many workers
including Kellyt-SckUs>in°|ev-(ihl^) It is now known that virtually all
organisms* from E. Coli to man have heat shock proteins (Schlesinger
et al, 1982). Major heat shock proteins were thought to have been
strongly conserved in structure through evolution, indicating that
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they play a role in the survival of the organism. Their presence
appears to enhance the cell's ability to recover from stress, but
precisely how is the question many workers are trying to answer.
The molecular weight of heat shock proteins is thought to be small,
being in the range of 20 - 90 KDA. It is believed that the small
molecular weight heat shock proteins form large insoluble aggregates
after heat shock, but these aggregates dissociate during cell recovery
(Collier cv^xd. ScUl«-"S(.n^ev-, i^?O.
Cells from different organisms respond differently, depending on
the extent of the temperature stress. This may probably explain the
difference in heat response by the placenta (Hock •+BolWv4wr°|l I0)?0; Ramani
et al, 1986) and the prostate (Figure 21) in this report.
Serendipity is the gift of finding valuable or agreeable things
not sought for, and it accounts for many important discoveries. The
heat shock phenomenon is no exception. The way heat shock proteins
help a cell tolerate heat remains a mystery. It has been assumed
that the consequence of heat shock is always denaturation of proteins
followed by degradation, but it has now been shown that this is not
always the case. Munro+RtlUo.^ (1984) showed that there was stabilisation
of proteins after heat shock.
Earlier reports indicated absence of EGF receptors in the human
BPH tissue (Gregory et al, 1986). This prompted investigation into
some of the possible factors that could influence EGF receptor levels
in BPH.
Comparison of urogastrone binding, with the binding of mEGF to
the human BPH particulate fraction showed that the level of specific
binding produced by mEGF was 70% more than what was observed for
urogastrone (TABLE 4). This means that using urogastrone, the level
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of EGF receptor in BPH is grossly underestimated by as much as 70%.
This degree of underestimation could have important implications on
the EGF receptor measurement, particularly when EGF receptor levels
are low in the tissue. Low result could also be further accentuated
if microsomal fractions are used instead of total particulate fraction
(TABLE 3).
Although the above report confirms the findings of Savage
£+ aL (1972) and Gregory (1975), the degree of binding to BPH by
each ligand is found to be very different. The difference in the
binding characteristics of the two ligands may be due to their
different affinities for EGF receptor in BPH. Since the work of
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Gregory et al (1986) involved interaction between I-urogastrone
and the human BPH, it is tempting to speculate that the absence of
receptors obtained could be due to low affinity of human urogastrone
for BPH and probably the use of microsomal fraction.
The prostate tissue was further investigated for the presence of
endogenous EGF or its receptor. The use of MgCl^ and dextran coated
charcoal (DCC) failed to establish the presence of endogenous EGF in
BPH (Figure 24A). The absence of endogenous EGF in the human prostate
had been previously established (Elder et al, 1978; Gregory et al,
1986) using immunocytochemical methods. The absence of endogenous
EGF in the rat prostate was also recently established using MgC^ and
DCC, but Leake et al (1983), on the other hand, were able to improve
prolactin binding in the human prostate using these reagents. MgCl^
has been shown to dissociate tightly bound endogenous ligands from
their receptors, whilst DCC removes possible binding inhibitors from
the tissue extracts (Kelly et al, 1979). However, Hirata and Orth
(1979) measured a small quantity of EGF (less than IngEGF/g) from
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the prostate of a 48 year old man obtained at autopsy, using radio¬
immunoassay technique. Similarly, Traish-t-(1987) also measured
large quantities of EGF (5 - 10 ng/g) in the rat prostate, using a radio¬
immunoassay technique basedon a commercial kit.
These reports showed that the choice of technique had important
implications on detection or measurement of endogenous ligand or its
receptor. Furthermore, on the basis of these reports, it would seem
that the human prostate contains very little endogenous EGF (less than
1 ng/g), but the establishment of the EGF receptors in the prostate
argues for a role for the ligand in the human BPH tissue. Whether
the small quantity of EGF in the prostate is a normal requirement of
the prostate, is not known. Furthermore, whether the prostate depends
on EGF from another source or not is also not known, but recently
Gregory et al (1986) measured large quantities of urogastrone EGF in
the human prostatic fluid. Levels found in BPH were half those found
in age matched normal controls. The lower level found in BPH is
interesting. It is a clear-cut biochemical difference between the
two groups. The questions that should be addressed are: Why is
the level in the prostatic fluid of BPH lower than in the normal
prostatic fluid by as much as 50%? Does EGF in the prostatic fluid
diffuse into the prostate tissue to function by interacting with its
receptors in the tissue? Whether the high level of EGF seen in the
normal prostatic fluid is due to refractoriness of the normal prostate
tissue to EGF is not clear. Normal human urothelium has been shown
to exhibit refractoriness to EGF (Messing-t&auk^, 1987). Furthermore,
loss of refractoriness of tissue to EGF has been suggested as an early
event in the development of dysplasia and neoplasia (Messing +
1987). It is speculated that in BPH there may be loss of refractoriness
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which may now allow the ligand to diffuse into the tissue to interact
with its receptor, hence the lower levels of EGF remaining in the BPH
prostatic fluid. There is yet another possibility. In a preliminary
investigation, it was revealed that the normal prostate expressed no,
or very little, EGF receptors. (The source of normal prostate was
from whole body donors, aged less than 30 years, but this investigation
was curtailed because of the di^cuM-iuS. in obtaining this kind of tissue.)
It is possible that the absence of EGF receptors in the normal prostate
may be responsible for the lack of effect of EGF in normal tissue. In this
regard, any synthesised EGF in the normal prostate may be secreted
into the prostatic fluid, but the presence of EGF receptors in BPH
may allow some of the synthesised ligand to be retained probably to
function there. It is hoped that some of these speculations may
help to establish the reason for the difference in the level of EGF-
urogastrone between normal and BPH prostatic fluid.
Alternatively, prostatic growth and development may not only
depend on EGF but also on other growth factors present in the prostatic
tissue which may be functioning in concert with EGF. Recently many
workers have described many mitogenic factors isolated from human BPH,
rat prostate and adenocarcinoma of the human prostate (Jacob and
Lawson, 1980; Story et al, 1983; Jinno et al, 1986; Maehama et al,
1986; Koutsileris et al, 1987). These mitogens were shown to be
different from EGF as they all have different physicochemical and
biological characteristics from those of EGF and also from one another.
They have been implicated in BPH formation. Recently, the impact of
multiple growth factors and the multifunctional role of growth factors
on tissue growth, development and maintenance has been highlighted
(Sporn and Roberts, 1988). It is suggested that the fine tuning
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required by adult tissue is provided not by one growth factor but by
multiple growth factors and the multifunctional activities of growth
factors. The mechanism by which this fine tuning of the tissue is
achieved is not clear but may result from interaction between growth
factors (Roberts et al, 1985) or growth factor receptor interaction
(Bowen-Pope et al, 1983; Zacharyti(czaTY''«-t.i985).
It is noteworthy that some of the mitogenic factors described
have almost identical characteristics as TGFp in terms of molecular
weight, presence of disulphide bonds and stability in heat and acid
(Maehama et al, 1986). The inhibitory effect of TGFp on fibroblast cjm-iU
in the presence of EGF is documented (Roberts et al, 1985). Furthermore,
the molecular weight of one of the species described as a mitogen in
BPH and CaP is 10,000 daltons. This is very close to that of EGF
(6,045 daltons) (Koutsii'zris et al, 1987). It is possible that on
further purification, the 10,000 daltons molecular weight species may
turn out to be EGF. These findings give an insight into the nature of
mitogenic growth factors that may be functioning in the prostate and
therefore may be implicated in BPH and CaP formation. It is likely
that these growth factors may include EGF and TGFjB.
Further evidence of the presence of the EGF receptor in the human
prostate was achieved by cross-linking and phosphorylation studies.
These studies established the molecular weight of the receptor and
demonstrated phosphorylation of the EGF receptor in BPH. Affinity
labelling, chemical cross-linking with DSS followed by SDS-PAGE
analysis of the cross-linked complexes and autoradiography produced
a wide band between 150 and 170 KDa molecular weights (Figure 26
Lane A), as determined by molecular weight markers. The specificity
of the band was demonstrated by its disappearance in the presence of
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excess unlabelled EGF (Figure 26 Lane B). The molecular weight of
EGF receptor is known to be 170 KDa (Cohen et al, 1980; 1982), but
sometimes a minor protein (150,000 daltons molecular weight) is also
observed, which is believed to be a fragment of 170 KDa molecular
weight protein produced by proteolysis (Lisley and Fox, 1980; Cohen
et al, 1982; Cassel, 1982). EGF receptor expression in the human
BPH compared to other tissues (human placenta, rat uterus and human
breast tumour etc) is relatively low. Usually only a small proportion
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of the receptors are crosslinked to I-EGF. This presents a problem
when the receptors in the tissue under investigation are low. It was
therefore with considerable difficulty that a positive cross-linked
EGF receptor complex was demonstrated in this investigation. It is
recommended that further work should be done in this area, using BPH
tissue which contains much higher EGF receptor levels to improve upon
the quality of bands obtained in this report.
However, results are consistent with the findings of earlier
workers (Mukku and Stancel, 1985; Ramani et al, 1986; Traish and Wotiz,
1987)- Furthermore, the earliest reported response of EGF binding to
cell surface receptors is the phosphorylation of its own receptor.
Evidence in other systems suggest that EGF binding, the kinase activity
and phosphorylation site for the kinase all reside in the same molecule
(Cohen et al, 1980; 1982). These observations are consistent with the
findings in this report. The addition of labelled ATP to BPH particulate
fraction in the presence of EGF, followed by SDS-PAGE and autoradio¬
graphy revealed that there was phosphorylation of a major protein
(molecular weight 170,000 daltons) (Figure 27 Lane A). The presence
of the minor protein (molecular weight 150,000 daltons) was not
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demonstrated. The molecular weight of the phosphorylation spot was ascertained
by the use of molecular weight standards. The phosphorylation experiment was
repeated but in the absence of unlabelled EGF. It is noteworthy
that the spot of interest appeared only in the presence of (Figure 27
Lane A) but not in the absence of (Figure 27 Lane B) EGF. The reason
is not clear, but it sthat in vitro phosphorylation of
EGF receptor in BPH only occurred in the presence of exogenous EGF,
lending support to the EGF stimulated phosphorylation of its receptor.
This investigation also presented identical problems to the cross-
linking experiments. Further work is again suggested in this area to
improve upon the phosphorylation results.
The presence of EGF receptors in BPH tissue was further confirmed by using
monoclonal antibody specific for the EGF receptor site (Waterfield ,
1982) employing two immunocytochemical techniques. Positive staining
of BPH section was indicated by brown colour (Plate 2) or red colour
(Plate 4). Positivity which showed the presence of the EGF receptor
was confined to the basal layers of the epithelial cells, whilst the
stromal areas remained clear (Plates 2, 4). When the use of the
monoclonal antibody was omitted no positive staining was observed
(Plates 1, 3) indicating that the presence of the monoclonal antibody
was a prerequisite to the development of the positive staining reaction.
The localisation of the EGF receptor to the epithelial cells of
BPH was in agreement with other reports. McKeehan et al (1984)
observed that EGF was implicated in the proliferation of rat prostate
epithelial cell populations. This by implication suggested the
presence of receptors in the epithelial cells. Furthermore, most
recently, Shuurmans et al (1988) measured EGF receptors in the human
prostate tumour cell line (LN CaP), an epithelial line. This also
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lent support to the fact that EGF receptors were confined to the
epithelial cells, but the localisation of EGF to a cell type has not
been reported, although EGF has been measured in the prostate (Hirata
and Orth, 1979; Traish-t-WcWz., 1987). This uncertainty of localisation
of EGF means that the mode of EGF action in the prostate still remains
undefined. However, the findings of Shikata et al (1984) who localised
EGF to the epithelial cells of the guinea pig prostate would seem to
suggest an autocrine mode of action for EGF in the prostate. Further
work is required to identify the cell type which contains the ligand
in the human prostate so as to establish the mode of action. Cunha
et al (1986) and Tenniswood (1986) are of the opinion that growth
factors are produced in the stromal cells of the prostate but have
their proliferative effect on the epithelial cells, suggesting a
paracrine mode of action for growth factors in the prostate.
When EGF receptor levels in BPH, determined biochemically, were
compared with the corresponding staining intensities, it was realised
that there was a good correlation between the biochemical method and
the immunocytochemical techniques. Staining scores were in agreement
with biochemical results expressed in fmol/mg protein for the
corresponding levels of receptors in the human prostate. These
findings indicated that the EGF receptor levels could also be assessed
by degree of staining intensity.
Using biochemical and immunocytochemical techniques, the presence
of EGF receptors was also established in CaP. Scatchard plot analysis
revealed only one class of binding sites with only high affinity
dissociation constant (Kd) (mean = 1.6 - SD 0.4) receptors
(Figure 29). The lower affinity receptors seen in BPH (Figure 18)
were not observed. It is not clear whether the disappearance of the
211
low affinity receptors plays any role in the transformation of BPH
to well differentiated CaP. Boonstra et al (1985) showed that the
presence of low affinity EGF receptors was associated with inhibition
of differentiation.
The presence of the EGF receptors was also confirmed by immuno-
cytochemical methodswhich showed that the receptors were confined to
the epithelial cells, whilst the stromal elements remained unstained
(Plates 5, 6).
4.3 COMPARISON OF EGF RECEPTOR LEVELS BETWEEN BPH AND CaP
The use of biochemical and immunocytochemical techniques was
also employed to establish the difference in the receptor expression
between BPH and CaP. Clearly BPH expresses more copies of EGF
receptors than CaP (p<0.01). It is noteworthy that the bulk of the
receptors in the CaP is confined to the well differentiated CaP.
In this regard, there is no statistical difference between receptor
levels in BPH and well differentiated CaP. However, there is a
gradual disappearance of the receptor as the tumour becomes less
differentiated. This indicates that the receptors are expressed
according to the histologic grades of the CaP (Figure 30B). The
loss of receptors in the moderately and poorly differentiated CaP
is the main reason for the low mean levels observed in CaP compared
to BPH (Figure 30A).
These biochemical findings were confirmed using immunocytochemical
method which depends on staining intensity as a measure of receptor
level. In this regard BPH and well differentiated CaP exhibited
the same order of high intensity staining consistent with high EGF
receptor levels produced by the biochemical technique (Plates 7, 8,
10, 11), but the intensity started to decrease as the tumour became
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less differentiated. Total or near total disappearance of staining
was observed when the tumour became poorly differentiated (Plates 9,
12). This intensity varied according to the histologic grade of the
tumour. The use of immunocytochemistry had the advantage of demonstra¬
ting the neoplastic status of the CaP. The cellular
localisation of the receptor and the degree of cellular differentiation
were also evident. In well differentiated CaP glandular status is
still maintained and comparison with BPH could be easily made. CaP
has no basal layers but the staining is still confined to the
epithelial cells. In CaP there are more acinar glands and less
stromal spaces whereas BPH acinar glands are not as many but are
large and there are more stromal spaces. Furthermore, in the moderately
and poorly differentiated CaP, the histological derangement is more
accentuated. In the poorly differentiated Cap particularly there
is a complete loss of glandular formation and no discernible acinar
arrangement can be seen.
The intensity of staining may therefore reflect an alteration
in the expression of the EGF receptors by the different cellular
differentiation stages. Loss of EGF receptors may therefore be
associated with loss of glandular formation. Loss of EGF binding
could also be explained in terms of presence of v-erb B oncogene
product. Comparison of the EGF receptor with the v-erb B oncogene
product by molecule cloning (Ullrich et al, 1984) revealed that the
v-erb B protein was homologous only with the transmembrane and cyto¬
plasmic domains of the EGF receptor but latKd majority of the extra¬
cellular binding domain. It has been hypothesised that v-erb B protein
which cannot bind EGF in a constitutively active state contributes
to uncontrolled growth and division of infected cells (Downward et al,
1984).
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To test this hypothesis, the human prostate was investigated for
presence ofv-erb B product or truncated EGF receptor by immunocyto-
chemistry using monoclonal antibody which recognises only the internal
domain of the EGF receptor (MAB F4).
Comparison of the staining results on BPH sections (Plates 14, 18)
and well-differentiated CaP sections (Plates 15, 19) clearly demonstrate
positivity of staining indicating that the monoclonal antibody recog¬
nised the internal domain of the receptor, in that staining was mainly
cytoplasmic. The poorly-differentiated CaP on the other hand showed
a negative staining exupt isolated areas which showed faint
positivity (Plates 16, 20) indicating that the internal domain of the
receptor disappeared in the poorly differentiated CaP. The results
obtained using both the monoclonal antibodies to external and internal
domains of the receptor show that there is total disappearance of the
receptor from the poorly-differentiated CaP, the external disappearing
faster than the internal domain.
It is noteworthy that the staining picture produced after using the
technique of immunoperoxidase involving the use of monoclonal antibody
F4 was not in any way clear at all (Plates 13, 14, 15, 16) compared
to labelled avidin biotin technique (Plates 17, 18, 19, 20). The
immunoperoxidase technique produced an intense non-specific stromal
staining which completely overshadowed the epithelial staining, making
interpretation difficult. This problem has also been mentioned by
Berger et al (1987) after staining lung tumours. Since these authors
also used the immunoperoxidase technique, it would appear that the
problem is associated with that technique because it is not seen in
the labelled avidin biotin method. It will be interesting to
investigate this phenomenon.
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However, the presence of EGF receptors in BPH and CaP has been
recently confirmed (Eaton et al, 1988) but these authors did not
observe cwy correlation between the EGF receptor expression and the
histologic grades of the cancer. Furthermore, they observed that
CaP tissues expressed more EGF receptors than BPH. The fact that
they did not observe any correlation of the receptor level with the
histologic grades of the CaP provided an explanation for the higher
receptor levels in CaP than BPH which they observed. If low, or no,
EGF receptors were observed in moderately and poorly-differentiated
CaP respectively, then it should be expected that the mean level of
EGF receptors in CaP would be lower than that of BPH. On the other
hand, if the moderately and poorly-differentiated CaP expressed equal
receptor levels as in well-differentiated CaP, it is unlikely that
CaP tissues would have more receptors than BPH. No statistical
difference between BPH and well-differentiated CaP was observed in
the report of this thesis, although the receptor level is lower in
CaP than BPH. Furthermore, another important consideration lies in
the selection of pure CaP tissues, for the assay. CaP chips of one
particular histologic grade are usually mixed with BPH chips and this
may reduce the proportion of cancerous chips in the mixture and
decrease one's chances of selecting the correct cancerous chip.
The consequence of this is the use of wrong type of tissue. In this
regard, it is important to use also immunocytochemical approach to
confirm the histologic grade of the CaP. However, the correlation
between EGF receptor level and the state of neoplastic progression
observed in this report, has also been observed by many workers using
a whole range of other tissues or cells. For example, increased
expression of receptors was observed in well-differentiated human
215
squamous cell lung cancers but less in poorly-differentiated counter¬
parts (Hendler+Oz<x*w«( 1984). Comparison of EGF receptor expression
between normal and malignant tissues revealed that the bulk of the
receptors were associated with the well-differentiated malignant
tissues, whilst the normal and poorly-differentiated tumours had only small
amounts of the receptors (Gusterson et al, 1984). Furthermore, Libermann
et al (1985) also reported increased expression of EGF receptors in
well-differentiated primary human glioblastoma whilst the poorly-
differentiated tumours had much reduced levels. Associatiion between low
receptor level and poor differentiation has also been reported in
Chinese hamster embryo fibroblasts (Wakshull et al, 1985). Recently
well-differentiated squamous carcinoma cell line was observed to be
associated with high levels of EGF receptor (Cowley et al, 1986).
These authors observed that the well-differentiated cells possessed
ten times mofz. receptor than the poorly-differentiated cells.
These findings are in accord with those presented in this report, in
that increased EGF receptors were seen to be associated with well-
differentiated CaP whilst the poorly-differentiated CaP expressed
little or no receptors. On the contrary, however, other workers
also observed that high EGF receptor expression was associated with
poor differentiation and lymph node metastasis of breast cancer
(Sainsbury et al, 1985) and invasiveness of bladder cancer (Neal
et al, 1985). These examples indicate that the receptor expression
could be used as either a tumour marker or an index of metastatic
potential of the tumour, although this may not be the general rule.
Hwang et al (1986) did not observe any correlation between EGF
receptor expression and the histologic grades of lung cancer, but
with regard to gastric carcinoma the picture is unclear. Whilst
Sakai et al (1986) did not observe any correlation between EGF
receptor levels and the histologic grades of gastric cancer, Yasui et
al (1988) were able to correlate EGF and its receptor levels to the
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histologic grades of gastric carcinoma. The reason for the
difference in the results is not understood. In a recent study,
Sainsbury et al (1987) used the EGF receptor status as predictor of
early recurrence of, and death from, breast cancer.
The reasons for the high or low EGF receptor expression in the
poorly differentiated and metastatic cancers are not clear. However,
some possibilities have been put forward to explain. The following
are some of the reasons for absence of EGF binding in tissues and cells.
It has been shown that binding of EGF to its receptor leads to a decrease
in the receptor density on the cell surface (down regulation) as the
growth factor receptor complex is internalised (Pastan + i^I;
Cohen, 1987). Most transformed cells produce transforming growth
factor cA (TGFo^) (Salomon et al, 1987) which interacts with the EGF
receptor and mimics most of the actions of EGF, i.e. they bind with
high affinity to the receptor, stimulate EGF receptor autophosphoryla-
tion and also cause down regulation during the process of internal-
isation (Todaro et al, 1980). This autocrine stimulation
renders the transformed cell independent of exogenous EGF requirement.
This has been proposed as a model for carcinogenesis.
The implication of the v-erb B oncogene product as another instance
of autocrine stimulation of the cytoplasmic EGF receptor has been
fully discussed under section 1.4(c).
Androgens have been shown to modulate EGF receptor levels
(Traish-+U/o|iz.i 1987). EGF receptor levels in the rat prostate were
increased after castration, but levels were reduced when the castrated
rats were treated with 5^ dihydrotestosterone. The mechanism by which
this modulation is achieved is not well understood. Androgens have
been shown to down regulate and oestrogens to up regulate LH receptors
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in granulosa cells in culture (Jia et al, 1985). These
observations suggest that androgens may modulate the response of
prostatic cells through regulation of other hormone or growth factor
receptors. Androgens are known to elicit the synthesis of growth
promoting substances in the stroma which may have their proliferative
influences on the adjacent epithelial cells (Cunha et al, 1986).
It is tempting to speculate that the presence of androgens may cause
the synthesis of large amounts of EGF in the prostate which may down
regulate the EGF receptors on the membrane surface, thereby causing
their disappearance from the cell surface, but the most recent findings
of Shuurmans et al (1988) are at variance with those of Traish et al
(1987). Shuurmans et al (1988) observed that androgens increased EGF
receptor levels in human prostate tumour cell line (LN CaP). Whether
these differences between the two results were due to the type of
human cell line used by Shuurmans and associates or to species
differences (human and rat), is not clear. This makes the direction
of androgen modulation of EGF receptor levels in the prostate unclear.
EGF receptor loss can also occur through other physical factors.
The human prostate is known to contain a large amount of proteases
(Gotterer et al, 1956; Mannf Alcorn, 1981; Isaacs and Coffey, 1984).
Storage of the prostate tissue is known to aggravate the physical and
proteolytic degradation of receptors in the prostate, but storage of
BPH tissues and particulate fraction at -70°C for 16 weeks did not
alter the EGF receptor levels (Figure 25). This finding is consistent
with those of Trachtenberg et al (198I) who did not observe any change
in androgen receptor level after 90 days storage of human prostate
at -70°C. However, storage of prostate tissue at -20°C resulted in
a 50% fall of androgen receptor level after three months (Smith et al,
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1983). Since all tissues were stored at -70°C, the loss of EGF
receptors in the poorly differentiated CaP could not have been a
consequence of storage.
Furthermore, the proteolytic activities of the enzymes present
in the prostate may also result in inactivation of the EGF receptor
during homogenisation of the tissue and during the incubation period in the
course of EGF receptor assay. This may result in loss of EGF
receptor, but this possibility was ruled out after establishing the
effect of BPH interactions with various enzymes and enzyme inhibitors.
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I-EGF binding with BPH exhibited different binding characteristics
in the presence of various enzymes and enzyme inhibitors. PMSF and
leupeptin improved the EGF binding by up to 15% of control. Aprotinin
and DNASE however maintained the level of receptors without showing
any inhibitory or stimulatory effect. Although trypsin and ^ chymo-
trypsin completely inactivated the EGF receptor, a mixture of trypsin
and antitrypsin (soybean) improved the binding to the same extent as
leupeptin and PMSF (Figure 23). These findings indicate that PMSF,
leupeptin and soybean trypsin inhibitor are effective in removing inhibitory
substances that may be associated with EGF binding with BPH.
Inclusion of PMSF in the buffer ensures stability of the receptors
during tissue processing.
Furthermore, studies concerning influence of pH on EGF binding
with BPH showed that pH 7.4 was optimal. At pH 8 and above binding
fell sharply to basal levels (Figure 20), whilst low levels were also
observed at pH below 7.
These precautionary measures show that loss of receptors seen in
the poorly differentiated CaP was not due to any physical factors but
is associated with the grade of histologic differentiation of the cancer.
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It is also believed that tumour promoters cause inhibition of
EGF binding to the target tissues. The mechanism by which this is
achieved is not clear, but tetradecanoylphorbol-13-acetate (TPA) for
example is thought to activate protein kinase C. By this action
the need for Ca*"*" and diacylglycerol for the activation of protein
kinase C decreases (Nishizuka, 1984; Cochet et al, 1984; Friedman et
al, 1984). Therefore the consequence of either TPA or protein kinase C
)
causes phosphorylation of the EGF receptor. It has been shown that
the action of TPA is typical of other tumour promoters (Nishizuka, 1984;
Cochet et al, 1984).
Receptor loss has also been associated with lack of gene expression.
Molecular evidence has been produced to demonstrate that the lack of
EGF receptor in small cell lung carcinoma cells is due to lack of
the EGF receptor gene expression in the cells (Gamou et al, 1987).
This observation may tempt one to speculate a simular occurrence in
the poorly-differentiated CaP where the receptor loss may be a
consequence of lack of receptor gene expression.
Further evidence of the link between receptor number and biologic
behaviour of the cell was given by a demonstration of the fact that
human oesophageal carcinoma cells have fewer but higher affinity EGF
receptors (Banks-Schlegel and Quintero, 1986). The mechanisms by
which the fewer receptors are expressed is not clear, but may probably
be a consequence of receptor gene reduction or down regulation of most
of the receptors.
Several lines of evidence have been produced in an attempt to
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explain the reason for the increased EGF receptor expression in some
cancerous cells and tissues, although the mechanism is still poorly
understood. Such increases are usually thought to be due to
receptor gene amplification and over expression or gene translocation,
amplification and rearrangement. The high receptor levels observed
in primary human glioblastoma have been found to result from amplifica¬
tion and over expression of the EGF receptor gene (Libermann et al, 1985).
On the other hand, an increase of EGF receptors in epidermoid malignancies
has been attributed to receptor gene translocation, amplification and
rearrangement (Ozanne et al, 1985). EGF receptors have been shown
to increase and cells differentiate in the presence of retinoic acid
(Adamson and Rees, 1981). Retinoic acid binding proteins have recently
been localised in the human prostate (Boyd, 1985). It may, therefore,
play a role in the modulation of the EGF receptors in the BPH and
differentiation of the prostatic cells. It is noteworthy that Boyd
(1985) observed lower level of retinoic acid in poorly differentiated
CaP than in well differentiated counterparts. Glucocorticoids have
also been implicated in increase EGF binding. Binding studies
indicated that dexamethazone treated cells exhibited a 50 - 100%
increase m the.oJoilify to bind trace concentrations of I-EGF and this
was dependent on the concentration of dexamethazone used (Baker et al,
1978). The mechanism, as explained by Baker q_\ cvt, (1978),
involved conversion of receptors to a form having four-fold increased
affinity.
More recently, Shuurmans et al (1988) showed that androgens
paradoxically increased EGF receptors in the human prostate tumour
cell lines (LN CaP). Contrast this report with that of Traish j- Wctix.
(1987), who observed that androgens decreased EGF receptor levels,
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but such results should be interpreted cautiously. The LN CaP cell
lines have been passaged over many years and therefore it is possible
that they might have undergone phenotypic changes which may have
important implications on the androgen EGF receptor interaction.
The link between high EGF receptor expression and poor differen¬
tiation and metastatic potential as observed in the bladder (Neal et
al, 1985) and breast (Sainsbury et al, 1985) cancers is not understood
but in this case, the phase of the cell cycle has been implicated.
The presence of EGF receptors on a cell may be partly a reflection of
the means by which it undergoes rapid division. This was demonstrated
by the fact that three chemically transformed cell lines showed greater
binding of EGF when they were rapidly dividing than when they were
arrested in G1 phase by deficiency of nutrients (Robinson et al, 1982),
but the three non-transformed parent cell lines showed no increase in
EGF binding when they were rapidly dividing (Robinson et al, 1982).
The presence of EGF receptors probably may represent one feature
of the genetic alteration that orchestrates the behaviour of the
malignant cell. EGF receptor level has been shown to be associated
with the capacity of the cell to differentiate. Boonstra et al
(1985) observed in normal and transformed keratinocytes that EGF
receptor expression was related to the state of differentiation and
capacity of cells to differentiate. Furthermore, it was observed
that low affinity binding sites increased considerably as cells were
less able to differentiate. These observations underline the role
of EGF receptors in cancer differentiation.
The reports presented indicate quite clearly that EGF
receptor expression may change in any stage of the neoplastic progres¬
sion. The level expressed may depend upon the type of tissue or cell
and the histologic grade and differentiation of the tumour.
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It seems therefore that the receptor expression could be a
useful tumour marker. Furthermore, it is speculated that the
presence of high EGF receptors in BPH may play some role in the
transformation of the tissue. The basis of this speculation stems
from the fact that EGF receptor expression in BPH and that in well
differentiated CaP are almost identical. This follows that those
tissues which contain high EGF receptor levels are at risk of being
transformed.
This idea is not novel. It has been suggested that elevated
numbers of EGF receptors may represent an important step in neoplastic
progression (Banks-SchlegeltQuinte.ro, 1124), This is again strengthened by
the speculation that increased expression of the EGF receptor above a
certain critical level may result in transformation (Downward et al,
1984). Consistent with these two assertions is the view that the
chronic production of growth factor at a local premalignant site would
precede the immortalising step. This implies that hyperplastic
lesions caused by excess of growth factor or its receptor could
transform to a neoplastic lesion (Burgess, 1986).
It is interesting to note that the relationships between BPH and
cancer of the prostate are traditionally controversial. BPH has been
proposed as a direct cause of prostatic carcinoma or as an intermediate
state between causative factors and carcinoma (Armenian et al, 1974).
However, more recent evidence supports the concept of BPH and CaP as
unrelated diseases which may have different pathogenesis rather than
being part of the same disease spectrum (Hodges and Wan, 1982; Brendler
et al, 1985).
In the light of findings in this report, supported by other reports
which have been discussed in this presentation, concerning the status of
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EGF and its receptor in carcinogenesis, it is tempting to speculate
that there is a direct link between BPH and CaP. This is consistent
with the old school of thought that BPH was thought to be a direct
cause of prostate cancer as stated above (Armenian et al, 1974).
It is the opinion of the author that BPH is transformed to well
differentiated CaP, probably due to the presence of relatively high
levels of EGF receptor in BPH. In the poorly-differentiatedtotal
disappearance of receptors was observed, probably due to lack of EGF
receptor gene expression in the poorly differentiated CaP. Although
increased expression of the EGF receptor may play a role in the
generation of carcinomas, it may also provide a possible site for
adjuvant hormonal or immunotherapy which has* become.attractive
alternative to standard methods of adjuvant therapy (Gilland et al,
1980; Order et al, 1985; Epenestos et al, 1985). In this regard,
experiments were designed to block the binding sites of the EGF
receptor using monoclonal antibody to the external domain of the EGF
receptor, but these experiments failed to achieve any blocking effect
(TABLE 7. Plates 21,22). This may stem from the fact that the mono¬
clonal antibody recognised a site distal to the EGF binding site.
However, monoclonal antibodies are now used in antibody guided
immunotherapy in which the monoclonal antibodies are labelled with
isotopes or toxins. This method is only used in EGF receptor-positive
tissues. Furthermore, the development of monoclonal antibody to the
internal domain of the EGF receptor (F4) (Berger et al, 1987) may also
argue for a role for the use of the monoclonal in antibody-guided
immunotherapy, but these are techniques for the future.
In this report, it has been shown that the human BPH tissue is a
target for EGF by the demonstration of presence of EGF receptors which
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are confined to the epithelium. The receptors have been shown to
be present also in CaP tissues, but the receptor levels in CaP vary
according to the histologic grades of the cancer; well differentiated
expressing more receptors whilst poorly differentiated express little
or none. Furthermore, BPH has more EGF receptors than CaP. The
internal domain of the receptor has also been demonstrated. Poorly
differentiated CaP has no internal domain.
4.4 CONCLUSIONS
In conclusion, the presence of EGF receptors in BPH shows that
EGF has a role in the development, maintenance and abnormal growth
of the human prostate. Furthermore, the presence and distribution
of EGF receptor levels according to the histologic grades of CaP
shows that EGF has a role in the development of CaP and the differen¬
tiation of the tumour. The absence of truncated receptors in the
poorly differentiated CaP shows that the EGF receptors disappear
completely with loss of differentiation of the tumour, but whether
the loss of the receptors is a consequence of the histologic grade of
the tumour, or vice versa, is not clear. When other reports on
growth factor interaction with the prostate are considered together
with the report presented -in this investigation, it is clear that BPH
and CaP may not be caused by a single growth factor. Instead,
multiple growth factors including EGF and related peptides functioning
in concert, and also multifunctional activities of growth factors, may
be implicated in the pathogenesis of the two conditions. Interaction
between growth factors, and also between growth factors and receptors
are thought to be necessary to achieve the fine tuning required by
adult tissue. Derangement of these activities may therefore produce
undesirable consequences. But the production of these mitogenic
225
growth factors is believed to be under the influence of androgens
(Byyny et al, 1974; Cunha et al, 1986; Tenniswood, 1986). This
means androgens have a modulatory role on growth factor activities.
Recently, this contention was tested (Traish-trUcli-z., 1987; Shuurmans
et al, 1988) but the conclusions derived from these studies indicate
that the relationship between androgens and growth factors is still
nebulous.
4.5 FUTURE STUDIES
There are a few areas which need to be investigated and these
have been summarised under future studies, as follows
1) Measurement of EGF in the human prostate should be made
with a view to establishing the mode of EGF action in
the human prostate.
2) The identity of the two forms of BPH protein seen in the
second linearity during protein measurement and during
the heat experiments should be established.
3) The link between the EGF receptors in the human BPH and
EGF-uro in the human prostatic fluid should be established.
4) The identity of other mitogenic growth factors present
in the prostate should be established.
5) The link between retinoic acid and EGF receptor expression
should be clarified.
6) The cross-linking and phosphorylation experiments need to
be done again using a prostate tissue containing much
higher EGF receptor levels.
7) Characterisation of the proteins of the 800g crude heavy
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ABSTRACT
The receptor for epidermal growth factor (EGF) was
characterized in the particulate fraction from human
benign prostatic hyperplasia (BPH) and was present
in 85% of tissues analysed. The uptake of 125I-
labelled EGF by BPH was dependent on both time
and temperature, with maximum specific uptake
achieved after incubation for 90 min at 37 °C. Binding
characteristics revealed two classes of binding sites
of higher (mean dissociation constant (A/d) + s.d.=
0-8±0-2nmol/l) and lower (ATd = 7-6±2-8 nmol/1)
affinities. Competition studies demonstrated the speci¬
ficity of the receptor assay since the binding of
labelled EGF was abolished with excess unlabelled
EGF but not with excess unlabelled human GH,
human insulin, venom nerve growth factor, human
FSH, human LH and human prolactin. There was a
complex biphasic relationship between specific
binding and protein concentration in the range
0-1-8 mg/ml. Subcellular fractionation of BPH
homogenates demonstrated that the bulk of the speci¬
fic binding was confined to the 800# (crude heavy
pellet) and 15 000# (mitochondrial pellet) fractions.
The 105 000# (microsomal pellet) and the 105 000#
(cytosol fraction) exhibited low and variable binding
capacities for the growth factor. The presence of EGF
receptor was also confirmed by immunocytochemical
staining of frozen sections from BPH using mono¬
clonal antibody specific for EGF receptors. A positive
correlation between 125I-labelled EGF binding and
the intensity of staining was found. The presence of a
specific EGF-binding receptor protein in human BPH
tissues suggests that EGF may play a role in the
pathogenesis of human BPH.
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INTRODUCTION
Mouse epidermal growth factor (mE&F), of molecu¬
lar weight 6045, was first isolated from mouse sub¬
maxillary gland (Cohen, 1962). Human EGF (hEGF;
urogastrone; molecular weight 5400) was, however,
isolated from human urine (Cohen & Carpenter, 1975;
Gregory, 1975). Both mEGF and hEGF exhibit the
same intrinsic biological activities and share the
same cellular receptor sites in human fibroblasts
(Hollenberg & Gregory, 1976; Carpenter & Cohen,
1979). Thus the term EGF may be conveniently used
to designate the two peptides.
Epidermal growth factor is a powerful mitogen. It
exerts pronounced hypertrophic and hyperplastic
effects on epidermal tissue in vivo (Cohen & Elliot,
1963) and in vitro (Cohen, 1965) and it has also
been shown to enhance the growth of fibroblasts
(Carpenter & Cohen, 1979). Recent studies have also
demonstrated that EGF stimulates proliferation of
rat prostate epithelial cell populations (McKeehan,
Adams & Rosser, 1984), although its role in human
benign prostatic hyperplasia (BPH) remains uncertain
(Story, Jacobs & Lawson, 1983).
The biological effects of EGF are thought to be
mediated by the interaction with specific plasma mem¬
brane receptors in target cells and this has been
established in a whole range of tissues (O'Keefe,
Hollenberg & Cuotrecasas, 1974; Carpenter & Cohen,
1979; Hollenberg, 1979; Taketani & Oka, 1982).
Although earlier reports on the human prostate
revealed the absence of EGF and EGF receptors when
characterized by biochemical and immunocytochemi¬
cal techniques (Elder, Williams, Lacey & Gregory,
1978; Gregory, Willshire, Kavanagh et al. 1986), other
workers have suggested that growth factors might be
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implicated in the pathogenesis of human BPH (Jinno,
Ueda, Otaguro et al. 1986).
In view of the confusion regarding the status of
EGF receptors in the human prostate and their role in
the pathogenesis of BPH, we undertook to study in
detail the nature of the interaction between BPH and
growth factors. We now report the outcome of our
investigations which demonstrate the presence of
EGF receptors in BPH tissues.
MATERIALS AND METHODS
Hormones and growth factors
Mouse EGF and venom nerve growth factor were
purchased from Sigma, Poole, Dorset, as electro-
phoretically pure and were used without further pro¬
cessing. Human prolactin, human follicle-stimulating
hormone (hFSH), human luteinizing hormone (hLH),
human growth hormone (hGH) and human insulin
were generously donated by NIADDK, Bethesda,
MD, U.S.A.
Iodination
Iodination of EGF was by the Iodo-gen method,
based on the technique of Fraker & Speck (1978).
Briefly, films of l,3,4,6-tetrachloro-3a,6a-diphenyl-
glycouril (Iodo-gen; Sigma) were prepared by dissolu¬
tion in methylene chloride and plating on plastic
reaction vessels made to react rapidly in the solid
phase with aqueous mixtures of Na125I (specific
activity 350-600 mCi/ml; Amersham International
pic, Bucks) and EGF (5-10 pg) to yield the iodinated
peptide. The iodinated peptide was purified by
column chromatography (1 x46cm) using Sephadex
G-50. The percentage bound was calculated after pre¬
cipitation with trichloroacetic acid. The final specific
activity varied between 30 and 70 pCi/pg.
Other chemicals
The anti-human-EGF-receptor monoclonal antibody
(EGF-R1) was a generous gift from Drs M. D.
Waterfield and P. Bennett of the Imperial Cancer
Research Fund Laboratories, London. Normal
rabbit serum was obtained from Scottish Antibody
Production Unit, Carluke, Lanarkshire; peroxidase-
conjugated rabbit anti-mouse immunoglobulins were
from Dako Ltd, Glostrup, Denmark. Diaminobenze-
dine and Harris haematoxylin stain were obtained
from BDH Chemicals Ltd, Poole, Dorset. All other
reagents were of analytical grade except for bovine
serum albumin (BSA; Fraction V) which was obtained
from Sigma. The following buffers were used through¬
out the investigation: buffer A containing Tris
(10 mmol/1), EDTA (1 mmol/1), EGTA (1 mmol/1),
sucrose (0-25 mol/1) and phenylmethylsulphonyl
fluoride (0 05 mmol/1), pH 7-4; buffer B containing
Tris (10 mmol/1), sodium chloride (0 9%, w/v) and
BSA (01%, w/v), pH 7-4; buffer C containing Tris
(100nmol/l) and MgCl2 (4 mol/1), pH 5-8; buffer D
containing Tris (25 mmol/1), MgCl2 (10 mmol/1),
charcoal (0-3%, w/v) and dextran (0 03%, w/v), pH
7-5; buffer E containing Na2HP04.2H20 (0 05 mol/1),
NaH2P04.H20 (0 05 mol/1) and NaCl (0 9%, w/v),
pH 7-4; and buffer F containing Tris-HCl (10 mmol/1),
pH 7 4.
Tissue preparation
Prostate tissue obtained by transurethral resection
was transported to the laboratory in ice-cold saline.
The tissue was either used fresh or snap-frozen in
liquid nitrogen and stored at — 70 °C until analysis.
Fragments of every prostatic tissue included in the
study were examined histologically and in each case
BPH was confirmed. Unless specified, all subsequent
procedures were carried out at 4 °C. About 1-2 g tis¬
sue was washed in buffer A, blotted dry and cut into
small pieces. Preliminary dispersion of the tissue was
carried out on a microdismembrator (B. Braun A.G.,
Melsungen, F.R.G.) for 20 s in a prechilled Teflon
container. The tissue was further homogenized in 3
volumes of buffer A using an Ystral homogenizer
(Scottish Scientific Instruments Centre Ltd,
Edinburgh), for two periods of 20 s and 15 s at pos¬
ition 6 with 1-min cooling intervals. The homogenate
was subsequently filtered through a metal strainer and
the filtrate spun for 40 min at 105 000#. The resultant
pellet (total particulate fraction) was resuspended in
buffer B and dispersed further in a glass Dounce
homogenizer using 50 strokes with the loose fitting
pestle followed by 10 strokes with the tight fitting
pestle. The protein concentration of the final total
particulate fraction was adjusted to 1 mg/ml and this
was used for all subsequent studies except where
indicated otherwise. For experiments designed to
determine the subcellular distribution of the specific
EGF binding protein, the subcellular fractions were
prepared according to the method of Leake, Chisholm
& Habib (1983) to provide a crude heavy pellet
(800#), the mitochondrial pellet (15 000#), the micro¬
somal pellet (105 000 g) and the 105 000 g supernatant
fraction (cytosol).
Protein concentrations in tissue fractions were
measured by the method of Bradford (1976) using
BSA as standard.
Binding studies
Binding of EGF was determined by a modification of
the methods of Edery, Pang, Larson et al. (1985) and
Sainsbury, Sherbert, Farndon & Harris (1985).
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D vfiv homogenate samples were incubated with
fo nmol l (200 000 c.p.m.) 125I-labelled EGF (specific
, in-70 uCi/pg) in the presence and absence of
3CS foId excess (300nmol/l) unlabelled EGF. The
aI volume of the incubation mixture was 400 pi
j n 0f 200 pi buffer B with or without unlabelled
EGF 100 pi 125I-labelled EGF and 100 pi sample,
incubation took place at 37 °C and the reaction was
terminated by the addition of 1 ml cold (4 °C) buffer
B The samples were harvested by filtration under
reduced pressure on glass microfibre filters (Whatman
GF A, Whatman Ltd, Maidstone, Kent) and rapidly
w ashed with 2 x 1 ml aliquots of buffer B. Preliminary
studies revealed that two washes were optimal and
this was therefore adopted throughout our binding
studies. The radioactivity retained by the filter
was measured on an LKB gamma counter with an
efficiency of 52% and the specific binding was cal¬
culated by subtraction of non-specific from total
binding.
In another experiment, saturation analysis was per¬
formed over a range of 0-5-24 nmol 125I-labelled
EGF/1 in the presence or absence of a 50-fold excess
of unlabelled EGF at each concentration of 125I-
unlabelled EGF. The dissociation constant (/fd) and
binding sites were estimated by the Scatchard (1949)
method. The impact of time and temperature on
binding was investigated by incubating homogenate
samples as described above at 4, 25 and 37 °C for
varying times and the specific binding calculated for
each set of conditions. Values are always expressed as
means+ s.D.
Competition studies
Specificity of binding was assessed by incubating
125I-labelled EGF (6 nmol/1; 36 ng/ml) in the absence
and presence of the following unlabelled competitors:
hGH, hFSH, human prolactin, human insulin, hLH
and venom nerve growth factor, all at a concentration
of 1000 ng/ml, and specific binding was calculated.
Effect of heat and trypsinization
Before incubation with 125I-labelled EGF, the hom¬
ogenate sample was pretreated with trypsin (0-05%,
w/v), bovine pancrease type I (Sigma Chemicals), at
37 °C for 90 min or heated at 45 °C for 10 min. After
one wash the binding was subsequently assessed by
incubating the suspension with 6 0 nmol 125I-labelled
EGF/1 as described above.
Pretreatments with MgCl2 and dextran-coated
charcoal
Membrane suspension was mixed with 2 ml buffer C
at room temperature for 10 min as detailed by Leake
et al. (1983). The membrane suspensions were subse¬
quently centrifuged at the appropriate# force and the
resultant pellets reconstituted in buffer A.
For experiments designed to determine the effects
of dextran-coated charcoal on EGF binding, the
membrane suspensions were exposed to 0-2 ml buffer
D for 10 min at room temperature. The suspensions
were subsequently layered on buffer B and centrifuged
at 800 # for 10 min to remove the dextran-coated char¬
coal. In all these incubations the specific binding was
assessed as described above.
Immunocytochemical staining with antibodies against
EGF receptors
The presence of EGF receptors in BPH was also
sought by an indirect immunoperoxidase technique
with a murine EGF monoclonal-receptor antibody.
Briefly 3-4 pm cryostat sections were cut and collected
on lysine-coated slides. After drying with a fan for 30
min the sections were fixed in acetone for 20 min and
allowed to dry. Primary antibody (50 pi) at a dilution
of 1/30 (v/v) was applied to the sections and these
were allowed to incubate for 30 min before being
gently washed in Tris-saline for 10 min. A peroxidase
conjugate of rabbit anti-mouse immunoglobulin was
then applied to the sections for 30 min at room tem¬
perature followed by a further 10 min of gentle wash¬
ing in Tris-saline. The peroxidase enzyme was then
visualized by immersion in 0 05% (w/v) diaminoben-
zedine with hydrogen peroxide for 10 min after
which the sections were washed in water. Sections
were counterstained with haematoxylin and then
dehydrated, cleared and mounted. For each staining
experiment a negative control section was included
with the primary antibody omitted from the staining
procedure.
RESULTS
Time and temperature studies
Text-figure 1 illustrates the patterns of binding of
EGF to the 105 000# membrane pellet at three
temperatures. Clearly the binding is time- and
temperature-dependent, with maximal binding
obtained at 37 °C after 45 min of incubation. The
maximal binding was sustained for a further 75 min
beyond which a decline was observed, probably due to
the instability of the membranes under these con¬
ditions. Although the binding at 25 °C was slightly
lower than that observed at 37 °C, the binding profiles
for both temperatures were similar, whereas at 4 °C
receptor-ligand interaction was considerably slower
and significantly reduced. It was therefore decided to
undertake all subsequent incubations at 37 °C.
J. Endocr. (1987) 113, 147-153
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Time of incubation (min)
text-figure 1. Effect of incubation time and temperature on specific bind¬
ing of 125I-labelled epidermal growth factor (EGF) (200 000 c.p.m.;
6 nmol/1) to the total particulate fraction (105 000 g pellet) prepared from
human hyperplastic prostate. The pellet suspensions were incubated in the
presence and absence of unlabelled EGF (50-fold excess) for 90 min at
4 ( O), 25 (•) and 37 °C ( A ). Values are means ± s.d. of six different
specimens each analysed in duplicate.
Effect of protein concentrations on receptor estimations
In order to determine the limit to which tissue hom-
ogenates must be diluted with buffer for accurate
receptor estimations, total particulate fraction pellets
were resuspended in different volumes of buffer to
provide a wide range of protein concentrations. The
EGF binding was found to be linear with dilutions
corresponding to protein concentrations between 01
and 1 mg/ml (Text-fig. 2). As demonstrated below,
these protein concentrations provided good quality
Scatchard plots, and we therefore restricted all our
experiments to this range of concentrations. A second
linearity was also observed between 1-5 and 8 mg/ml
(data not shown).
Subcellular distribution
Subcellular fractions were prepared from specimens
obtained from four patients and the specific 125I-
labelled EGF binding was assessed in each compo¬
nent. The data outlined in Table 1 reveal that just over
68% of the specific binding was associated with the
800 g (crude heavy pellet) fraction. The remainder of
the binding was distributed between the microsomal
and the mitochondrial pellets, whereas no specific
binding of radiolabeled EGF was detected in the
cytosol.
Affinity and specificity of the binding
Scatchard analysis of the data from saturation assays
carried out on ten separate prostates revealed two
binding sites, the first of high affinity (ae1 = 0'8±
0-2 nmol/1) and the second of a lower affinity
(Axl = 7-6 ±2-8 nmol/1). The mean binding capacities
for the two components were 14+1-4 fmol/mg pro¬
tein and 137 + 23 fmol/mg protein respectively. A
typical Scatchard plot for the specific binding to the
particulate fraction is shown in Text-fig. 3. The speci¬
ficity of the binding was also examined. The data out¬
lined in Table 2 demonstrate that human prolactin,
human insulin, hFSH, hLH and venom nerve growth
factor at concentrations of lOOOng/ml failed to com¬
pete with EGF for the receptor sites whereas hGH
(1000 ng/ml) exhibited about 13% competition with
the radiolabeled EGF.
Effect of heat and trypsin
Pretreatment of the particulate fraction with either
protease or heat, before incubation with the radio-
labelled ligand, "totally inactivated EGF binding
(data not shown). The data suggest that 125I-labelled
EGF was bound by a proteinaceous macromolecule
associated with the total particulate fractions of the
cell.
Pretreatment with MgCl2 and dextran-coated charcoal
When the particulate fraction was pretreated with
either 4mol MgCl2/l or dextran-coated charcoal, no
increase in specific binding was observed. MgCl2 was
found to increase both the total and non-specific bind¬
ing whereas dextran-coated charcoal treatment inhi¬
bited these bindings with the overall impact being that
of a net loss in specific binding (data not shown).
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Membrane protein concentration (mg/ml)
text-figure 2. Effect ofprotein concentration of the total particulate frac¬
tion (1 05 000 g pellet) on the estimation of epidermal growth factor
(EGF)-receptor levels in human prostate. Aliquots (100 pi) of the suspen¬
sion containing 0-1 to 8 mg protein/ml were incubated with 125I-labelled
EGF (200 000 c.p.m.; 6 nmol/1) in the presence and absence of a 50-fold
excess of unlabelled EGF for 90 min at 37 °C. Values are means + s.d. of four
different specimens each analysed in duplicate.
table 1. Subcellular distribution of epidermal growth factor
(EGF) receptors in benign hyperplastic prostate. Pellets,
resuspended in 100 pi buffer containing Tris (10 mmol/1),
sodium chloride (0-9%, w/v) and BSA (0-1 %, w/v) (pH 7-4)
were incubated with 125I-labelled EGF (6 0 nmol/1) at 37 °C
for 90 min in the presence and absence of unlabelled EGF
(50-fold excess). Each value represents the mean + s.d. of




800# crude pellet 11-82 + 1-73
15 000 g pellet (mitochondria) 3-65 + 0-53
105 000 g pellet (microsome) 1-88 + 0-25








The pattern of immunoperoxidase reactivity observed
in BPH is illustrated in the Plate. Staining by the anti¬
body was confined only to the basal layers of the
epithelial cells whilst the adjacent stroma remained
clear. There was no apparent nuclear staining but the
immunoperoxidase fraction was limited to cell mem¬
branes. Staining of epithelial cells was predominantly
uniform throughout the same specimen but there was
considerable variability in the intensity of staining
between different tissues. In general, there was very
good correlation between the intensity of staining and
receptor positivity as measured by ligand exchange
assay. Staining of sections was assessed by three inde¬
pendent observers and graded as negative, moderate
















text-figure 3. Saturation curve and Scatchard plot of speci¬
fic 125I-labelled epidermal growth factor (EGF) binding to
human prostates. Aliquots (100 pi) of the total particulate
fraction (105 000 g pellet) were incubated with 12 5I-labelled
EGF (0-5-24 nmol/I) in the presence and absence of a
50-fold excess of unlabelled EGF. The specific binding data
was analysed by the Scatchard (1949) method.
occurred in all ten tissues examined: six specimens
demonstrated intense immunocytochemical staining
and this corresponded to high specific binding
(>6 d.p.m./l x 10~6) whereas moderate or negative
staining corresponded to binding less than 6 d.p.m./
lxl(T6.
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table 2. Specificity of 125I-labelled epidermal growth factor
(EGF) binding to benign hyperplastic prostate tissue mem¬
branes. The particulate fraction was resuspended in buffer B
containing Tris (10 mmol/1), sodium chloride (0-9%, w/v)
and BSA (0-1%, w/v) (pH 7-4) and 100 pi of the suspension
was incubated with 6 0 nmol 125I-labelled EGF/1 (approx.
36 ng/ml) at 37 °C for 90 min in the presence and absence of
the competitor (1000 ng/ml). 100% competition was taken
as the amount of12 5I-labelled EGF displaced by 1000 ng
unlabelled EGF/ml. Each value represents the mean + s.d. of
four different specimens, each analysed in duplicate
Specific binding Competition
(d.p.m./l x 10"6) (%)
Unlabelled
hormone
Venom nerve 3-34 + 0-3 4
growth factor
Human GH I0-88±l-2 13
Human prolactin 3-38 + 0-8 4
Human FSH 3-36 + 0 4 4
Human LH 3-50 + 0-9 4
Human insulin 3-30 + 0-6 4
Mouse EGF 83-69 + 8-2 100
DISCUSSION
The results presented in this study suggest for the first
time that BPH tissues contain receptor proteins with a
high affinity and low capacity for EGF. The charac¬
teristics of these receptors were similar to those
established for other EGF receptors measured in
human placenta (Hock & Hollenberg, 1980), normal
mammary cells (Taketani & Oka, 1982), human
breast cancer (Sainsbury et al. 1985), human bladder
cancer (Neal, Bennet, Hall et al. 1985), human fibro¬
blasts (Carpenter & Cohen, 1979) and human cervical
and ovarian cancer (Gullick, Marsden, Whittle et al.
1986).
In common with other reports (O'Keefe et al. 1974;
Hofmann, Rao, Barrows et al. 1984), our binding
data for EGF were found to be essentially biphasic
since Scatchard plots yielded two classes of binding
sites. The presence of multiple binding sites has been
attributed primarily to the heterogeneity of the tissue
under investigation (Hofmann et al. 1984). In a recent
study on whole mammary gland membranes, two sets
of independent receptor sites were identified (Edery et
al. 1985) whereas only one class of receptors was
demonstrated in isolated epithelial cells obtained from
the same gland. Since the prostate also consists of a
mixture of glandular and stromal tissues, it is conceiv¬
able that the heterogeneity of the specimen analysed
could be responsible for the curvilinear Scatchard
plots obtained in this study. However our immuno-
cytochemical investigations suggest the absence of
EGF receptors in the stroma.
Contrary to earlier findings (Hock & Hollenberg,
1980) pretreatment with MgCl2 and dextran-coated
charcoal did not appear to affect the binding of EGF
to its receptor. MgCl2 has been shown to dissociate
tightly bound endogenous ligands from their recep¬
tors whilst dextran-coated charcoal removes possible
binding inhibitors from the tissue extracts (Kelly,
Leblanc & Djiane, 1979). Our findings may therefore
reflect the possibility that BPH contains little
endogenous EGF; this is supported by the recent find¬
ings of Gregory et al. (1986) who failed to show the
presence of EGF within the cells of the BPH prostate
by immunocytochemical methods. The other possibi¬
lity is that the binding between the EGF and its recep¬
tors in the prostate is not so strong as that observed in
other target tissues and this might allow for a com¬
plete and effective exchange between endogenous and
exogenous ligands; it is notable though that the mean
A/d values measured in the present study were in the
region of 0-8 nmol/1 and much higher values were
found in other cells (0-53-0-007 nmol/1; Boonstra, de
Laat & Ponec, 1985).
It is quite evident from our subcellular distribution
experiments that the bulk of the EGF binding (68%)
was associated with the 800 g pellet which incorpor¬
ates the cell membrane along with the EGF receptors.
Further confirmatory support for the presence of
these receptors stem from our immunocytochemical
staining experiments which revealed their presence in
epithelial basal cells. The intensity of the immunocyto¬
chemical staining corresponded with the number of
binding sites measured by the ligand binding assay.
The localization of the receptors on the epithelial cells
is in line with recent reports of the ability of EGF to
stimulate rat prostate epithelial cells (McKeehan et al.
1984). However, our inability to demonstrate any
EGF binding along the stromal components of the
prostate tissue is at variance with the observations
implicating the action of EGF on fibroplastic prolifer¬
ation in the development of BPH (Jinno et al. 1986).
Nonetheless, at this stage we cannot discard the possi¬
bility that an EGF-like growth factor, synthesized by
the stromal component of the prostate, is in some way
implicated in the growth and proliferation of the
gland. It is noteworthy that in recent studies a number
of workers have identified prostatic growth factors in
homogenates of human BPH (Story et al. 1983; Jinno
et al. 1986); whether the components are similar to
EGF remains to be established.
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DESCRIPTION OF PLATE
Immunoperoxidase staining of frozen sections of human benign prostatic hyperplasia.
( x 320.) Primary monoclonal epidermal growth factor-receptor (EGF-R1) antibody
was used at a dilution of 1:30. The sections were lightly counterstained with haema-
toxylin. A positive reaction for EGF-R1 appears as a dark stain along the basal
epithelial cells.
figure 1. Section processed in the absence of the primary antibody.
figure 2. Section incubated with EGF-R1 monoclonal antibody.
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ARE EPIDERMAL GROWTH FACTOR
RECEPTORS PRESENT IN THE HUMAN
PROSTATE
FOUAD K. HABIB and SAMUEL Q. MADDY
Department of Surgery, University of Edinburgh Medical School, Teviol Place,
Edinburgh EH8 9AG, Scotland, U.K.
ABSTRACT
The identification and characterisation of epideraal growth factor (EGF) receptors in
hyperplastic and malignant human prostate is described. Two methods were employed: A
biochemical technique using a ligand exchange assay and an imrnunocytochemical approach
employing a monoclonal antibody to the EGF receptor.
KEYWORDS
Epidermal growth factor - receptors: immunocytochemical staining: benign prostatic
hyperplasia: cancer of the prostate.
INTRODUCTION
Epidermal growth factor (EGF) is a low molecular weight polypeptide found in high
concentrations in human urine and prostatic fluid (Gregory et al, 1986). Its
physiological function is not clear, although it has been shown that EGF may induce some
biological effects both in vivo and in organ culture by promoting proliferation of the
basal cell layers of various epithelia of ectodermal origin (Cohen and Taylor, 1974).
It has also been reported that EGF may stimulate the growth and proliferation of rat and
human prostate epithelial cell populations (McKeehan et al, 1984; Chaproniere and
McKeehan, 1986). These prostatic responses are probably induced following the
interaction of the growth factor with specific plasma membrane receptors located on the
surface of the human prostate cell (Maddy et al, 1987).
Although no one has so far investigated the relative expression of these receptors in
prostate specimens obtained from patients with different pathological conditions, the
earlier reports on prostate fluid (Gregory et al, 1986) suggest that EGF secreted by the
hyperplastic prostate (BPH) is approximately half that of age-matched controls. It
therefore appears that the secretion of EGF by the human prostate is in part dependent
on the pathophysiology of the gland but whether this would also result in a parallel
change in the concentrations of tissue EGF-receptors remains to be established.
However it is worth noting that in the earlier studies on human lung tumours (Hwang et
al, 1986) and human gastric cancer (Sakai et al, 1986) it was shown that the binding
activity of EGF to the receptor was either decreased or increased when compared to
normal tissues depending on the type of tissue examined.
We now wish to extend some of these studies to the human prostate and compare the levels
of EGF receptors in benign and cancerous tissues. Attempts will also be made to assess
the impact of histological differentiation in cancer on the expression of these
receptors.
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MATERIALS AND METHODS
Human tissues
Prostate specimens were taken from 18 patients with benign prostatic hyperplasia (BPH)
and 19 patients with cancer of the prostate (CaP). None of the patients from whom the
tumour samples were obtained received chemotherapy or radiation prior to the removal of
their tissue. Histopathologically, the cancerous specimens consisted of 4 well
differentiated, 10 moderately differentiated and 5 poorly differentiated tumours.
Grading has also been carried out by a single pathologist according to the Gleason
system (Gleason and Mellinger, 1974). The specimens were immediately frozen in liquid
nitrogen and kept at -70°C pending analysis.
Measurement of EGF receptors (Ligand exchange assay)
The receptor binding assay was essentially the same as previous described (Maddy et al,
1987) with minor modifications. Following the incubation of the JDSOOOg membrane
preparation with the I-labelled derivatives of mouse EGF, the I-EGF-receptor
complex was precipitated with equal volume of 20% polyethylene glycol 8000 (PEG)
containing 0.1% bovine serum albumin (BSA) at 4°C for 10 min. The mixture was
centrifuged for 20 min at 3000 rpm and the resultant pellet was washed once with 10% PEG
and 0.05% BSA and centrifuged again as before. The bound radioactivity in the final
pellet was measured on a Gamma counter.
Inmunohistochemical studies
3-4 urn thick frozen prostate sections were cut on a cryostat. Sections were transferred
to microscope slides coated with lysine, fixed in acetone for 20 min and allowed to dry.
Sections were subsequently incubated at room temperature with a murine monoclonal
antibody (EGFR-1; donated by Dr. M. Waterfield) at a dilution of 1:30 (v/v) for 30 min
followed by a peroxidase conjugate of rabbit anti-mouse immunoglobulin and finally the
hydrogen peroxide and diaminobenzidine with tris-saline washes between each stage.
Rabbit serum obtained prior to the immunisation schedule served as a control and
tris-saline as a blank by replacing EGFR-1 in the incubation sequence. The intensity of
the staining of each prostate section was assessed by 3 independent investigators using
reference slides. The scores for staining ranged from 1+ (weak staining) to 3+ (intense
staining); 1- represents a negative reaction. Details of these procedures have been
described in our previous paper (Kaddy et al, 1987).
RESULTS
125
The binding of I-labelled m-EGF to human prostate membrane preparations was found to
be saturable and biphasic since Scatchard plots yielded 2 classes of binding sites (data
not shown); the first of high affinity K. = 0.8 + 0.2 nmol/1 and the second of a low
affinity K. = 7.6+2.8 nmol/1. These binding siTes were essentially proteinaceous in
composition since pretreatment of the particulate fraction wi,th either trypsin (0.05%;
w/v) or heat (45°C; 10 min) prior to the incubation with I-labelled EGF totally
abolished the binding. Furthermore our investigations indicated that the interaction
between the ligand and the receptor protein was specific to EGF because excess
unlabelled competitors (1000 ng/ml) such as nerve growth factor, human growth hormone,
human prolactin, human FSH, human LH and human insulin totally failed to inhibit the EGF
binding.
Analysis of our receptor, jgeasurement data on 18 hyperplastic prostates revealed an
average of 125 fmol of I-labelled EGF/mg protein (Table 1) (range: 0-360 fmol/mg
protein). In contrast the preliminary data on 19 patients with cancer of the prostate
demonstrated a marked reduction in specific EGF binding (mean +_ SD = 50 + 11 fmol/mg
protein; range: 0-120 fmol/mg protein). In spite of an overlap between The 2 groups
there was a statistically significant difference between the mean levels of
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Table 1. EGF-RECEPTORS: COMPARISON OF BIOCHEMICAL AND IMMUNOCYTOCHEMICAL
METHODS IN BPH AND CANCER OF THE PROSTATE.







BPH 125 + 20 - / +++ 17/18
2-4 84 + 13 + / ++ 4/4
Cap 5-7 52 + 8 - / ++ 5/10
8-10 N.D. - / - 0/5
EGF-receptors in BPH and cancer of the prostate (p<0.01). Although the bulk of the
benign prostates assayed for EGF-receptors were found to be positive, this was not the
case in malignancy where 10/19 glands were devoid of EGF binding or at least below the
detection limits of the assay (12 fmol/mg protein).
In addition to the differences observed between BPH and cancer of the prostate, we were
also able to detect a strong relationship between the levels of EGF receptor binding and
histological differentiation in cancer (Table 1). In fact, well differentiated tumours
(Gleason sura 2-4) maintained significantly larger (p<.0.01) concentrations of EGF
receptors (mean +_ SD = 84 + 13 fmol/mg protein) than in the poorly differentiated
tumours (Gleason sum 8-10T which were devoid of EGF binding. The receptor
concentrations within the moderately differentiated tumours (Gleason score 5-7) were of
an intermediate range (52 + 8 fmol/mg protein) but nonetheless considerably lower than
those measured in the well differentiated tumours.
The presence of EGF receptors in BPH and cancer was also confirmed by immunocytochemical
staining. Staining by the antibody was confined only to the basal layers of the
epithelial cells whilst the adjacent stroma remained clear. Although the staining of
the epithelial cells was predominantly uniform throughout the same specimen, there was
considerable variability in the intensity of staining between different tissues and
particularly amongst the cancer specimens (Table 1) where well differentiated tumours
demonstrated intense immunocytochemical staining (3+) whereas poorly differentiated
tumours showed no staining whatsoever (negative). Furthermore, there was a very good
correlation between the intensity of staining and receptor positivitity as measured by
ligand exchange assay (Table 1). Agreement between the 2 techniques occurred in all 37
specimens examined.
DISCUSSION
Data presented in this report suggest that the human prostate has an ability to
specifically bind EGF. The presence of EGF receptors on the epithelial cells of benign
prostatic hyperplasia and cancer of the prostate was initially established by a ligand
exchange assay and subsequently confirmed by immunocytochemical staining employing a
monoclonal antibody to the EGF-receptor. Furthermore our study reveals that malignant
prostates have a decreased ability to bind EGF when compared with the benign
hyperplastic gland. Suppressed EGF was also found in a number of other human
malignancies including gastric (Sakai et al, 1985) and liver (Costreni and Beck, 1983).
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These data were interpreted to mean fewer copies of EGF receptors/cell although no
evidence was presented to support such a contention. The possibility exists that
decrease binding of radiolabelled ligand may reflect other factors e.g.:(l) Alteration
of the EGF receptor molecule with a reduced binding affinity for ligand. (2) The
presence of interfering endogenous EGF. (3) Enzymatic inactivation of EGF. (4) The
production of a TGF which can down regulate the receptor by the transformed cells. In
this study we found no alteration in the dissociation constant (K.) for EGF binding in
prostate cancer (data not shown). Thus, it would seem unlikely tnat endogenous ligand
and/or alteration in the EGF receptor molecule can account for our observations of
suppressed binding in malignancy. Also since various enzyme inhibitors including
anti-trypsin did not augment radioligand binding in the prostate membrane fractions
(data not shown), it is unlikely that the difference in EGF receptor values between both
sets of tissues is a consequence of enhanced activation of the macromolecule in prostate
cancer. For these reasons the possibility that prostate EGF receptors is being
expressed in reduced amounts in cancerous tissue must be entertained and as indicated
above such a concept is not novel.
In view of the reduced levels of EGF receptors in malignant tissue compared to BPH, it
was not surprising to find a correlation between the levels of these binding sites and
the histological differentiation of the tumour. To the best of our knowledge this is
the first time that such a correlation has been established in cancer specimens and
though it is very difficult at this stage to assess the aetiological significance of
these findings, the possibility exists that these data might be of prognostic
significance. In this regard low EGF binding in patients with BPH could be used to
identify those who, in time would progress to a malignancy. Furthermore the use of an
EGF receptor cDNA probe could provide further information with respect to the genomic
organisation of the EGF receptor gene and the level of the expression of these genes in
these tumours as compared to normal and benign prostates.
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